Type I Diabetes

🏷

Classifications

Harrison's Part

◈

Mechanistic Hypotheses

1

Viral-Interferon Beta-Cell Autoimmunity Model

viral_interferon_beta_cell_autoimmunity_model EMERGING

Evidence balance 6 support

Enteroviral or other viral exposure in a genetically susceptible host induces interferon signaling in pancreatic islets, increasing beta-cell antigen presentation, chemokine release, and stress programs that may bridge innate antiviral responses to durable adaptive beta-cell autoimmunity.

Retained as EMERGING per the 2026 openscientist hypothesis-search report (kb/hypotheses/Type_I_Diabetes/viral_interferon_beta_cell_autoimmunity_model/openscientist.md). The report judged the model partially supported: the beta-cell interferon arm is the best-supported component, while pathogen-specific causality, same-person temporal ordering from viral exposure to autoantibody seroconversion, and applicability beyond rapid/fulminant presentations remain unresolved. Kept at EMERGING after a 2026 assessment of that report even though both arms now have a positive interventional trial behind them, because both are phase 2 with no replication: antiviral treatment (pleconaril plus ribavirin, n=96) and JAK inhibition (baricitinib, n=91) each preserved stimulated C-peptide in new-onset disease. The report also overstated two of its own sources, reading a co-expressed islet signature as a timed interferon to chemokine to MHC sequence and attaching the wrong odds ratio to the IFIH1 risk allele; both are corrected where the underlying findings are curated.

Pathograph links

Environmental Triggers -> Interferon-Driven Beta Cell Response INDIRECT KNOWN INTERMEDIATES Viral exposures may induce local islet interferon programs that make beta cells more immunogenic and stressed. Intermediates: Beta-cell viral RNA sensing and local interferon signaling

Environmental Triggers -> Persistent Low-Grade Islet Enteroviral Infection INDIRECT UNKNOWN INTERMEDIATES Enteroviral exposure can leave a low-abundance, non-cultivable viral footprint in islet cells rather than resolving as an acute lytic infection.

Environmental Triggers -> Gut-Pancreas Lymph Node Crosstalk INDIRECT KNOWN INTERMEDIATES Upper-intestinal viral infection can reprogram shared draining lymph-node immune traffic toward pancreatic islet inflammation in a mouse model. Intermediates: Shared pancreas-duodenum lymph-node drainage; Migratory dendritic-cell and beta-cell-reactive T-cell inflammatory polarization

Environmental Triggers -> Autoimmune Destruction of Beta Cells INDIRECT UNKNOWN INTERMEDIATES

Persistent Low-Grade Islet Enteroviral Infection -> Interferon-Driven Beta Cell Response INDIRECT KNOWN INTERMEDIATES Enteroviral capsid protein positivity in islet cells travels with HLA class I hyperexpression, the histological footprint of local interferon exposure. Intermediates: Islet-cell sensing of viral RNA; Local type I interferon release

Gut-Pancreas Lymph Node Crosstalk -> Autoimmune Destruction of Beta Cells INDIRECT KNOWN INTERMEDIATES Pro-inflammatory shared lymph-node crosstalk may increase pancreatic islet lymphocyte infiltration and accelerate beta-cell autoimmunity. Intermediates: Beta-cell-reactive T-cell inflammatory polarization in shared draining lymph nodes

Interferon-Driven Beta Cell Response -> Autoimmune Destruction of Beta Cells INDIRECT KNOWN INTERMEDIATES Interferon-exposed beta cells may amplify autoimmune recognition through antigen-presentation and chemokine programs. Intermediates: HLA class I upregulation; CXCL10-mediated lymphocyte recruitment

Deep research

OpenScientist citations 40 citations 2026-06-03T12:00:25.394760

Show evidence (6 references)

PMID:40375390 SUPPORT Human Clinical

"epidemiological data point to a role of environmental factors, notably enteroviral infections, in the disease, although precise causative links between specific pathogens and T1D have been difficult to establish."

Review evidence supports enteroviral infection as an epidemiologic lead while explicitly preserving the knowledge gap around specific causal pathogens.

PMID:38409439 SUPPORT In Vitro

"These data suggest that IFN-α and IFN-γ are key cytokines at the islet level in human type 1 diabetes, contributing to the triggering and amplification of autoimmunity."

Human beta-cell cytokine perturbation and comparison with type 1 diabetes islet signatures support interferons as the beta-cell intrinsic arm of the model.

PMID:37557168 SUPPORT Model Organism

"duodenal viral infections rendered non-intestinal migDCs and β-cell-reactive T cells more pro-inflammatory in all shared LNs, resulting in elevated pancreatic islet lymphocyte infiltration."

Mouse lymph-node drainage experiments provide a candidate gut-pancreas crosstalk mechanism linking intestinal viral infection to pancreatic autoimmunity.

+ 3 more references

?

Discussions and Knowledge Gaps

2

Which viral-exposure context converts transient islet interferon signaling and gut-pancreas lymph-node inflammatory crosstalk into durable beta-cell autoimmunity in HLA-risk individuals?

KNOWLEDGE GAP OPEN gap_t1d_viral_interferon_autoimmunity_bridge

Attached to

pathophysiology#Environmental Triggers pathophysiology#Interferon-Driven Beta Cell Response pathophysiology#Gut-Pancreas Lymph Node Crosstalk pathophysiology#Autoimmune Destruction of Beta Cells

The entry can now represent viral exposure as both an upstream islet interferon trigger and a candidate gut-pancreas lymph-node accelerator, but human causal ordering remains unresolved. Distinguishing transient antiviral beta-cell stress from a self-sustaining adaptive autoimmune program would determine whether the actionable window is antiviral prevention, interferon/JAK blockade, lymph-node immune modulation, beta-cell stress protection, or combinations stratified by HLA and islet-autoantibody stage.

Proposed experiments

HLA-stratified islet lymph-node viral-interferon bridge assay

human islet immune coculture perturbation experiment

exp_t1d_hla_islet_ln_viral_interferon_bridge

Pair HLA-DQ2/DQ8-stratified human islets or stem-cell-derived beta-cell clusters with autologous dendritic cells and T cells in a lymph-node-like microphysiological coculture; compare enterovirus or viral-RNA exposure, IFNAR/JAK blockade, and chemokine blockade for their effects on beta-cell antigen presentation, CXCL10 output, T-cell activation, and beta-cell survival.

Model systems

HLA-stratified human islet immune lymph-node-on-chip

Human islet or iPSC-derived beta-cell microphysiology system connected to autologous dendritic-cell and T-cell compartments to test whether antiviral interferon exposure is sufficient to license beta-cell-reactive adaptive immune activation.

ORGAN ON CHIP namo:OrganOnChip link

human NCBITaxon:9606

pancreas UBERON:0001264

type B pancreatic cell CL:0000169 dendritic cell CL:0000451 T cell CL:0000084

Perturbations

Enterovirus or viral-RNA exposure

pathophysiology#Environmental Triggers

Apply infectious enterovirus under containment or a viral-RNA mimic to induce beta-cell antiviral sensing and local interferon responses.

Effect: induces antiviral interferon signaling

IFNAR/JAK pathway blockade

pathophysiology#Interferon-Driven Beta Cell Response

Block type I interferon receptor or downstream JAK signaling to test whether beta-cell immunogenicity and T-cell activation require interferon signaling.

Effect: decreases interferon signaling

Readouts

Beta-cell antigen-presentation and chemokine induction

pathophysiology#Interferon-Driven Beta Cell Response

Quantify beta-cell HLA class I antigen presentation, interferon-stimulated genes, CXCL10 secretion, oxidative phosphorylation, and survival.

Beta-cell-reactive T-cell activation

pathophysiology#Autoimmune Destruction of Beta Cells

Measure T-cell activation, cytokine production, beta-cell killing, and persistence after viral or interferon stimuli are withdrawn.

Decision criterion

A sustained beta-cell-reactive T-cell response that persists after viral stimulus withdrawal, and is prevented by interferon/JAK or chemokine-axis blockade, would support a causal viral-interferon bridge rather than a transient bystander antiviral state.

What decides whether the interferon programs induced in a beta cell favour destruction, through MHC class I overexpression and chemokine release, or protection, through PD-L1 and HLA-E checkpoint ligands?

KNOWLEDGE GAP OPEN gap_t1d_interferon_protective_versus_destructive_balance

Attached to

pathophysiology#Interferon-Driven Beta Cell Response pathophysiology#Autoimmune Destruction of Beta Cells

The same interferon-alpha exposure that raises antigen presentation and chemokine output on human beta cells also raises the checkpoint ligands PD-L1 and HLA-E, so this node carries opposing programs rather than a single destructive one. Two clinical observations bracket the question without answering it. Blocking PD-1 or PD-L1 pharmacologically produces insulin-dependent diabetes in close to one percent of treated cancer patients, which shows the protective arm is load-bearing in people. Sustained exogenous interferon-alpha in chronic hepatitis C produces the disease at ten to eighteen times background rate, which shows enough interferon overwhelms that arm. What is missing is any quantitative account of where the crossover sits, whether it is set by interferon dose, by duration, by genotype, or by disease stage. Without it the entry cannot say why most viral infections never produce autoimmune diabetes, and cannot predict who would benefit from interferon or JAK blockade rather than be harmed by it.

Show evidence (1 reference)

PMID:29937434 SUPPORT Human Clinical

"We conclude that autoimmune, insulin-dependent diabetes occurs in close to 1% of patients treated with anti-PD-1 or -PD-L1 CPIs."

Establishes the premise of this gap in humans. Removing the PD-1 and PD-L1 brake pharmacologically is by itself sufficient to precipitate insulin-dependent diabetes, so the protective arm of the interferon response is load-bearing and the balance between the two arms is a real determinant rather than a modelling convenience.

⚙

Pathophysiology

13

Genetic Susceptibility

HLA class II risk haplotypes (HLA-DQ2 and HLA-DQ8, encoded jointly by HLA-DQA1 and HLA-DQB1 alleles) and other susceptibility loci such as the INS VNTR (IDDM2) increase the risk of developing Type I Diabetes.

HLA-DQA1 hgnc:4942 HLA-DQB1 hgnc:4944 INS hgnc:6081

Downstream

Autoimmune Destruction of Beta Cells

Show evidence (6 references)

PMID:11554771 SUPPORT Human Clinical

"The HLA-DQ genes are the primary susceptibility genes within this region, although other genes may also contribute. The IDDM2 locus maps to a variable number of tandem repeats in the insulin gene region on chromosome 11."

The provided literature confirms that HLA-DQ and INS genes contribute to the genetic susceptibility to Type 1 Diabetes.

PMID:31331105 SUPPORT Human Clinical

"HLA DQA1*05 and DQB1*02 alleles encoding the DQ2.5 molecule and HLA DQA1*03 and DQB1*03 alleles encoding DQ8 molecules are strongly associated with celiac disease (CD) and type 1 diabetes (T1D), two common autoimmune diseases (AD)"

The presence of HLA-DQ2 and HLA-DQ8 variants contributing to the genetic susceptibility of Type I Diabetes is supported.

PMID:3309680 SUPPORT Human Clinical

"Over half of the inherited predisposition to insulin-dependent diabetes mellitus maps to the region of chromosome 6 that contains the highly polymorphic HLA class II genes which determine immune responsiveness."

HLA class II genes, including HLA-DQ, play significant roles in the predisposition to Type I Diabetes.

+ 3 more references

Environmental Triggers

Viral infections or early dietary factors (cow's milk, gluten) may trigger or accelerate the autoimmune response in genetically susceptible individuals.

Viral-Interferon Beta-Cell Autoimmunity Model

Downstream

Interferon-Driven Beta Cell Response Viral exposures may induce local islet interferon programs that make beta cells more immunogenic and stressed.

Persistent Low-Grade Islet Enteroviral Infection Enteroviral exposure can leave a low-abundance, non-cultivable viral footprint in islet cells rather than resolving as an acute lytic infection.

Gut-Pancreas Lymph Node Crosstalk Upper-intestinal viral infection can reprogram shared draining lymph-node immune traffic toward pancreatic islet inflammation in a mouse model.

Autoimmune Destruction of Beta Cells

Show evidence (5 references)

PMID:10522815 SUPPORT Human Clinical

"Various exogenous triggers, such as certain dietary factors and viruses, are thought to induce the autoimmune process leading in some individuals to extensive beta-cell destruction and ultimately to the clinical manifestation of type 1 diabetes."

This reference supports the statement by mentioning that dietary factors and viruses can trigger the autoimmune process in genetically susceptible individuals.

PMID:21162649 SUPPORT Human Clinical

"The ability to induce strong cellular immune responses and to cause inflammation in the target organ makes viral infections prime candidates for the initiation of islet autoreactivity."

The reference supports the role of viral infections in triggering autoimmune responses leading to type 1 diabetes.

PMID:18357774 SUPPORT Human Clinical

"The most often cited environmental agents implicated as initiators of T1D are the human enteroviruses, in particular the group B coxsackieviruses (CVB)."

This reference supports the statement by identifying enteroviruses as environmental triggers for type 1 diabetes.

+ 2 more references

Persistent Low-Grade Islet Enteroviral Infection

Enteroviral capsid protein and enteroviral RNA are detectable in islet cells of donors with type 1 diabetes and of autoantibody-positive donors without diabetes, at very low abundance and without recoverable replication-competent virus. The pattern fits a persisting, slowly replicating islet infection rather than an acute lytic one, and supplies a candidate standing stimulus for local antiviral interferon signaling.

Viral-Interferon Beta-Cell Autoimmunity Model

type B pancreatic cell CL:0000169

persisting enteroviral replication in islet cells GO:0019079 islet-cell antiviral defense response GO:0051607

pancreas UBERON:0001264

Downstream

Interferon-Driven Beta Cell Response Enteroviral capsid protein positivity in islet cells travels with HLA class I hyperexpression, the histological footprint of local interferon exposure.

Show evidence (2 references)

PMID:34390364 SUPPORT Human Clinical

"At least in some patients, the EV strain in the pancreatic islets may represent a slowly replicating persisting virus."

Laparoscopic biopsies from six living adults with newly diagnosed disease found enterovirus RNA in islets that could not be isolated in enterovirus-permissive cell lines, which the authors read as a slowly replicating persisting virus rather than an acute infection.

PMID:40090995 SUPPORT Human Clinical

"In contrast, VP1 positivity was found at higher frequency among T1D-ICI donors (77.5%, 31/40, p<0.001 vs all groups except AAb++)."

Enteroviral capsid protein is present in islet cells of most donors who have the disease and retain insulin-containing islets, and the same study detects it during the autoantibody-positive preclinical stage, so the infection is not simply a consequence of established diabetes.

Gut-Pancreas Lymph Node Crosstalk

Shared draining lymph nodes for the pancreas and upper small intestine may integrate gut-derived viral inflammation with pancreatic antigen presentation, shifting beta-cell-reactive T cells toward inflammatory phenotypes and increasing islet infiltration.

Viral-Interferon Beta-Cell Autoimmunity Model

migratory dendritic cell CL:0000451 beta-cell-reactive T cell CL:0000084

dendritic cell migration GO:0036336 adaptive immune response GO:0002250

lymph node UBERON:0000029 pancreas UBERON:0001264 duodenum UBERON:0002114

Downstream

Autoimmune Destruction of Beta Cells Pro-inflammatory shared lymph-node crosstalk may increase pancreatic islet lymphocyte infiltration and accelerate beta-cell autoimmunity.

Show evidence (1 reference)

PMID:37557168 SUPPORT Model Organism

"Our study uncovers immune crosstalk through LN co-drainage as a powerful force regulating pancreatic autoimmunity."

Model-organism evidence supports shared lymph-node co-drainage as a regulator of pancreatic autoimmunity and motivates curation as an emerging mechanism rather than established human causality.

Interferon-Driven Beta Cell Response

Type I and type II interferons upregulate antigen presentation and chemokine production in beta cells while downregulating oxidative phosphorylation, increasing immunogenicity and metabolic stress.

Viral-Interferon Beta-Cell Autoimmunity Model

type B pancreatic cell CL:0000169

type I interferon signaling pathway GO:0060337 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 chemokine production GO:0032602 oxidative phosphorylation GO:0006119 ↓ DECREASED defense response to virus GO:0051607

Downstream

Autoimmune Destruction of Beta Cells Interferon-exposed beta cells may amplify autoimmune recognition through antigen-presentation and chemokine programs.

Show evidence (5 references)

PMID:38409439 SUPPORT In Vitro

"The IFN-induced gene signatures have a strong correlation with those observed in beta cells from individuals with type 1 diabetes, and the level of expression of specific IFN-stimulated genes is positively correlated with proteins present in islets of these individuals, regulating beta cell..."

This study identifies interferons as key drivers of beta cell inflammatory responses, upregulating antigen presentation and chemokine production.

PMID:29305625 SUPPORT In Vitro

"IFN-α mediates a long-lasting and preferential MHC class I overexpression in human beta cells, which is not affected by the subsequent addition of JAK inhibitors."

Separates the reversible arms of the beta-cell interferon response from the durable one. Inflammation and ER stress markers decay within a day or two of cytokine withdrawal while surface MHC class I stays elevated for at least a week, so a transient interferon exposure leaves a lasting window of raised beta-cell immunogenicity that later JAK blockade does not reverse.

PMID:32444635 SUPPORT In Vitro

"Beta cells also up-regulate the checkpoint proteins PDL1 and HLA-E that may exert a protective role against the autoimmune assault."

The same interferon exposure that expands presented antigen also induces checkpoint ligands on beta cells, so this node carries protective as well as pro-autoimmune programs. Basis for the PD-L1 and HLA-E entries listed under chemical entities.

+ 2 more references

Autoimmune Destruction of Beta Cells

The immune system mistakenly targets and destroys insulin-producing beta cells in the pancreas through T cell-mediated cytotoxicity and autoantibody production.

type B pancreatic cell CL:0000169 CD8-positive, alpha-beta cytotoxic T cell CL:0000794 CD4-positive, alpha-beta T cell CL:0000624 regulatory T cell CL:0000815 B cell CL:0000236 dendritic cell CL:0000451 macrophage CL:0000235

T cell mediated cytotoxicity GO:0001913 autoantibody production GO:0002377 ⚠ ABNORMAL cytokine-mediated signaling pathway GO:0019221

pancreatic islet UBERON:0000006

Downstream

Insulin Deficiency Autoimmune destruction of pancreatic beta cells leads to absolute or near-absolute insulin deficiency.

Show evidence (8 references)

PMID:12185667 SUPPORT Human Clinical

"Type 1 diabetes mellitus is a T-cell-mediated autoimmune disease that results in the destruction of the insulin-producing beta cells in the pancreatic islets of Langerhans."

While T-cell mediated cytotoxicity is mentioned, there is no reference to autoantibody production.

PMID:23774118 SUPPORT Human Clinical

"Phenotypes of infiltrating cells around and/or into islets were mainly dendritic cells, macrophages and CD8+ T cells."

Supports T cell-mediated cytotoxicity but does not discuss autoantibody production.

PMID:27659143 SUPPORT Human Clinical

"The autoimmune destruction of the pancreatic islet beta cells is due to a targeted lymphocyte attack."

Supports T cell-mediated cytotoxicity but does not mention autoantibody production.

+ 5 more references

Insulin Deficiency

Loss of beta cells leads to a deficiency of insulin, a hormone required for glucose uptake.

Downstream

Hyperglycemia

Impaired Glucose Utilization

Increased Lipolysis

Show evidence (5 references)

PMID:35254878 SUPPORT Human Clinical

"Type 1 diabetes mellitus (T1DM) is an endocrine disorder in which pancreatic beta cells stop producing insulin, typically due to autoimmune destruction."

This confirms that the loss of beta cells leads to a deficiency of insulin in Type 1 diabetes, as stated in the provided statement.

PMID:21281836 NO_EVIDENCE Human Clinical

"Insulin resistance and defective glucose sensing at the beta-cell are the central pathophysiologic determinants that together cause hyperglycemia."

Although it primarily discusses prediabetes and Type 2 diabetes, the excerpt supports the idea that beta-cell issues lead to hyperglycemia.

PMID:2006409 SUPPORT Human Clinical

"Glucose uptake into pancreatic beta cells by means of the glucose transporter GLUT-2, which has a high Michaelis constant, is essential for the normal insulin secretory response to hyperglycemia."

This indicates the importance of beta cells in glucose regulation and the resulting hyperglycemia when their function is impaired.

+ 2 more references

Hyperglycemia

Lack of insulin results in high blood glucose levels, as glucose cannot be efficiently taken up by cells.

Downstream

Glucosuria

Polyuria

Polydipsia

Diabetic Ketoacidosis (DKA)

Show evidence (5 references)

PMID:33970586 SUPPORT Human Clinical

"Type 1 diabetes is defined as a state of hyperglycemia due to insulin deficiency caused by autoimmune pancreatic beta-cell destruction."

The abstract from PMID:33970586 confirms that type 1 diabetes is characterized by hyperglycemia due to insulin deficiency, which supports the statement regarding elevated blood glucose and related downstream effects.

PMID:37921158 SUPPORT Human Clinical

"HbA1c offers a trustworthy indicator of chronic hyperglycemia and strongly correlates with the likelihood of long-term consequences from diabetes."

Although this reference supports the relationship between elevated HbA1c and hyperglycemia, it does not specifically address all the downstream effects such as Glucosuria, Polyuria, Polydipsia, and Diabetic Ketoacidosis (DKA).

PMID:21281836 NO_EVIDENCE Human Clinical

"The phenotype of prediabetes includes dyslipidemia and higher arterial blood pressure."

This study does not specifically address the pathophysiology of type 1 diabetes or the particular assays and downstream effects mentioned in the statement.

+ 2 more references

Impaired Glucose Utilization

Without insulin, cells are unable to utilize glucose for energy production, leading to cellular energy deficiency.

Downstream

Weight Loss

Fatigue

Show evidence (2 references)

PMID:12477252 SUPPORT Human Clinical

"Type 1 or insulin-dependent diabetes mellitus is caused by autoimmune attack and selective destruction of the pancreatic beta cells."

The lack of insulin in type 1 diabetes mellitus leads to impaired glucose utilization as described in the statement.

PMID:15137354 SUPPORT Human Clinical

"The following article reviews the basic pathophysiology of both type 1 diabetes mellitus and type 2 diabetes mellitus as we understand it today."

This article explains that in diabetes, particularly type 1, the lack of insulin results in impaired glucose utilization, leading to characteristic symptoms like weight loss and fatigue.

ER Stress and Unfolded Protein Response

Inflammatory cytokines induce endoplasmic reticulum stress in beta cells, activating the unfolded protein response and contributing to beta cell dysfunction and apoptosis.

type B pancreatic cell CL:0000169

endoplasmic reticulum unfolded protein response GO:0030968 apoptotic process GO:0006915

Downstream

Autoimmune Destruction of Beta Cells

Show evidence (1 reference)

PMID:38409439 SUPPORT In Vitro

"The IFN-induced gene signatures have a strong correlation with those observed in beta cells from individuals with type 1 diabetes, and the level of expression of specific IFN-stimulated genes is positively correlated with proteins present in islets of these individuals, regulating beta cell..."

This study shows interferons drive beta cell stress responses including ER stress pathways that contribute to beta cell dysfunction and death.

Increased Lipolysis

Insulin deficiency also leads to increased breakdown of fat (lipolysis) for energy, resulting in the production of ketones.

Downstream

Diabetic Ketoacidosis (DKA)

Show evidence (3 references)

PMID:6409465 SUPPORT Human Clinical

"Insulin deficiency results in increased rates of lipolysis and provides increased substrate (free fatty acids) for ketogenesis."

The article explains that insulin deficiency leads to increased lipolysis, which eventually results in the production of ketone bodies. This supports the statement's claim about the pathophysiology involving lipolysis and ketone production in Type I Diabetes.

PMID:15137354 SUPPORT Human Clinical

"The article points out the signs and symptoms to be aware of when the person is in the acute state of diabetic ketoacidosis."

The article suggests that DKA is a critical concern in Type I Diabetes due to insufficient insulin, which is aligned with the statement indicating the downstream effect of heightened lipolysis and ketone production.

PMID:34922394 SUPPORT Human Clinical

"the involvement of B:9-23rPep-specific IFN-gamma-related immunoreactivity in the pathophysiology of some unprovoked A-beta+ KPD."

Although the study highlights immune responses related to ketosis-prone Type 2 Diabetes, it indirectly supports the notion that immune-mediated processes can contribute to ketosis and DKA.

Chronic Complications

Persistent hyperglycemia over time can lead to damage in various tissues and organs.

Downstream

Diabetic Retinopathy

Diabetic Neuropathy

Diabetic Nephropathy

Coronary Artery Disease

Stroke

Show evidence (4 references)

PMID:31346658 SUPPORT Human Clinical

"Hyperglycaemia, dyslipidaemia and hypertension combine with the duration and type of diabetes to define the distinct pathophysiology underlying diabetic kidney disease, diabetic retinopathy and diabetic neuropathy."

The literature indicates that hyperglycemia is a significant factor in the pathophysiology of diabetic complications including kidney disease (nephropathy), retinopathy, and neuropathy, thereby supporting the claim.

PMID:34407376 SUPPORT Human Clinical

"Hyperglycemia is the common denominator for most of the chronic diabetic vascular complications, which represent the main cause of life reduction in T1D patients."

This reference indicates that hyperglycemia underlies various chronic vascular complications in type 1 diabetes, thus supporting the statement.

PMID:3528691 SUPPORT Human Clinical

"The remaining 15 to 20% of patients have insulin-dependent diabetes mellitus, a disorder caused by the destruction of insulin-producing endocrine cells within the pancreas and currently considered to be the result of an autoimmune process. During the course of both types of diabetes mellitus,..."

The study confirms that type 1 diabetes, which involves insulin-dependent diabetes mellitus, results in long-term complications such as retinopathy, nephropathy, neuropathy, and cardiovascular disease.

+ 1 more reference

Diabetic Ketoacidosis (DKA)

Life-threatening metabolic emergency from insulin deficiency

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

16

Cardiovascular 2

Coronary Artery Disease Coronary artery atherosclerosis HP:0001677

Show evidence (1 reference)

PMID:16567818 SUPPORT Human Clinical

"Increased HRs were found for acute coronary events (3.0 and 7.6 in type 1 diabetic men and women, respectively, versus nondiabetic subjects), coronary revascularizations (5.0 in men, 16.8 in women)"

UK general-practice cohort (7,479 type 1 diabetic subjects vs. 38,116 age/sex-matched non-diabetic controls) quantifies elevated hazard ratios for acute coronary events and revascularization in type 1 diabetes.

Stroke HP:0001297

Show evidence (1 reference)

PMID:16567818 SUPPORT Human Clinical

"for stroke (3.7 in men, 4.8 in women)"

Same UK cohort quantifies elevated stroke hazard ratios in type 1 diabetic men and women versus non-diabetic controls.

Digestive 1

Vomiting FREQUENT HP:0002013

Endocrine 1

Diabetic Ketoacidosis OCCASIONAL HP:0001953

Life-threatening complication of insulin deficiency

Sequelae: Abdominal Pain Vomiting Rapid Breathing Confusion

Show evidence (4 references)

PMID:12474677 SUPPORT Human Clinical

"Diabetic ketoacidosis is an emergency medical condition that can be life-threatening if not treated properly. Diabetic ketoacidosis occurs most often in patients with type 1 diabetes (formerly called insulin-dependent diabetes mellitus); however, its occurrence in patients with type 2 diabetes..."

The literature supports that diabetic ketoacidosis is a life-threatening complication of type 1 diabetes and mentions symptoms such as abdominal pain and vomiting. However, it does not specify the frequency as 'occasional'.

PMID:17627511 SUPPORT Human Clinical

"A small group of patients affected by type 1 diabetes mellitus is characterized by a severe instability of glycemic values with frequent and unpredictable hypoglycemic and/or ketoacidosis episodes which cannot be explained by errors of patients or diabetologists."

This reference supports the occurrence of diabetic ketoacidosis in type 1 diabetes and mentions its life-threatening nature but does not confirm the frequency as 'occasional'.

PMID:15137354 SUPPORT Human Clinical

"The article points out the signs and symptoms to be aware of when the person is in the acute state of diabetic ketoacidosis, hyperglycemic hyperosmolar nonketotic coma (or state), and severe hypoglycemia."

The reference confirms that diabetic ketoacidosis is a life-threatening complication of type 1 diabetes and includes symptoms like confusion and rapid breathing but does not specify the frequency as 'occasional'.

+ 1 more reference

Eye 1

Diabetic Retinopathy HP:0000488

Leading cause of blindness, due to chronic hyperglycemia. Frequency band removed: every citation attached here is graded NO_EVIDENCE with an explanation stating the source does not establish frequency in type 1 diabetes, so OCCASIONAL was unsupported (and contradicted a now-removed duplicate entry asserting FREQUENT for the same HPO term).

Show evidence (4 references)

PMID:24864506 NO_EVIDENCE Human Clinical

"Diabetes mellitus (DM), due to its epidemic prevalence and high occurrence of associated disability, is now one of the priority medical and social problems. Incapacitating manifestations of diabetes include visual impairment. Thus, diabetic retinopathy (DR), a late nonspecific vascular..."

The literature mentions diabetic retinopathy as a leading cause of blindness in the working-age population but does not provide specific information on its frequency in Type I Diabetes.

PMID:37469057 NO_EVIDENCE Human Clinical

"The commonest morbidity was cataract12,607(28.8%), followed by refractive errors 8,508(19.5%), vision-threatening diabetic retinopathy 2,553(5.83%) and suspected glaucoma 1,211(2.76%)."

The study provides data on the prevalence of diabetic retinopathy in a diabetic population but does not specify it as occasional in Type I Diabetes.

PMID:38272591 SUPPORT Human Clinical

"Type 1 diabetes is associated with both acute and chronic complications. Acute complications include diabetic ketoacidosis and severe hypoglycemia. Chronic complications can be microvascular or macrovascular. Microvascular complications include retinopathy, nephropathy, and neuropathy."

Directly establishes retinopathy as a microvascular complication of type 1 diabetes, which is the phenotype claim. Reclassified from NO_EVIDENCE, which had been assigned because the source does not quantify frequency; the frequency band has now been removed from this phenotype instead.

+ 1 more reference

Genitourinary 3

Polyuria FREQUENT HP:0000103

Caused by osmotic diuresis from hyperglycemia

Show evidence (2 references)

PMID:35254878 SUPPORT Human Clinical

"Symptoms include polyuria, polydipsia, and weight loss."

This reference confirms that polyuria is a frequent symptom of Type I Diabetes.

PMID:2923250 SUPPORT Human Clinical

"Poorly controlled insulin-dependent diabetes mellitus is associated with considerable elevations of plasma vasopressin concentrations, although well-controlled diabetics have normal osmoregulated thirst and vasopressin release."

This reference discusses the association of poorly controlled insulin-dependent diabetes mellitus (Type I Diabetes) with symptoms such as polyuria.

Diabetic Nephropathy HP:0000112

Kidney damage from chronic hyperglycemia

Show evidence (4 references)

PMID:23290727 NO_EVIDENCE Human Clinical

"Renal failure in type 2 diabetes has been termed 'a medical catastrophe of worldwide dimension'."

This study primarily discusses renal failure in type 2 diabetes, not type 1 diabetes.

PMID:27903991 SUPPORT Human Clinical

"Diabetic nephropathy (DN) is a serious complication of diabetes mellitus, and its prevalence has been increasing in developed countries."

The study mentions diabetic nephropathy as a serious complication of diabetes mellitus in general, without specifying the frequency in type 1 diabetes.

PMID:1490695 SUPPORT Human Clinical

"The most serious complication of diabetes mellitus is clinical nephropathy."

The study highlights nephropathy as a serious complication of diabetes mellitus but does not specify its frequency in type 1 diabetes.

+ 1 more reference

Glucosuria FREQUENT Glycosuria HP:0003076

Metabolism 1

Hyperglycemia VERY_FREQUENT HP:0003074

Sequelae: Diabetic Ketoacidosis

Show evidence (3 references)

PMID:38272591 SUPPORT Human Clinical

"Type 1 diabetes is associated with both acute and chronic complications. Acute complications include diabetic ketoacidosis and severe hypoglycemia. Chronic complications can be microvascular or macrovascular. Microvascular complications include retinopathy, nephropathy, and neuropathy."

This source supports the statement by associating Type I Diabetes with hyperglycemia and chronic complications such as retinopathy and neuropathy, as well as acute complications like diabetic ketoacidosis.

PMID:28544185 SUPPORT Human Clinical

"Participation in prospective follow-up studies reduces the frequency of DKA in children at diagnosis of T1D, but genetic screening alone does not decrease DKA risk."

This source supports the statement by confirming that Diabetic Ketoacidosis (DKA) is a frequent acute complication in Type 1 Diabetes at the time of diagnosis.

PMID:34362315 SUPPORT Human Clinical

"Although SH was usually benign and long-term treatment was superfluous, it might be the first sign of insulinopenic status such as type 1 DM (T1DM)"

This source supports the statement by describing stress hyperglycemia as a potential initial presentation of Type 1 Diabetes, thereby confirming hyperglycemia as a very frequent occurrence.

Nervous System 3

Polydipsia FREQUENT HP:0001959

Excessive thirst due to dehydration from polyuria

Show evidence (1 reference)

PMID:35254878 SUPPORT Human Clinical

"Symptoms include polyuria, polydipsia, and weight loss."

The reference clearly states that polydipsia is a symptom of Type 1 Diabetes Mellitus, supporting the statement that it is a frequent systemic occurrence.

Diabetic Neuropathy Peripheral neuropathy HP:0009830

Nerve damage from chronic hyperglycemia

Show evidence (4 references)

PMID:28159476 SUPPORT Human Clinical

"Aggressive glucose control can result in treatment induced neuropathy of diabetes (TIND) if glycemic control is achieved too quickly."

This reference supports the statement by indicating that aggressive glycemic control can lead to diabetic neuropathy, which is a neurologic complication of Type I Diabetes.

PMID:33071962 SUPPORT Human Clinical

"Glycemic variability (GV) may attribute to the pathogenesis of diabetic neuropathy."

This reference supports the statement that diabetic neuropathy is a neurologic complication associated with glycemic variability, which can be linked to chronic hyperglycemia.

PMID:33715053 NO_EVIDENCE Human Clinical

"Emerging evidence suggests that hyperglycemia and time in range may be more important for brain development than episodes of hypoglycemia."

This reference supports the statement by highlighting the role of hyperglycemia in neurocognitive complications, which can be related to diabetic neuropathy in Type I Diabetes.

+ 1 more reference

Confusion FREQUENT HP:0001289

Respiratory 1

Rapid Breathing FREQUENT Tachypnea HP:0002789

Constitutional 2

Fatigue FREQUENT HP:0012378

Abdominal Pain FREQUENT HP:0002027

Growth 1

Weight Loss FREQUENT HP:0001824

Due to inability to utilize glucose for energy

Show evidence (5 references)

PMID:23075321 SUPPORT Human Clinical

"Immune-mediated (auto-immune) Type 1 diabetes mellitus is not a homogenous entity, but nonetheless has distinctive characteristics. In children, it may present with classical insulin deficiency and ketoacidosis at disease onset, whereas autoimmune diabetes in adults may not always be insulin dependent."

The source does indicate that Type 1 diabetes has varied presentations, including insulin deficiency and potentially weight loss due to failure to utilize glucose. However, the excerpt does not specifically mention weight loss as a frequent phenotype.

PMID:12949265 NO_EVIDENCE Human Clinical

The provided literature does not directly discuss weight loss as a frequent systemic phenotype of Type 1 diabetes.

PMID:11508279 NO_EVIDENCE Human Clinical

This reference discusses the Accelerator Hypothesis and weight gain in diabetes but does not address weight loss in Type 1 diabetes.

+ 2 more references

🧬

Genetic Associations

13

HLA-DQ2 (Susceptibility)

relationship_type: RISK_FACTOR variant_origin: GERMLINE

Affected regions (reference genome)

HLA-DQ2.5 haplotype (DQA1*05-DQB1*02)

Overlaps genes: HLA-DQA1 hgnc:4942 HLA-DQB1 hgnc:4944

The DQ2.5 risk molecule is encoded by a cis haplotype of HLA-DQA1*05 and HLA-DQB1*02 alleles in the HLA class II region; both genes contribute a chain of the antigen-presenting heterodimer.

Show evidence (2 references)

PMID:22184118 SUPPORT Human Clinical

"HLA-DQ2 and HLA-DQ8 are strongly predisposing haplotypes for type 1 diabetes (T1D)."

This study identifies HLA-DQ2 as a strongly predisposing haplotype for type 1 diabetes susceptibility.

PMID:31331105 SUPPORT BACKGROUND Human Clinical

"HLA DQA1*05 and DQB1*02 alleles encoding the DQ2.5 molecule and HLA DQA1*03 and DQB1*03 alleles encoding DQ8 molecules are strongly associated with celiac disease (CD) and type 1 diabetes (T1D)"

Identifies the HLA-DQA1 and HLA-DQB1 alleles that together encode the DQ2.5 risk molecule.

HLA-DQ8 (Susceptibility)

relationship_type: RISK_FACTOR variant_origin: GERMLINE

Affected regions (reference genome)

HLA-DQ8 haplotype (DQA1*03:01-DQB1*03:02)

Overlaps genes: HLA-DQA1 hgnc:4942 HLA-DQB1 hgnc:4944

The DQ8 risk molecule is encoded by a cis haplotype of HLA-DQA1*03:01 and HLA-DQB1*03:02 alleles in the HLA class II region.

Show evidence (3 references)

PMID:22184118 SUPPORT Human Clinical

"HLA-DQ2 and HLA-DQ8 are strongly predisposing haplotypes for type 1 diabetes (T1D)."

This statement specifically mentions HLA-DQ8 as a strong predisposing haplotype for type 1 diabetes, supporting the association with susceptibility.

PMID:26492519 SUPPORT Human Clinical

"The DR3-DQ2/DR4-DQ8 genotype conferred the highest detected risk for T1D."

This study identifies the DR4-DQ8 genotype as highly associated with a risk for developing type 1 diabetes, thus supporting the genetic susceptibility.

PMID:34946827 SUPPORT Human Clinical

"The combination of HLA-DQA1*03:01 and DQB1*03:02 alleles (summarized as 'HLA-DQ8') is reported to be among the two most prevalent HLA class II haplotypes in Caucasian type 1 diabetes patients."

This reference confirms that HLA-DQ8 is one of the most prevalent haplotypes among type 1 diabetes patients in the studied population, supporting its association with susceptibility.

INS (Susceptibility)

Gene: INS hgnc:6081 gene page relationship_type: SUSCEPTIBILITY variant_origin: GERMLINE

Show evidence (6 references)

PMID:15529622 SUPPORT Human Clinical

"Our results indicate an exceptionally strong association of the class I INS-VNTR alleles with T1DM for the Romanian population."

The study presents evidence of a strong association between INS-VNTR alleles of the insulin gene and susceptibility to type 1 diabetes in the Romanian population.

PMID:8934932 SUPPORT Human Clinical

"Genetic susceptibility predominantly results from specific alleles in the HLA complex and insulin gene region."

This paper states that genetic susceptibility to insulin-dependent diabetes mellitus predominantly results from specific alleles, including those in the insulin gene region.

PMID:11845220 SUPPORT Human Clinical

"However, only within the past decade has it been possible to systematically attempt to identify the genes that increase susceptibility to this disorder using linkage and association analysis of genetic markers distributed across the genome."

This study discusses the identification of susceptibility genes for type 1 diabetes, including the insulin gene.

+ 3 more references

PTPN22 (Susceptibility)

Gene: PTPN22 hgnc:9652 gene page relationship_type: SUSCEPTIBILITY variant_origin: GERMLINE

Show evidence (1 reference)

PMID:15734872 SUPPORT Human Clinical

"The homozygous genotype for the T allele encoding the 620W residue is associated with an increased risk for developing type 1 diabetes"

This study demonstrates that the PTPN22 R620W polymorphism confers significant genetic susceptibility to type 1 diabetes in Caucasian populations.

IL2RA (Susceptibility)

Gene: IL2RA hgnc:6008 gene page relationship_type: SUSCEPTIBILITY variant_origin: GERMLINE

Show evidence (1 reference)

PMID:22461703 SUPPORT Human Clinical

"CD4(+)CD25(+) regulatory T cells (Tregs) from individuals with a range of human autoimmune diseases, including type 1 diabetes, are deficient in their ability to control autologous proinflammatory responses"

This study demonstrates that IL2RA variants associated with type 1 diabetes lead to diminished IL-2 responsiveness and impaired regulatory T cell function.

CTLA4 (Susceptibility)

Gene: CTLA4 hgnc:2505 gene page relationship_type: SUSCEPTIBILITY variant_origin: GERMLINE

Show evidence (1 reference)

PMID:9353155 SUPPORT Human Clinical

"the presence of a G-containing CTLA-4 genotype confers a moderate but significant RR for IDDM that is independent of age and genetic or immune disease markers"

This study demonstrates that CTLA4 gene polymorphisms confer susceptibility to type 1 diabetes independent of other genetic and immune markers.

TYK2 (Susceptibility)

Gene: TYK2 hgnc:12440 gene page relationship_type: SUSCEPTIBILITY variant_origin: GERMLINE

Show evidence (1 reference)

PMID:26239055 SUPPORT In Vitro

"TYK2-silenced human β-cells exposed to polyinosinic-polycitidilic acid (PIC) (a mimick of double-stranded RNA produced during viral infection) showed less type I IFN pathway activation and lower production of IFNα and CXCL10."

Places the protective TYK2 variants on the beta-cell side of the viral interferon model. Silencing TYK2 in human beta cells blunts the type I interferon response, chemokine output and MHC class I induction that follow a viral RNA mimic, matching the reduced disease risk carried by loss-of-function alleles.

IFIH1 (Susceptibility)

Gene: IFIH1 hgnc:18873 gene page relationship_type: SUSCEPTIBILITY variant_origin: GERMLINE

Show evidence (3 references)

PMID:35867130 SUPPORT Human Clinical

"Furthermore, we found that individuals carrying the predisposing allele (946Thr) of the common variant in IFIH1 (rs1990760, Thr946Ala) are more likely to test positive for enterovirus in peripheral blood (OR 3.07; 95% CI 1.02, 8.58; p=0.045)."

Links the IFIH1 risk allele to measurable enterovirus carriage in patients, which is the genetic-environmental junction the viral interferon model requires. The odds ratio is modest with a confidence interval close to unity.

PMID:35867130 REFUTE Human Clinical

"In contrast, using immunohistochemistry, there was no correlation between the common variant in IFIH1 and detection of enteroviral VP1 protein in the pancreatic islets of donors with type 1 diabetes."

The same study finds no relationship between the IFIH1 variant and enteroviral protein in the target organ. Carried alongside the positive blood result so the genotype-to-islet step is not read as established.

PMID:39373578 SUPPORT INDIRECT In Vitro

"We found that in cell lines overexpressing the risk variant IFIH1946T there was an elevated level of basal type I IFN signaling and increased basal IFN-stimulated gene expression."

Supplies the proposed mechanism, a gain of basal interferon signaling by the risk MDA5 protein, but only in overexpressing cell lines. The same paper saw no significant change in type I interferon or interferon stimulated genes in primary blood mononuclear cells from risk-allele carriers infected with coxsackievirus B3, so the effect is graded indirect.

BACH2 (Susceptibility)

Gene: BACH2 hgnc:14078 gene page relationship_type: SUSCEPTIBILITY variant_origin: GERMLINE

TNFAIP3 (GWAS)

Gene: TNFAIP3 hgnc:11896 gene page relationship_type: SUSCEPTIBILITY variant_origin: GERMLINE

EGR2 (GWAS)

Gene: EGR2 hgnc:3239 gene page relationship_type: SUSCEPTIBILITY variant_origin: GERMLINE

IRF4 (GWAS)

Gene: IRF4 hgnc:6119 gene page relationship_type: SUSCEPTIBILITY variant_origin: GERMLINE

IKZF1 (GWAS)

Gene: IKZF1 hgnc:13176 gene page relationship_type: SUSCEPTIBILITY variant_origin: GERMLINE

💊

Medical Actions

10

Insulin Therapy

Action: insulin treatment Ontology label: Injected Insulin Diabetes Therapy NCIT:C179441

Essential treatment to replace the missing insulin and regulate blood glucose levels.

Mechanism Target:

RESTORES Insulin Deficiency — Type 1 diabetes is absolute insulin deficiency from autoimmune beta-cell loss, so treatment is hormone REPLACEMENT: exogenous insulin directly corrects the deficiency node, normalizing the downstream metabolic abnormalities (hyperglycemia, lipolysis) and attenuating complications. This is the graph-level distinction from type 2 — insulin acts on the deficiency itself, not on insulin resistance or hepatic glucose output.

Show evidence (9 references)

PMID:21584767 SUPPORT Human Clinical

"Insulin therapy is a vital hormone replacement therapy in type 1 diabetes mellitus."

PMID:36476434 SUPPORT Human Clinical

"The current standard method for type 1 diabetes (T1D) management majorly focuses on controlling blood glucose levels with exogeneous insulin administration."

PMID:32342453 SUPPORT Human Clinical

"T1DM is caused by absolute lack of insulin secretion, so the current treatment for T1DM patients is exogenous insulin replacement therapy."

+ 6 more references

Blood Glucose Monitoring

Action: blood glucose assessment Ontology label: Blood Glucose Measurement NCIT:C92744

Regular monitoring to manage glucose levels effectively.

Show evidence (4 references)

PMID:30215903 SUPPORT Human Clinical

"There is considerable benefit of tight glucose control in patients with type 1 diabetes mellitus. ... Greater frequency of glucose monitoring and continuous glucose monitoring are both associated with lower A1C levels."

The abstract emphasizes the importance of glucose monitoring in managing type 1 diabetes, supporting the statement that regular monitoring is crucial for effective glucose level management.

PMID:32256447 SUPPORT Human Clinical

"Regular self-monitoring of blood glucose levels, and ketones when indicated, is an essential component of type 1 diabetes (T1D) management."

The abstract reaffirms that regular monitoring of blood glucose is essential for managing type 1 diabetes, supporting the statement.

PMID:38551884 SUPPORT Human Clinical

"Blood glucose monitoring has been an integral part of diabetes treatment for many years, whether for type 1 diabetic patients on multiple daily injections of insulin, insulin pumps or artificial pancreas, and now for patients with type 2 diabetes..."

The abstract describes blood glucose monitoring as a cornerstone in diabetes treatment, which includes the management of type 1 diabetes, thus supporting the statement.

+ 1 more reference

Lifestyle Modifications

Action: Lifestyle Therapy NCIT:C15900

Maintaining a balanced diet, regular physical activity, and adherence to treatment plans.

Show evidence (5 references)

PMID:9314011 SUPPORT Human Clinical

"Nutrition therapy and physical activity can assist persons with diabetes to achieve metabolic goals. Several lifestyle strategies can be used."

The text supports the assertion that maintaining a balanced diet and regular physical activity can assist in managing diabetes through lifestyle modifications.

PMID:16529680 SUPPORT Human Clinical

"The patient and physician must work together to optimize glucose control involving both insulin administration and caloric intake. Exercise has numerous benefits and the type 1 diabetic should take advantage of these benefits."

This supports the statement that lifestyle modifications, including diet and physical activity, are important in managing type 1 diabetes.

PMID:24485215 SUPPORT Human Clinical

"Poor lifestyle habits (poor diet quality, sedentary behaviours and smoking) are known to be driving factors for increased CMR factors in the general population."

The text underlines the significance of maintaining a good lifestyle, including a balanced diet and physical activity, as part of diabetes management.

+ 2 more references

Immunotherapy (Teplizumab)

Action: Pharmacotherapy NCIT:C15986

Agent: teplizumab NCIT:C88647

Platform: Monoclonal antibody

T-cell-targeting therapy that delays progression from stage 2 to stage 3 disease by approximately 2-3 years in early-stage patients.

Mechanism Target:

INHIBITS Autoimmune Destruction of Beta Cells — Teplizumab (anti-CD3 monoclonal antibody) targets the autoimmune T-cell attack itself — the upstream driver node — rather than its downstream metabolic consequences, blunting T-cell-mediated beta-cell destruction to delay progression from Stage 2 to clinical Stage 3 disease. It is the only T1D therapy that acts on the autoimmune mechanism node instead of the insulin-deficiency/hyperglycemia consequences, which is why it is disease-modifying (delays onset) rather than purely glucose-lowering.

Show evidence (1 reference)

PMID:36877454 SUPPORT Human Clinical

"In November 2022, teplizumab was approved in the USA to delay the onset of Stage 3 T1D in adults and pediatric patients 8 years of age and older with Stage 2 T1D"

This article documents the FDA approval of teplizumab as the first immunotherapy for delaying type 1 diabetes progression.

Rituximab (Anti-CD20 Immunotherapy)

Action: Pharmacotherapy NCIT:C15986

Agent: rituximab NCIT:C1702

Platform: Monoclonal antibody

B-cell-depleting monoclonal antibody targeting CD20-expressing autoantibody-producing B cells to delay beta-cell destruction in recent-onset disease.

Mechanism Target:

INHIBITS Autoimmune Destruction of Beta Cells — Rituximab depletes CD20+ B cells responsible for producing islet autoantibodies, thereby reducing the autoimmune attack on beta cells and delaying functional decline.

Show evidence (2 references)

PMID:42496430 SUPPORT Human Clinical

"The administration of rituximab results in the depletion of autoantibody-producing B cells and delayed C-peptide decline by approximately 8.2 months in a phase 2 trial of recent-onset T1DM"

Phase 2 trial data demonstrate rituximab's mechanism of B-cell depletion leads to measurable preservation of residual beta-cell function.

PMID:42496430 REFUTE Human Clinical

"A subsequent trial combining rituximab with autologous expanded regulatory T cells (Tregs) did not achieve statistically significant delay in disease progression, despite numerically improved outcomes compared with Treg monotherapy"

The follow-on combination trial failed to reproduce a significant delay in progression, so this source does not support rituximab as an established disease-modifying therapy.

Abatacept (Costimulation Blockade)

Action: Pharmacotherapy NCIT:C15986

Agent: abatacept NCIT:C28898

Platform: Other

CTLA4-Ig fusion protein that blocks T-cell costimulation to reduce autoreactive T-cell activation and beta-cell destruction.

Mechanism Target:

INHIBITS Autoimmune Destruction of Beta Cells — Abatacept blocks CD80/CD86-CD28 T-cell costimulatory signaling, impairing autoreactive T-cell activation and reducing beta-cell-directed immune attack.

Show evidence (1 reference)

PMID:42496430 SUPPORT Human Clinical

"Abatacept (costimulation blockade), low-dose IL-2 (to expand regulatory T cells), and golimumab (anti-TNF-α) have each shown biological activity in phase 2 trials"

Phase 2 trial data report biological activity for costimulation blockade in type 1 diabetes.

Golimumab (Anti-TNF-α Therapy)

Action: Pharmacotherapy NCIT:C15986

Agent: golimumab NCIT:C87766

Platform: Monoclonal antibody

TNF-α inhibitor that reduces pro-inflammatory signaling driving beta-cell autoimmunity and preserves residual beta-cell function.

Mechanism Target:

INHIBITS Autoimmune Destruction of Beta Cells — Golimumab inhibits TNF-α-mediated inflammatory signaling that drives T-cell activation and beta-cell destruction, preserving remaining functional beta cells.

Show evidence (1 reference)

PMID:42496430 SUPPORT Human Clinical

"golimumab (anti-TNF-α) have each shown biological activity in phase 2 trials, including a 43% reduction in C-peptide decline with golimumab after 52 weeks"

Phase 2 trial data demonstrate significant C-peptide preservation with TNF-α inhibition in recent-onset disease.

Rotavirus Vaccination

Action: Vaccination NCIT:C15346

Agent: rotavirus vaccine NCIT:C96394

Platform: Vaccine

Vaccine strategy investigated on the basis of a reduced T1DM incidence observed in rotavirus-vaccinated cohorts.

Show evidence (1 reference)

PMID:42496430 SUPPORT Human Clinical

"A large nationwide cohort study by Rogers et al. (2019) reported a 33% reduction in T1DM risk associated with the completion of all rotavirus vaccine doses"

Population-level cohort evidence demonstrates protective association between rotavirus vaccination and reduced type 1 diabetes incidence.

BCG Vaccination

Action: Vaccination NCIT:C15346

Agent: BCG vaccine NCIT:C298

Platform: Vaccine

Bacillus Calmette-Guérin vaccine proposed to modulate T-lymphocyte responses and delay T1DM progression in at-risk individuals.

Mechanism Target:

INHIBITS Autoimmune Destruction of Beta Cells — BCG vaccine modulates T-lymphocyte responses, favoring regulatory and cytotoxic T-cell populations, thereby reducing pathogenic T-cell-mediated beta-cell destruction.

Show evidence (1 reference)

PMID:42496430 SUPPORT Human Clinical

"The Bacillus Calmette–Guérin (BCG) vaccine has been proposed to confer some protection against T1DM progression, with one study by Doupis et al. (2021) reporting a delay of approximately 2.5 years with a single dose administered at age 9"

One study reported a delay in T1DM progression after a single BCG dose, the observation behind the proposed immunomodulatory mechanism.

Continuous Glucose Monitoring

Action: continuous blood glucose assessment Ontology label: Blood Glucose Measurement NCIT:C92744

Real-time glucose monitoring systems for improved glycemic control and reduced hypoglycemic events.

Show evidence (1 reference)

PMID:34872983 SUPPORT Human Clinical

"After CGM introduction, the odds ratio (OR) of achieving the HbA1c target of <7.0% improved at 12 months (OR 2.5, P < 0.001) and was maintained at 24 months"

This population-based study demonstrates that continuous glucose monitoring significantly improves glycemic control with sustained improvements in HbA1c target achievement.

🌍

Environmental Factors

2

Viral Infections

May trigger the autoimmune response in genetically susceptible individuals

Show evidence (9 references)

PMID:23393684 SUPPORT Other

"One of the environmental risk factors identified by a series of independent studies is represented by viral infection, with strong evidence showing that viruses can indeed infect pancreatic beta cells with consequent effects ranging from functional damage to cell death."

This reference mentions that viral infections are a strong environmental risk factor for Type I Diabetes, affecting pancreatic beta cells which can lead to autoimmunity.

PMID:22891485 SUPPORT Human Clinical

"Environmental factors must be involved such as viral infections, toxins from food, cow milk during childhood (instead of breast feeding) or vitamin D deficiency."

This reference suggests that viral infections are among several environmental factors associated with Type I Diabetes, but does not pinpoint them as the singularly most critical factor.

PMID:34942009 SUPPORT Human Clinical

"Enteroviruses, especially CoxB and Echo, are most represented."

This reference supports the role of viral infections in Type I Diabetes, mentioning enteroviruses among others.

+ 6 more references

Mechanism Target:

TRIGGERS Environmental Triggers — This node names viral infection in its own text as a trigger acting in genetically susceptible individuals, so the exposure is the node's own content. The evidence is unusually deep for this backfill, and the two items carried here are the two that do different work: one takes the virus as far as the beta cell, and the other is the single infection the literature treats as settled rather than candidate.

Show evidence (2 references)

PMID:23393684 SUPPORT Other

"One of the environmental risk factors identified by a series of independent studies is represented by viral infection, with strong evidence showing that viruses can indeed infect pancreatic beta cells with consequent effects ranging from functional damage to cell death."

States that viruses can infect pancreatic beta cells with effects ranging from functional damage to cell death. It reaches the target tissue rather than stopping at association.

PMID:11334504 SUPPORT Other

"Congenital rubella is the only infection clearly associated with the development of type 1A diabetes."

Names congenital rubella as the only infection clearly associated with the disease. The word clearly is doing real work: most of this entry's viral evidence is explicitly candidate-level, and this item is not.

Early Dietary Factors

Possible risk factors include early exposure to cow's milk and gluten

Show evidence (4 references)

PMID:8741809 SUPPORT Other

"There is a relationship between early cow's milk exposure and the development of Type 1 diabetes in humans, and between early cow's milk exposure and the development of autoimmune diabetes in rodent models of Type 1 diabetes."

The reference supports early dietary factors such as cow's milk exposure but indicates that the data are insufficient to conclude a causal relationship.

PMID:26605913 NO_EVIDENCE Human Clinical

"Recently, the results of two large randomized trials have shown that breastfeeding in general, breastfeeding during gluten introduction, and early or delayed gluten introduction do not influence the total risk of CD in genetically predisposed individuals."

The reference suggests that early or delayed introduction of gluten does not influence the risk of celiac disease, type 1 diabetes mellitus, and wheat allergy, providing no supporting evidence for early dietary factors as risk factors for Type 1 diabetes.

PMID:20640941 SUPPORT Other

"Given that type 1 diabetes, and its preclinical autoimmunity, appear early in life, infant and childhood diet have been implicated as potential initiating exposures in the etiology of the disease."

The reference implicates early dietary factors in the risk of Type 1 diabetes but also highlights inconsistencies and the need for further research.

+ 1 more reference

Mechanism Target:

PREDISPOSES Environmental Triggers — Named at the same node as viral infection but graded below it throughout, because the evidence points both ways and the entry already records that. The refuting item is carried on the link deliberately rather than left in the exposure block: the TRIGR trial removed intact cow's milk protein from infant feeding, measured type 1 diabetes itself, and found no reduction over a median of 11.5 years. Keeping it here means the negative result travels with the claim rather than sitting where a reader of the pathograph would never meet it. An earlier version of this link carried a different negative trial summary whose endpoint was celiac disease rather than this disease; that item has no bearing on the claim and was removed.

Show evidence (3 references)

PMID:8741809 SUPPORT Other

"There is a relationship between early cow's milk exposure and the development of Type 1 diabetes in humans, and between early cow's milk exposure and the development of autoimmune diabetes in rodent models of Type 1 diabetes."

Reports a relationship between early cow's milk exposure and the disease in humans and in rodent models. An association, and the entry's own explanation concedes the data do not establish causation.

PMID:29297078 REFUTE Human Clinical

"Among infants at risk for type 1 diabetes, weaning to a hydrolyzed formula compared with a conventional formula did not reduce the cumulative incidence of type 1 diabetes after median follow-up for 11.5 years"

The TRIGR trial removed intact cow's milk protein from infant feeding and measured type 1 diabetes itself over a median 11.5 years. It found no reduction, which is evidence against the cow's milk hypothesis this exposure rests on. Carried on the link so the negative result is visible at the point of the claim rather than only in the exposure block.

PMID:20640941 SUPPORT Other

"Given that type 1 diabetes, and its preclinical autoimmunity, appear early in life, infant and childhood diet have been implicated as potential initiating exposures in the etiology of the disease."

Notes that because the disease and its preclinical autoimmunity appear early in life, infant diet has been implicated as a potential initiating exposure. Implication rather than finding.

🔬

Biochemical Markers

3

Blood Glucose (Elevated)

Show evidence (3 references)

PMID:6378696 SUPPORT Human Clinical

"Elevations of fasting blood glucose and peak glucose during oral glucose tolerance tests were not observed until the year before onset of clinically overt diabetes."

This reference suggests that elevated blood glucose is present, but only becomes noticeable in the year before the onset of type 1 diabetes, not necessarily 'VERY_FREQUENT' earlier on.

PMID:33595181 NO_EVIDENCE Human Clinical

"Glycogenic hepatopathy (GH) in type 1 diabetes-mellitus (T1DM) is characterized by hepatomegaly and perturbations of liver chemistries (LC) that have not been well studied."

The focus of this study is on liver chemistries in glycogenic hepatopathy associated with type 1 diabetes, not specifically on the frequency of elevated blood glucose.

PMID:18502304 SUPPORT Human Clinical

"Type 1 diabetes is associated with a substantially increased risk of cardiovascular disease... microvascular complications...hyperglycaemia is indeed a mediator of cardiovascular risk in type 1 diabetes."

This reference supports that elevated blood glucose (hyperglycaemia) is a common and significant factor in type 1 diabetes, indicating that it is 'VERY_FREQUENT'.

Hemoglobin A1c (HbA1c) (Elevated)

Show evidence (2 references)

PMID:22847316 SUPPORT Human Clinical

"The measure of glycated hemoglobin (HbA1c) concentration is the gold standard of glycemic control index in diabetes management and is well known as a marker for diabetes complications."

Hemoglobin A1c is frequently measured in the management of diabetes, including Type I diabetes, and elevated levels are indicative of poor glycemic control.

PMID:26397266 SUPPORT Human Clinical

"Hemoglobin A1c is the accepted measure of long-term plasma glucose control in diabetics (levels >/=7 percent reflect poor blood glucose control)."

Elevated HbA1c levels are a common indicator used in the management of diabetes, supporting the claim of frequent elevated HbA1c in Type I diabetes.

NMR metabolomic risk score (MetRS)

Context: In the UK Biobank metabolome-phenome atlas, MetRS classified prevalent type 1 diabetes with an area under the curve of 0.944, the highest of the four diagnostic areas under the curve the source reports (type 1 diabetes 0.944, type 2 diabetes 0.941, diabetic maculopathy 0.940, chronic kidney disease 0.933). The source does not rank it highest across the whole analysis, and this entry does not claim that. No presence value is recorded because MetRS is a derived multi-analyte score rather than a measured analyte. The score is a readout of the systemic metabolic consequences of insulin deficiency in people who already have the disease; it carries no information about islet autoimmunity, and nothing here supports using metabolomics in place of autoantibody-based staging or to distinguish type 1 from type 2 diabetes. The cohort is middle-aged and older adult volunteers, so prevalent cases are largely long-standing and insulin-treated.

Pathograph Readouts

Correlates With Hyperglycemia Positive Diagnostic

The glycolysis-related, ketone-body, amino-acid and lipoprotein measures that dominate MetRS shift with sustained hyperglycemia and insulin deficiency, so the score reads out the systemic metabolic state rather than the autoimmune process that causes it.

Show evidence (1 reference)

PMID:40973818 SUPPORT Computational

"The MetRS witnessed excellent diagnosis for type 1 diabetes (T1D; AUC = 0.944), T2D (AUC = 0.941), diabetic maculopathy (AUC = 0.940) and chronic kidney disease (CKD; AUC = 0.933)."

Quotes the reported diagnostic areas under the curve directly, giving both the type 1 diabetes figure of 0.944 and the three comparators it is ranked against in the context field.

📈

Progression

1

Onset

Age: Childhood-Adolescence

Show evidence (5 references)

PMID:33825933 SUPPORT Human Clinical

"The incidence of type 1 diabetes (T1D) has been rising steadily over the last 30 years, especially among children and adolescents, with the result that the number of cases in this age group doubles every 20 years."

This study discusses the rising incidence of type 1 diabetes in children and adolescents, which aligns with the progression of T1D during childhood and adolescence.

PMID:30628751 SUPPORT Human Clinical

"Twenty-one percent of subjects developed T1D by age 6. Logistic regression modeling identified 5 significant predictors."

This study focuses on predictors of T1D progression in children with high-risk HLA genes followed in The TEDDY study, providing partial support since it includes childhood but doesn't explicitly cover adolescence.

PMID:26404926 SUPPORT Human Clinical

"Stage 3 as onset of symptomatic disease ... Adoption of this staging classification provides a standardized taxonomy for type 1 diabetes."

This reference discusses the presymptomatic stages of T1D leading to symptomatic onset, supporting the progression during childhood and adolescence.

+ 2 more references

📊

Prevalence

1

Global

0.1-0.2

Show evidence (3 references)

PMID:34599655 REFUTE Human Clinical

"Global numbers of incident and prevalent cases of type 1 diabetes were estimated to be 234,710 and 9,004,610, respectively, in 2017...Globally, type 1 diabetes represents about 2% of the estimated total cases of diabetes."

The prevalence of type 1 diabetes globally is estimated to be around 2%, not 0.1-0.2%.

PMID:16085737 NO_EVIDENCE Human Clinical

"The global prevalence of diabetes for all age groups is estimated to be 2.8%. Type 2 diabetes accounts for at least 90% of diabetes worldwide."

This study provides global prevalence data for diabetes in general and specifically mentions Type 2 diabetes but does not give a percentage for the prevalence of Type 1 diabetes.

PMID:27959859 REFUTE Human Clinical

"The incidence of childhood-onset type 1 diabetes has been increasing at a rate of 3%-5% per year globally...no means for a practical 'cure' exist."

The increasing incidence suggests a prevalence higher than 0.1-0.2%.

📊

Related Datasets

2

Whole exome sequencing in family trios reveals de novo mutations associated to Type 1 Diabetes Mellitus ega:EGAS00001007010

human WES

European Genome-phenome Archive study, matched because the disease is named in the study's own title ("type 1 diabetes mellitus"); description-level mentions were not accepted. EGA study_type: Exome Sequencing. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.

Proteomics of high density lipoprotein subfractions in type 1 diabetes mellitus and controls massive:MSV000087986

Toyoshima MTK. Proteomics and functionality of high-density lipoprotein subfractions and subclinical cardiovascular disease in type 1 diabetes mellitus. Faculdade de Medicina, Universidade de Sao Paulo 2021.

Located via OmicsDI, which aggregates across omics repositories; this record comes from massive. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("type 1 diabetes mellitus"). Retrieved 2026-08-02.

{ }

Source YAML

click to show

name: Type I Diabetes
creation_date: '2025-12-04T16:57:31Z'
description: >-
  Type 1 diabetes is a chronic autoimmune disease in which T-cell-mediated
  destruction of insulin-producing pancreatic beta cells leads to absolute
  insulin deficiency and lifelong dependence on exogenous insulin. Genetic
  susceptibility (notably HLA class II haplotypes) combines with environmental
  triggers to break immune tolerance, producing islet autoantibodies and
  progressive beta-cell loss. The resulting hyperglycemia drives osmotic
  symptoms, predisposes to diabetic ketoacidosis, and over time causes
  microvascular and macrovascular complications.
category: Metabolic Disorder
parents:
- Autoimmune Disease
- Diabetes Mellitus
mechanistic_hypotheses:
- hypothesis_group_id: viral_interferon_beta_cell_autoimmunity_model
  hypothesis_label: Viral-Interferon Beta-Cell Autoimmunity Model
  status: EMERGING
  description: >-
    Enteroviral or other viral exposure in a genetically susceptible host
    induces interferon signaling in pancreatic islets, increasing beta-cell
    antigen presentation, chemokine release, and stress programs that may
    bridge innate antiviral responses to durable adaptive beta-cell
    autoimmunity.
  notes: >-
    Retained as EMERGING per the 2026 openscientist hypothesis-search report
    (kb/hypotheses/Type_I_Diabetes/viral_interferon_beta_cell_autoimmunity_model/openscientist.md).
    The report judged the model partially supported: the beta-cell interferon
    arm is the best-supported component, while pathogen-specific causality,
    same-person temporal ordering from viral exposure to autoantibody
    seroconversion, and applicability beyond rapid/fulminant presentations
    remain unresolved. Kept at EMERGING after a 2026 assessment of that report
    even though both arms now have a positive interventional trial behind them,
    because both are phase 2 with no replication: antiviral treatment
    (pleconaril plus ribavirin, n=96) and JAK inhibition (baricitinib, n=91)
    each preserved stimulated C-peptide in new-onset disease. The report also
    overstated two of its own sources, reading a co-expressed islet signature as
    a timed interferon to chemokine to MHC sequence and attaching the wrong odds
    ratio to the IFIH1 risk allele; both are corrected where the underlying
    findings are curated.
  evidence:
  - reference: PMID:40375390
    reference_title: "Type 1 Diabetes: A Guide to Autoimmune Mechanisms for Clinicians."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      epidemiological data point to a role of environmental factors, notably
      enteroviral infections, in the disease, although precise causative links
      between specific pathogens and T1D have been difficult to establish.
    explanation: >-
      Review evidence supports enteroviral infection as an epidemiologic lead
      while explicitly preserving the knowledge gap around specific causal
      pathogens.
  - reference: PMID:38409439
    reference_title: "Interferons are key cytokines acting on pancreatic islets in type 1 diabetes."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      These data suggest that IFN-α and IFN-γ are key cytokines at the islet
      level in human type 1 diabetes, contributing to the triggering and
      amplification of autoimmunity.
    explanation: >-
      Human beta-cell cytokine perturbation and comparison with type 1 diabetes
      islet signatures support interferons as the beta-cell intrinsic arm of
      the model.
  - reference: PMID:37557168
    reference_title: "Lymph node sharing between pancreas, gut, and liver leads to immune crosstalk and regulation of pancreatic autoimmunity."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      duodenal viral infections rendered non-intestinal migDCs and β-cell-reactive
      T cells more pro-inflammatory in all shared LNs, resulting in elevated
      pancreatic islet lymphocyte infiltration.
    explanation: >-
      Mouse lymph-node drainage experiments provide a candidate gut-pancreas
      crosstalk mechanism linking intestinal viral infection to pancreatic
      autoimmunity.
  - reference: PMID:37390839
    reference_title: "Enteroviruses and risk of islet autoimmunity or type 1 diabetes: systematic review and meta-analysis of controlled observational studies detecting viral nucleic acids and proteins."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Meta-analysis of 56 studies showed associations between enteroviruses and
      islet autoimmunity (OR 2·1, 95% CI 1·3-3·3; p=0·002; n=18; heterogeneity
      χ2/df 2·69; p=0·0004; I2=63%), type 1 diabetes (OR 8·0, 95% CI 4·9-13·0;
      p<0·0001; n=48; χ2/df 6·75; p<0·0001; I2=85%)
    explanation: >-
      Quantifies the epidemiological arm of the model at both disease stages
      from 12,077 participants. Note the heterogeneity is substantial and the
      design is observational, so this establishes association strength and not
      the direction of causation.
  - reference: PMID:37789144
    reference_title: "Pleconaril and ribavirin in new-onset type 1 diabetes: a phase 2 randomized trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The primary endpoint was met with the serum C-peptide AUC being higher in
      the pleconaril and ribavirin treatment group compared to the placebo group
    explanation: >-
      The first interventional test of the viral arm. Six months of antiviral
      treatment in 96 children with new-onset disease preserved residual
      C-peptide at 12 months, which is what the model predicts if a persisting
      islet infection is still driving beta-cell loss after diagnosis. Phase 2,
      modest effect size, and no phase 3 replication exists.
  - reference: PMID:38055252
    reference_title: "Baricitinib and β-Cell Function in Patients with New-Onset Type 1 Diabetes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The median of the mixed-meal-stimulated mean C-peptide level at week 48
      was 0.65 nmol per liter per minute (interquartile range, 0.31 to 0.82) in
      the baricitinib group and 0.43 nmol per liter per minute (interquartile
      range, 0.13 to 0.63) in the placebo group
    explanation: >-
      Interventional test of the interferon arm. Baricitinib blocks JAK1 and
      JAK2, which transduce interferon receptor signals, and preserved
      stimulated C-peptide over 48 weeks in 91 patients with new-onset disease.
      JAK inhibition is not interferon-specific, so the trial supports the
      pathway rather than isolating type I interferon.
prevalence:
- population: Global
  percentage: 0.1-0.2
  evidence:
  - reference: PMID:34599655
    reference_title: "Type 1 diabetes in 2017: global estimates of incident and prevalent cases in children and adults."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: Global numbers of incident and prevalent cases of type 1 diabetes were estimated to be 234,710 and 9,004,610, respectively, in 2017...Globally, type 1 diabetes represents about 2% of the estimated total cases of diabetes.
    explanation: The prevalence of type 1 diabetes globally is estimated to be around 2%, not 0.1-0.2%.
  - reference: PMID:16085737
    reference_title: "Diabetes and ethnic minorities."
    supports: NO_EVIDENCE
    evidence_source: HUMAN_CLINICAL
    snippet: The global prevalence of diabetes for all age groups is estimated to be 2.8%. Type 2 diabetes accounts for at least 90% of diabetes worldwide.
    explanation: This study provides global prevalence data for diabetes in general and specifically mentions Type 2 diabetes but does not give a percentage for the prevalence of Type 1 diabetes.
  - reference: PMID:27959859
    reference_title: "Type 1 Diabetes Prevention: A Goal Dependent on Accepting a Diagnosis of an Asymptomatic Disease."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: The incidence of childhood-onset type 1 diabetes has been increasing at a rate of 3%-5% per year globally...no means for a practical 'cure' exist.
    explanation: The increasing incidence suggests a prevalence higher than 0.1-0.2%.
progression:
- phase: Onset
  age_range: Childhood-Adolescence
  evidence:
  - reference: PMID:33825933
    reference_title: "[Type 1 diabetes: an update]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The incidence of type 1 diabetes (T1D) has been rising steadily over the last 30 years, especially among children and adolescents, with the result that the number of cases in this age group doubles every 20 years.
    explanation: This study discusses the rising incidence of type 1 diabetes in children and adolescents, which aligns with the progression of T1D during childhood and adolescence.
  - reference: PMID:30628751
    reference_title: "Predicting progression to type 1 diabetes from ages 3 to 6 in islet autoantibody positive TEDDY children."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Twenty-one percent of subjects developed T1D by age 6. Logistic regression modeling identified 5 significant predictors.
    explanation: This study focuses on predictors of T1D progression in children with high-risk HLA genes followed in The TEDDY study, providing partial support since it includes childhood but doesn't explicitly cover adolescence.
  - reference: PMID:26404926
    reference_title: "Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Stage 3 as onset of symptomatic disease ... Adoption of this staging classification provides a standardized taxonomy for type 1 diabetes.
    explanation: This reference discusses the presymptomatic stages of T1D leading to symptomatic onset, supporting the progression during childhood and adolescence.
  - reference: PMID:31280235
    reference_title: "Children with type 1 diabetes of early age at onset - immune and metabolic phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We aimed to evaluate children with type 1 diabetes (T1D) with early age at onset (EAO) for clinical, immune and metabolic features in order to identify age-related disease phenotypes.
    explanation: This study focuses on early age at onset and disease phenotypes in children, but doesn't explicitly cover the entire range including adolescence.
  - reference: PMID:26816135
    reference_title: "Childhood and Youth Onset Diabetes: A Single Centre Experience."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Type 1 diabetes accounted for 368/421 (87.4 %) patients with age of onset <18 y and 99/156 (63.5 %) of patients with onset between 19 and 25 y of age.
    explanation: This study identifies the proportion of various types of diabetes in youth, including the onset of T1D in children and adolescents.
pathophysiology:
- name: Genetic Susceptibility
  description: HLA class II risk haplotypes (HLA-DQ2 and HLA-DQ8, encoded jointly by HLA-DQA1 and HLA-DQB1 alleles) and other susceptibility loci such as the INS VNTR (IDDM2) increase the risk of developing Type I Diabetes.
  genes:
  - preferred_term: HLA-DQA1
    term:
      id: hgnc:4942
      label: HLA-DQA1
  - preferred_term: HLA-DQB1
    term:
      id: hgnc:4944
      label: HLA-DQB1
  - preferred_term: INS
    term:
      id: hgnc:6081
      label: INS
  downstream:
  - target: Autoimmune Destruction of Beta Cells
  evidence:
  - reference: PMID:11554771
    reference_title: "Genetics of type 1 diabetes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The HLA-DQ genes are the primary susceptibility genes within this region, although other genes may also contribute. The IDDM2 locus maps to a variable number of tandem repeats in the insulin gene region on chromosome 11.
    explanation: The provided literature confirms that HLA-DQ and INS genes contribute to the genetic susceptibility to Type 1 Diabetes.
  - reference: PMID:31331105
    reference_title: "HLA-DQA1 and HLA-DQB1 Alleles, Conferring Susceptibility to Celiac Disease and Type 1 Diabetes, are More Expressed Than Non-Predisposing Alleles and are Coordinately Regulated."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: HLA DQA1*05 and DQB1*02 alleles encoding the DQ2.5 molecule and HLA DQA1*03 and DQB1*03 alleles encoding DQ8 molecules are strongly associated with celiac disease (CD) and type 1 diabetes (T1D), two common autoimmune diseases (AD)
    explanation: The presence of HLA-DQ2 and HLA-DQ8 variants contributing to the genetic susceptibility of Type I Diabetes is supported.
  - reference: PMID:3309680
    reference_title: "HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Over half of the inherited predisposition to insulin-dependent diabetes mellitus maps to the region of chromosome 6 that contains the highly polymorphic HLA class II genes which determine immune responsiveness.
    explanation: HLA class II genes, including HLA-DQ, play significant roles in the predisposition to Type I Diabetes.
  - reference: PMID:15342014
    reference_title: "The genetics of HLA-associated disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Accumulating evidence suggests that MHC susceptibility for T1D is recessive, with susceptibility alleles more common than protective alleles.
    explanation: The literature indicates that HLA alleles, specifically susceptibility alleles, are significant in the context of Type I Diabetes.
  - reference: PMID:17130534
    reference_title: "Genes influencing innate and acquired immunity in type 1 diabetes and latent autoimmune diabetes in adults."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: DQ8 and DQ2 are associated with susceptibility to and DQ6 with protection from type 1 diabetes mellitus (T1DM).
    explanation: The association of HLA-DQ2 and HLA-DQ8 with susceptibility to Type I Diabetes is supported by this reference.
  - reference: PMID:17496359
    reference_title: "Biomarkers of susceptibility to type 1 diabetes with special reference to the Indian population."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Susceptibility to T1D is strongly linked to a major genetic locus that is the major histocompatibility complex (MHC) and several other minor loci including insulin, CTLA4 that contribute to diabetes risk in an epistatic way.
    explanation: INS gene contribution to the susceptibility of Type I Diabetes is supported along with HLA genes.
- name: Environmental Triggers
  description: Viral infections or early dietary factors (cow's milk, gluten) may trigger or accelerate the autoimmune response in genetically susceptible individuals.
  triggers:
  - preferred_term: Viral Infections
  - preferred_term: Early Dietary Factors
  downstream:
  - target: Interferon-Driven Beta Cell Response
    description: Viral exposures may induce local islet interferon programs that make beta cells more immunogenic and stressed.
    hypothesis_groups:
    - viral_interferon_beta_cell_autoimmunity_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Beta-cell viral RNA sensing and local interferon signaling
    evidence:
    - reference: PMID:38409439
      reference_title: "Interferons are key cytokines acting on pancreatic islets in type 1 diabetes."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        The IFN-induced gene signatures have a strong correlation with those
        observed in beta cells from individuals with type 1 diabetes, and the
        level of expression of specific IFN-stimulated genes is positively
        correlated with proteins present in islets of these individuals,
        regulating beta cell responses to 'danger signals' such as viral
        infections.
      explanation: >-
        Supports a known-intermediate edge from viral danger signals to the
        interferon-induced beta-cell state seen in type 1 diabetes.
  - target: Persistent Low-Grade Islet Enteroviral Infection
    description: >-
      Enteroviral exposure can leave a low-abundance, non-cultivable viral
      footprint in islet cells rather than resolving as an acute lytic
      infection.
    hypothesis_groups:
    - viral_interferon_beta_cell_autoimmunity_model
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:39314969
      reference_title: "Detection of enterovirus RNA in pancreas and lymphoid tissues of organ donors with type 1 diabetes."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        These findings are consistent with the notion that both the subjects
        with type 1 diabetes and those with islet autoantibodies may carry a
        low-grade enterovirus infection in the pancreas and lymphoid tissues.
      explanation: >-
        The largest coordinated nPOD survey concludes that a low-grade
        enterovirus infection of the pancreas is carried by donors with the
        disease and by autoantibody-positive donors, which is the outcome this
        edge asserts for viral exposure.
  - target: Gut-Pancreas Lymph Node Crosstalk
    description: Upper-intestinal viral infection can reprogram shared draining lymph-node immune traffic toward pancreatic islet inflammation in a mouse model.
    hypothesis_groups:
    - viral_interferon_beta_cell_autoimmunity_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Shared pancreas-duodenum lymph-node drainage
    - Migratory dendritic-cell and beta-cell-reactive T-cell inflammatory polarization
    evidence:
    - reference: PMID:37557168
      reference_title: "Lymph node sharing between pancreas, gut, and liver leads to immune crosstalk and regulation of pancreatic autoimmunity."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        However, duodenal viral infections rendered non-intestinal migDCs and
        β-cell-reactive T cells more pro-inflammatory in all shared LNs,
        resulting in elevated pancreatic islet lymphocyte infiltration.
      explanation: >-
        Mouse experiments show that gut viral infection can alter shared
        lymph-node immune states and increase islet lymphocyte infiltration.
  - target: Autoimmune Destruction of Beta Cells
    hypothesis_groups:
    - viral_interferon_beta_cell_autoimmunity_model
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:10522815
    reference_title: "Environmental factors in the pathogenesis of type 1 diabetes mellitus."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Various exogenous triggers, such as certain dietary factors and viruses, are thought to induce the autoimmune process leading in some individuals to extensive beta-cell destruction and ultimately to the clinical manifestation of type 1 diabetes.
    explanation: This reference supports the statement by mentioning that dietary factors and viruses can trigger the autoimmune process in genetically susceptible individuals.
  - reference: PMID:21162649
    reference_title: "Protection against or triggering of Type 1 diabetes? Different roles for viral infections."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The ability to induce strong cellular immune responses and to cause inflammation in the target organ makes viral infections prime candidates for the initiation of islet autoreactivity.
    explanation: The reference supports the role of viral infections in triggering autoimmune responses leading to type 1 diabetes.
  - reference: PMID:18357774
    reference_title: "The CVB and etiology of type 1 diabetes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The most often cited environmental agents implicated as initiators of T1D are the human enteroviruses, in particular the group B coxsackieviruses (CVB).
    explanation: This reference supports the statement by identifying enteroviruses as environmental triggers for type 1 diabetes.
  - reference: PMID:9645989
    reference_title: "The pathogenesis of viral-induced diabetes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: dmsee@uci.edu Serologic case-control studies have suggested an association between coxsasckie group B viruses and insulin-dependent diabetes mellitus (IDDM)
    explanation: This reference supports the role of viral infections in the onset of type 1 diabetes.
  - reference: PMID:31593953
    reference_title: "Type 1 Diabetes Mellitus and Celiac Disease: Distinct Autoimmune Disorders That Share Common Pathogenic Mechanisms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Viral infections and early exposure to gluten or cow's milk in the infant diet have been implicated in disease pathogenesis.
    explanation: The reference supports the statement by linking viral infections and early dietary factors to the pathogenesis of type 1 diabetes.
- name: Persistent Low-Grade Islet Enteroviral Infection
  description: >-
    Enteroviral capsid protein and enteroviral RNA are detectable in islet
    cells of donors with type 1 diabetes and of autoantibody-positive donors
    without diabetes, at very low abundance and without recoverable
    replication-competent virus. The pattern fits a persisting, slowly
    replicating islet infection rather than an acute lytic one, and supplies a
    candidate standing stimulus for local antiviral interferon signaling.
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: type B pancreatic cell
    term:
      id: CL:0000169
      label: type B pancreatic cell
  biological_processes:
  - preferred_term: persisting enteroviral replication in islet cells
    term:
      id: GO:0019079
      label: viral genome replication
  - preferred_term: islet-cell antiviral defense response
    term:
      id: GO:0051607
      label: defense response to virus
  locations:
  - preferred_term: pancreas
    term:
      id: UBERON:0001264
      label: pancreas
  downstream:
  - target: Interferon-Driven Beta Cell Response
    description: >-
      Enteroviral capsid protein positivity in islet cells travels with HLA
      class I hyperexpression, the histological footprint of local interferon
      exposure.
    hypothesis_groups:
    - viral_interferon_beta_cell_autoimmunity_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Islet-cell sensing of viral RNA
    - Local type I interferon release
    evidence:
    - reference: PMID:40090995
      reference_title: "Enterovirus VP1 protein and HLA class I hyperexpression in pancreatic islet cells of organ donors with type 1 diabetes."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: INDIRECT
      snippet: >-
        For all donor groups combined, HLA-I hyperexpression occurred more
        frequently in VP1+ compared with VP1- donors (45.8% vs 16%, p<0.001).
      explanation: >-
        Across 188 nPOD donors, islet HLA class I hyperexpression is nearly
        three times as frequent in enterovirus VP1-positive donors. The paper
        is explicit that tissue association cannot establish causality, so the
        edge is supported indirectly.
  evidence:
  - reference: PMID:34390364
    reference_title: "Characterisation of enterovirus RNA detected in the pancreas and other specimens of live patients with newly diagnosed type 1 diabetes in the DiViD study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      At least in some patients, the EV strain in the pancreatic islets may
      represent a slowly replicating persisting virus.
    explanation: >-
      Laparoscopic biopsies from six living adults with newly diagnosed disease
      found enterovirus RNA in islets that could not be isolated in
      enterovirus-permissive cell lines, which the authors read as a slowly
      replicating persisting virus rather than an acute infection.
  - reference: PMID:40090995
    reference_title: "Enterovirus VP1 protein and HLA class I hyperexpression in pancreatic islet cells of organ donors with type 1 diabetes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In contrast, VP1 positivity was found at higher frequency among T1D-ICI
      donors (77.5%, 31/40, p<0.001 vs all groups except AAb++).
    explanation: >-
      Enteroviral capsid protein is present in islet cells of most donors who
      have the disease and retain insulin-containing islets, and the same study
      detects it during the autoantibody-positive preclinical stage, so the
      infection is not simply a consequence of established diabetes.
- name: Gut-Pancreas Lymph Node Crosstalk
  description: >-
    Shared draining lymph nodes for the pancreas and upper small intestine may
    integrate gut-derived viral inflammation with pancreatic antigen
    presentation, shifting beta-cell-reactive T cells toward inflammatory
    phenotypes and increasing islet infiltration.
  cell_types:
  - preferred_term: migratory dendritic cell
    term:
      id: CL:0000451
      label: dendritic cell
  - preferred_term: beta-cell-reactive T cell
    term:
      id: CL:0000084
      label: T cell
  biological_processes:
  - preferred_term: dendritic cell migration
    term:
      id: GO:0036336
      label: dendritic cell migration
  - preferred_term: adaptive immune response
    term:
      id: GO:0002250
      label: adaptive immune response
  locations:
  - preferred_term: lymph node
    term:
      id: UBERON:0000029
      label: lymph node
  - preferred_term: pancreas
    term:
      id: UBERON:0001264
      label: pancreas
  - preferred_term: duodenum
    term:
      id: UBERON:0002114
      label: duodenum
  downstream:
  - target: Autoimmune Destruction of Beta Cells
    description: Pro-inflammatory shared lymph-node crosstalk may increase pancreatic islet lymphocyte infiltration and accelerate beta-cell autoimmunity.
    hypothesis_groups:
    - viral_interferon_beta_cell_autoimmunity_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Beta-cell-reactive T-cell inflammatory polarization in shared draining lymph nodes
  evidence:
  - reference: PMID:37557168
    reference_title: "Lymph node sharing between pancreas, gut, and liver leads to immune crosstalk and regulation of pancreatic autoimmunity."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Our study uncovers immune crosstalk through LN co-drainage as a powerful
      force regulating pancreatic autoimmunity.
    explanation: >-
      Model-organism evidence supports shared lymph-node co-drainage as a
      regulator of pancreatic autoimmunity and motivates curation as an emerging
      mechanism rather than established human causality.
- name: Interferon-Driven Beta Cell Response
  description: Type I and type II interferons upregulate antigen presentation and chemokine production in beta cells while downregulating oxidative phosphorylation, increasing immunogenicity and metabolic stress.
  cell_types:
  - preferred_term: type B pancreatic cell
    term:
      id: CL:0000169
      label: type B pancreatic cell
  biological_processes:
  - preferred_term: type I interferon signaling pathway
    term:
      id: GO:0060337
      label: type I interferon-mediated signaling pathway
  - preferred_term: antigen processing and presentation of peptide antigen via MHC class I
    term:
      id: GO:0002474
      label: antigen processing and presentation of peptide antigen via MHC class I
  - preferred_term: chemokine production
    term:
      id: GO:0032602
      label: chemokine production
  - preferred_term: oxidative phosphorylation
    term:
      id: GO:0006119
      label: oxidative phosphorylation
    modifier: DECREASED
  - preferred_term: defense response to virus
    term:
      id: GO:0051607
      label: defense response to virus
  chemical_entities:
  - preferred_term: interferon-alpha
    description: Type I interferon that drives antiviral and antigen-presentation programs
  - preferred_term: interferon-gamma
    description: Type II interferon that induces HLA class I upregulation and chemokine production
  - preferred_term: C-X-C motif chemokine 10
    description: Chemokine (CXCL10) that recruits autoreactive T cells to islets
  - preferred_term: programmed cell death 1 ligand 1
    description: >-
      Checkpoint ligand (PD-L1) induced on beta cells by the same interferon
      exposure that raises MHC class I, and one of the protective arms of the
      response
  - preferred_term: HLA class I histocompatibility antigen, alpha chain E
    description: >-
      Non-classical MHC molecule (HLA-E) co-induced with PD-L1 and proposed to
      restrain cytotoxic lymphocyte attack
  downstream:
  - target: Autoimmune Destruction of Beta Cells
    description: Interferon-exposed beta cells may amplify autoimmune recognition through antigen-presentation and chemokine programs.
    hypothesis_groups:
    - viral_interferon_beta_cell_autoimmunity_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - HLA class I upregulation
    - CXCL10-mediated lymphocyte recruitment
    evidence:
    - reference: PMID:23434930
      reference_title: "Functional redundancy of CXCR3/CXCL10 signaling in the recruitment of diabetogenic cytotoxic T lymphocytes to pancreatic islets in a virally induced autoimmune diabetes model."
      supports: REFUTE
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Our present data in a viral mouse model challenge the notion that
        specific blockade of the CXCL10/CXCR3 chemokine axis halts T1D onset
        and progression.
      explanation: >-
        Argues against the second intermediate named on this edge. In a virally
        induced mouse model, blocking CXCL10-CXCR3 did not halt disease, so
        chemokine recruitment to islets is functionally redundant rather than a
        required step, even though both ligand and receptor are abundant in
        human disease.
  evidence:
  - reference: PMID:38409439
    reference_title: "Interferons are key cytokines acting on pancreatic islets in type 1 diabetes."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: The IFN-induced gene signatures have a strong correlation with those observed in beta cells from individuals with type 1 diabetes, and the level of expression of specific IFN-stimulated genes is positively correlated with proteins present in islets of these individuals, regulating beta cell responses to 'danger signals' such as viral infections.
    explanation: This study identifies interferons as key drivers of beta cell inflammatory responses, upregulating antigen presentation and chemokine production.
  - reference: PMID:29305625
    reference_title: "IFN-α induces a preferential long-lasting expression of MHC class I in human pancreatic beta cells."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      IFN-α mediates a long-lasting and preferential MHC class I overexpression
      in human beta cells, which is not affected by the subsequent addition of
      JAK inhibitors.
    explanation: >-
      Separates the reversible arms of the beta-cell interferon response from
      the durable one. Inflammation and ER stress markers decay within a day or
      two of cytokine withdrawal while surface MHC class I stays elevated for at
      least a week, so a transient interferon exposure leaves a lasting window
      of raised beta-cell immunogenicity that later JAK blockade does not
      reverse.
  - reference: PMID:32444635
    reference_title: "An integrated multi-omics approach identifies the landscape of interferon-α-mediated responses of human pancreatic beta cells."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Beta cells also up-regulate the checkpoint proteins PDL1 and HLA-E that
      may exert a protective role against the autoimmune assault.
    explanation: >-
      The same interferon exposure that expands presented antigen also induces
      checkpoint ligands on beta cells, so this node carries protective as well
      as pro-autoimmune programs. Basis for the PD-L1 and HLA-E entries listed
      under chemical entities.
  - reference: PMID:25574096
    reference_title: "Interferon therapy in hepatitis C leading to chronic type 1 diabetes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our data show that INF treatment increases the risk of developing T1DM by
      10-18 fold compared with the corresponding general population
    explanation: >-
      Human evidence that sustained exogenous interferon-alpha is by itself
      enough to precipitate autoimmune diabetes, with no viral infection of the
      islet required. A review of 107 published cases in chronic hepatitis C
      reports a 10 to 18 fold excess risk, most cases arising during treatment.
  - reference: PMID:27999109
    reference_title: "A Critical Role for the Type I Interferon Receptor in Virus-Induced Autoimmune Diabetes in Rats."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      IFNAR1 deficiency significantly delayed the onset and frequency of
      diabetes and greatly reduced the intensity of insulitis after poly I:C
      treatment.
    explanation: >-
      Loss of the type I interferon receptor in diabetes-prone LEW.1WR1 rats
      delays and reduces virus-induced diabetes and blunts insulitis, so
      interferon receptor signaling is a genuine causal contributor to this
      node rather than a marker of it. Note the effect is delay and reduction,
      not abolition.
- name: Autoimmune Destruction of Beta Cells
  description: The immune system mistakenly targets and destroys insulin-producing beta cells in the pancreas through T cell-mediated cytotoxicity and autoantibody production.
  cell_types:
  - preferred_term: type B pancreatic cell
    term:
      id: CL:0000169
      label: type B pancreatic cell
  - preferred_term: CD8-positive, alpha-beta cytotoxic T cell
    term:
      id: CL:0000794
      label: CD8-positive, alpha-beta cytotoxic T cell
  - preferred_term: CD4-positive, alpha-beta T cell
    term:
      id: CL:0000624
      label: CD4-positive, alpha-beta T cell
  - preferred_term: regulatory T cell
    term:
      id: CL:0000815
      label: regulatory T cell
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
  - preferred_term: dendritic cell
    term:
      id: CL:0000451
      label: dendritic cell
  - preferred_term: macrophage
    term:
      id: CL:0000235
      label: macrophage
  biological_processes:
  - preferred_term: T cell mediated cytotoxicity
    term:
      id: GO:0001913
      label: T cell mediated cytotoxicity
  - preferred_term: autoantibody production
    term:
      id: GO:0002377
      label: immunoglobulin production
    modifier: ABNORMAL
  - preferred_term: cytokine-mediated signaling pathway
    term:
      id: GO:0019221
      label: cytokine-mediated signaling pathway
  locations:
  - preferred_term: pancreatic islet
    term:
      id: UBERON:0000006
      label: islet of Langerhans
  downstream:
  - target: Insulin Deficiency
    description: Autoimmune destruction of pancreatic beta cells leads to absolute or near-absolute insulin deficiency.
    evidence:
    - reference: PMID:40734585
      reference_title: "The pathophysiology, presentation and classification of Type 1 diabetes."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Type 1 diabetes is characterised by the autoimmune destruction of pancreatic β‐cells, leading to an absolute or near‐absolute insulin deficiency.
      explanation: This 2025 review clearly establishes the causal chain from autoimmune destruction of beta cells to absolute insulin deficiency that characterizes Type 1 Diabetes.
  evidence:
  - reference: PMID:12185667
    reference_title: "Islet abnormalities in the pathogenesis of autoimmune diabetes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Type 1 diabetes mellitus is a T-cell-mediated autoimmune disease that results in the destruction of the insulin-producing beta cells in the pancreatic islets of Langerhans.
    explanation: While T-cell mediated cytotoxicity is mentioned, there is no reference to autoantibody production.
  - reference: PMID:23774118
    reference_title: "Pathophysiological mechanisms involving aggressive islet cell destruction in fulminant type 1 diabetes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Phenotypes of infiltrating cells around and/or into islets were mainly dendritic cells, macrophages and CD8+ T cells.
    explanation: Supports T cell-mediated cytotoxicity but does not discuss autoantibody production.
  - reference: PMID:27659143
    reference_title: "Immune and Pancreatic β Cell Interactions in Type 1 Diabetes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The autoimmune destruction of the pancreatic islet beta cells is due to a targeted lymphocyte attack.
    explanation: Supports T cell-mediated cytotoxicity but does not mention autoantibody production.
  - reference: PMID:27017348
    reference_title: "Life and death of β cells in Type 1 diabetes: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Type 1 diabetes (T1D) is an autoimmune disorder characterized by the destruction of insulin-producing pancreatic beta cells.
    explanation: Describes immune-mediated destruction of beta cells but does not specifically mention autoantibody production.
  - reference: PMID:16280652
    reference_title: "Autoimmune destruction of pancreatic beta cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Type 1 diabetes results from the destruction of insulin-producing pancreatic beta cells by a beta cell-specific autoimmune process.
    explanation: Supports T cell-mediated cytotoxicity but does not address autoantibody production.
  - reference: PMID:34691077
    reference_title: "Partners in Crime: Beta-Cells and Autoimmune Responses Complicit in Type 1 Diabetes Pathogenesis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Type 1 diabetes (T1D) is an autoimmune disease characterized by autoreactive T cell-mediated destruction of insulin-producing pancreatic beta-cells.
    explanation: Supports T cell-mediated cytotoxicity but lacks information on autoantibody production.
  - reference: PMID:33479911
    reference_title: "Regulatory B Cells in Type 1 Diabetes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Type 1 diabetes is an organ-specific autoimmune disease characterized by immune-mediated beta cell destruction in pancreatic islets.
    explanation: Describes immune-mediated destruction but not autoantibody production.
  - reference: PMID:28625830
    reference_title: "Bioengineering strategies for inducing tolerance in autoimmune diabetes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Type 1 diabetes is an autoimmune disease marked by the destruction of insulin-producing beta cells in the pancreatic islets.
    explanation: Indicates immune destruction of beta cells but does not mention autoantibody production.
- name: Insulin Deficiency
  description: Loss of beta cells leads to a deficiency of insulin, a hormone required for glucose uptake.
  downstream:
  - target: Hyperglycemia
  - target: Impaired Glucose Utilization
  - target: Increased Lipolysis
  evidence:
  - reference: PMID:35254878
    reference_title: "Type 1 Diabetes Mellitus."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Type 1 diabetes mellitus (T1DM) is an endocrine disorder in which pancreatic beta cells stop producing insulin, typically due to autoimmune destruction.
    explanation: This confirms that the loss of beta cells leads to a deficiency of insulin in Type 1 diabetes, as stated in the provided statement.
  - reference: PMID:21281836
    reference_title: "Pathophysiology of prediabetes."
    supports: NO_EVIDENCE
    evidence_source: HUMAN_CLINICAL
    snippet: Insulin resistance and defective glucose sensing at the beta-cell are the central pathophysiologic determinants that together cause hyperglycemia.
    explanation: Although it primarily discusses prediabetes and Type 2 diabetes, the excerpt supports the idea that beta-cell issues lead to hyperglycemia.
  - reference: PMID:2006409
    reference_title: "Diabetic hyperglycemia: link to impaired glucose transport in pancreatic beta cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Glucose uptake into pancreatic beta cells by means of the glucose transporter GLUT-2, which has a high Michaelis constant, is essential for the normal insulin secretory response to hyperglycemia.
    explanation: This indicates the importance of beta cells in glucose regulation and the resulting hyperglycemia when their function is impaired.
  - reference: PMID:11822099
    reference_title: "[Hepatogenic diabetes]."
    supports: NO_EVIDENCE
    evidence_source: HUMAN_CLINICAL
    snippet: Peripheral insulin-resistance and impairment of the hepatocellular function are two major possible causes of diabetes mellitus in liver cirrhosis.
    explanation: This reference is more about liver cirrhosis but supports the general mechanism where insulin deficiency, due to impaired beta-cell function, leads to diabetes.
  - reference: PMID:11508279
    reference_title: "The accelerator hypothesis: weight gain as the missing link between Type I and Type II diabetes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Loss of blood glucose control might result from failure of the beta cells to secrete insulin, resistance of the tissues to its action, or a combination of both.
    explanation: This also supports the idea that loss of beta cells leads to insulin deficiency and subsequent glucose control issues, relevant to both Type 1 and Type 2 diabetes.
- name: Hyperglycemia
  description: Lack of insulin results in high blood glucose levels, as glucose cannot be efficiently taken up by cells.
  conforms_to: "diabetic_vascular_complications#Chronic Hyperglycemia"
  assays:
  - preferred_term: Elevated Blood Glucose
  - preferred_term: Elevated Hemoglobin A1c (HbA1c)
  downstream:
  - target: Glucosuria
  - target: Polyuria
  - target: Polydipsia
  - target: Diabetic Ketoacidosis (DKA)
  evidence:
  - reference: PMID:33970586
    reference_title: "Diabetes: Type 1 Diabetes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Type 1 diabetes is defined as a state of hyperglycemia due to insulin deficiency caused by autoimmune pancreatic beta-cell destruction.
    explanation: The abstract from PMID:33970586 confirms that type 1 diabetes is characterized by hyperglycemia due to insulin deficiency, which supports the statement regarding elevated blood glucose and related downstream effects.
  - reference: PMID:37921158
    reference_title: "Multi-level Analysis of HbA1c in Diagnosis and Prognosis of Diabetic Patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: HbA1c offers a trustworthy indicator of chronic hyperglycemia and strongly correlates with the likelihood of long-term consequences from diabetes.
    explanation: Although this reference supports the relationship between elevated HbA1c and hyperglycemia, it does not specifically address all the downstream effects such as Glucosuria, Polyuria, Polydipsia, and Diabetic Ketoacidosis (DKA).
  - reference: PMID:21281836
    reference_title: "Pathophysiology of prediabetes."
    supports: NO_EVIDENCE
    evidence_source: HUMAN_CLINICAL
    snippet: The phenotype of prediabetes includes dyslipidemia and higher arterial blood pressure.
    explanation: This study does not specifically address the pathophysiology of type 1 diabetes or the particular assays and downstream effects mentioned in the statement.
  - reference: PMID:11921414
    reference_title: "The insulin gene in diabetes."
    supports: NO_EVIDENCE
    evidence_source: HUMAN_CLINICAL
    snippet: Lack of insulin production or abnormalities affecting insulin secretion are key to the development of almost all forms of diabetes.
    explanation: While it mentions insulin deficiency, this reference does not go into detail about the specific assays and downstream effects listed in the statement.
  - reference: PMID:15137354
    reference_title: "Pathophysiology of diabetes mellitus."
    supports: NO_EVIDENCE
    evidence_source: HUMAN_CLINICAL
    snippet: The article points out the signs and symptoms to be aware of when the person is in the acute state of diabetic ketoacidosis.
    explanation: This article touches on diabetic ketoacidosis but does not fully cover all the listed downstream effects and assays associated with type 1 diabetes pathophysiology.
- name: Impaired Glucose Utilization
  description: Without insulin, cells are unable to utilize glucose for energy production, leading to cellular energy deficiency.
  downstream:
  - target: Weight Loss
  - target: Fatigue
  evidence:
  - reference: PMID:12477252
    reference_title: "Challenges for gene therapy of type 1 diabetes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Type 1 or insulin-dependent diabetes mellitus is caused by autoimmune attack and selective destruction of the pancreatic beta cells.
    explanation: The lack of insulin in type 1 diabetes mellitus leads to impaired glucose utilization as described in the statement.
  - reference: PMID:15137354
    reference_title: "Pathophysiology of diabetes mellitus."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The following article reviews the basic pathophysiology of both type 1 diabetes mellitus and type 2 diabetes mellitus as we understand it today.
    explanation: This article explains that in diabetes, particularly type 1, the lack of insulin results in impaired glucose utilization, leading to characteristic symptoms like weight loss and fatigue.
- name: ER Stress and Unfolded Protein Response
  description: Inflammatory cytokines induce endoplasmic reticulum stress in beta cells, activating the unfolded protein response and contributing to beta cell dysfunction and apoptosis.
  cell_types:
  - preferred_term: type B pancreatic cell
    term:
      id: CL:0000169
      label: type B pancreatic cell
  biological_processes:
  - preferred_term: endoplasmic reticulum unfolded protein response
    term:
      id: GO:0030968
      label: endoplasmic reticulum unfolded protein response
  - preferred_term: apoptotic process
    term:
      id: GO:0006915
      label: apoptotic process
  chemical_entities:
  - preferred_term: interleukin-1beta
    description: Proinflammatory cytokine that contributes to beta-cell stress and ER dysfunction
  downstream:
  - target: Autoimmune Destruction of Beta Cells
  evidence:
  - reference: PMID:38409439
    reference_title: "Interferons are key cytokines acting on pancreatic islets in type 1 diabetes."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: The IFN-induced gene signatures have a strong correlation with those observed in beta cells from individuals with type 1 diabetes, and the level of expression of specific IFN-stimulated genes is positively correlated with proteins present in islets of these individuals, regulating beta cell responses to 'danger signals' such as viral infections.
    explanation: This study shows interferons drive beta cell stress responses including ER stress pathways that contribute to beta cell dysfunction and death.
- name: Increased Lipolysis
  description: Insulin deficiency also leads to increased breakdown of fat (lipolysis) for energy, resulting in the production of ketones.
  downstream:
  - target: Diabetic Ketoacidosis (DKA)
  evidence:
  - reference: PMID:6409465
    reference_title: "Glucose and ketone body kinetics in diabetic ketoacidosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Insulin deficiency results in increased rates of lipolysis and provides increased substrate (free fatty acids) for ketogenesis.
    explanation: The article explains that insulin deficiency leads to increased lipolysis, which eventually results in the production of ketone bodies. This supports the statement's claim about the pathophysiology involving lipolysis and ketone production in Type I Diabetes.
  - reference: PMID:15137354
    reference_title: "Pathophysiology of diabetes mellitus."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The article points out the signs and symptoms to be aware of when the person is in the acute state of diabetic ketoacidosis.
    explanation: The article suggests that DKA is a critical concern in Type I Diabetes due to insufficient insulin, which is aligned with the statement indicating the downstream effect of heightened lipolysis and ketone production.
  - reference: PMID:34922394
    reference_title: "Clinical Significance of Insulin Peptide-specific Interferon-γ-related Immune Responses in Ketosis-prone Type 2 Diabetes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: the involvement of B:9-23rPep-specific IFN-gamma-related immunoreactivity in the pathophysiology of some unprovoked A-beta+ KPD.
    explanation: Although the study highlights immune responses related to ketosis-prone Type 2 Diabetes, it indirectly supports the notion that immune-mediated processes can contribute to ketosis and DKA.
- name: Chronic Complications
  description: Persistent hyperglycemia over time can lead to damage in various tissues and organs.
  conforms_to: "diabetic_vascular_complications#Diabetic End-Organ Complications"
  downstream:
  - target: Diabetic Retinopathy
  - target: Diabetic Neuropathy
  - target: Diabetic Nephropathy
  - target: Coronary Artery Disease
  - target: Stroke
  evidence:
  - reference: PMID:31346658
    reference_title: "New insights into the mechanisms of diabetic complications: role of lipids and lipid metabolism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Hyperglycaemia, dyslipidaemia and hypertension combine with the duration and type of diabetes to define the distinct pathophysiology underlying diabetic kidney disease, diabetic retinopathy and diabetic neuropathy.
    explanation: The literature indicates that hyperglycemia is a significant factor in the pathophysiology of diabetic complications including kidney disease (nephropathy), retinopathy, and neuropathy, thereby supporting the claim.
  - reference: PMID:34407376
    reference_title: "Type 1 Diabetes and Associated Cardiovascular Damage: Contribution of Extracellular Vesicles in Tissue Crosstalk."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Hyperglycemia is the common denominator for most of the chronic diabetic vascular complications, which represent the main cause of life reduction in T1D patients.
    explanation: This reference indicates that hyperglycemia underlies various chronic vascular complications in type 1 diabetes, thus supporting the statement.
  - reference: PMID:3528691
    reference_title: "Insulin-dependent diabetes mellitus: pathophysiology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The remaining 15 to 20% of patients have insulin-dependent diabetes mellitus, a disorder caused by the destruction of insulin-producing endocrine cells within the pancreas and currently considered to be the result of an autoimmune process. During the course of both types of diabetes mellitus, the so-called long-term complications of diabetes invariably occur to some extent in all patients. These complications include retinopathy, nephropathy, neuropathy, and premature atherosclerosis.
    explanation: The study confirms that type 1 diabetes, which involves insulin-dependent diabetes mellitus, results in long-term complications such as retinopathy, nephropathy, neuropathy, and cardiovascular disease.
  - reference: PMID:35456511
    reference_title: "The Role of Epigenetic Modifications in Late Complications in Type 1 Diabetes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The prevention of hyperglycemia is very important to avoid or at least postpone the development of micro- and macrovascular complications, also known as late complications. These include diabetic retinopathy, chronic renal failure, diabetic neuropathy, and cardiovascular diseases.
    explanation: The literature points out that hyperglycemia leads to microvascular (retinopathy, nephropathy, neuropathy) and macrovascular (cardiovascular diseases) complications, supporting the statement.
- name: Diabetic Ketoacidosis (DKA)
  description: Life-threatening metabolic emergency from insulin deficiency
phenotypes:
- category: Endocrine
  name: Hyperglycemia
  frequency: VERY_FREQUENT
  diagnostic: true
  sequelae:
  - target: Diabetic Ketoacidosis
  evidence:
  - reference: PMID:38272591
    reference_title: "Acute and Chronic Adverse Outcomes of Type 1 Diabetes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Type 1 diabetes is associated with both acute and chronic complications. Acute complications include diabetic ketoacidosis and severe hypoglycemia. Chronic complications can be microvascular or macrovascular. Microvascular complications include retinopathy, nephropathy, and neuropathy.
    explanation: This source supports the statement by associating Type I Diabetes with hyperglycemia and chronic complications such as retinopathy and neuropathy, as well as acute complications like diabetic ketoacidosis.
  - reference: PMID:28544185
    reference_title: "Ketoacidosis at diagnosis of type 1 diabetes: Effect of prospective studies with newborn genetic screening and follow up of risk children."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Participation in prospective follow-up studies reduces the frequency of DKA in children at diagnosis of T1D, but genetic screening alone does not decrease DKA risk.
    explanation: This source supports the statement by confirming that Diabetic Ketoacidosis (DKA) is a frequent acute complication in Type 1 Diabetes at the time of diagnosis.
  - reference: PMID:34362315
    reference_title: "Stress hyperglycemia as first sign of asymptomatic type 1 diabetes: an instructive case."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Although SH was usually benign and long-term treatment was superfluous, it might be the first sign of insulinopenic status such as type 1 DM (T1DM)
    explanation: This source supports the statement by describing stress hyperglycemia as a potential initial presentation of Type 1 Diabetes, thereby confirming hyperglycemia as a very frequent occurrence.
  phenotype_term:
    preferred_term: Hyperglycemia
    term:
      id: HP:0003074
      label: Hyperglycemia
- category: Systemic
  name: Weight Loss
  frequency: FREQUENT
  notes: Due to inability to utilize glucose for energy
  evidence:
  - reference: PMID:23075321
    reference_title: "The broad clinical phenotype of Type 1 diabetes at presentation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Immune-mediated (auto-immune) Type 1 diabetes mellitus is not a homogenous entity, but nonetheless has distinctive characteristics. In children, it may present with classical insulin deficiency and ketoacidosis at disease onset, whereas autoimmune diabetes in adults may not always be insulin dependent.
    explanation: The source does indicate that Type 1 diabetes has varied presentations, including insulin deficiency and potentially weight loss due to failure to utilize glucose. However, the excerpt does not specifically mention weight loss as a frequent phenotype.
  - reference: PMID:12949265
    reference_title: "Type 1 diabetes mellitus."
    supports: NO_EVIDENCE
    evidence_source: HUMAN_CLINICAL
    explanation: The provided literature does not directly discuss weight loss as a frequent systemic phenotype of Type 1 diabetes.
  - reference: PMID:11508279
    reference_title: "The accelerator hypothesis: weight gain as the missing link between Type I and Type II diabetes."
    supports: NO_EVIDENCE
    evidence_source: HUMAN_CLINICAL
    explanation: This reference discusses the Accelerator Hypothesis and weight gain in diabetes but does not address weight loss in Type 1 diabetes.
  - reference: PMID:37065759
    reference_title: "Can type 1 diabetes be an unexpected complication of obesity?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The risk factors of weight gain included using exogenous insulin, intensifying insulin therapy, fear of hypoglycemia and related decrease in physical activity, and psychological factors, such as emotional eating and binge eating
    explanation: This reference addresses weight gain in relation to Type 1 Diabetes but does not state that weight loss is a frequent phenotype.
  - reference: PMID:19267337
    reference_title: "C-peptide in the natural history of type 1 diabetes."
    supports: NO_EVIDENCE
    evidence_source: HUMAN_CLINICAL
    explanation: The reference discusses the natural history of endogenous beta-cell function in Type 1 diabetes but does not mention weight loss being a frequent phenotype.
  phenotype_term:
    preferred_term: Weight loss
    term:
      id: HP:0001824
      label: Weight loss
- category: Systemic
  frequency: FREQUENT
  name: Polyuria
  notes: Caused by osmotic diuresis from hyperglycemia
  evidence:
  - reference: PMID:35254878
    reference_title: "Type 1 Diabetes Mellitus."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Symptoms include polyuria, polydipsia, and weight loss.
    explanation: This reference confirms that polyuria is a frequent symptom of Type I Diabetes.
  - reference: PMID:2923250
    reference_title: "Effect of blood glucose concentration on osmoregulation in diabetes mellitus."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Poorly controlled insulin-dependent diabetes mellitus is associated with considerable elevations of plasma vasopressin concentrations, although well-controlled diabetics have normal osmoregulated thirst and vasopressin release.
    explanation: This reference discusses the association of poorly controlled insulin-dependent diabetes mellitus (Type I Diabetes) with symptoms such as polyuria.
  phenotype_term:
    preferred_term: Polyuria
    term:
      id: HP:0000103
      label: Polyuria
- category: Systemic
  frequency: FREQUENT
  name: Polydipsia
  notes: Excessive thirst due to dehydration from polyuria
  evidence:
  - reference: PMID:35254878
    reference_title: "Type 1 Diabetes Mellitus."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Symptoms include polyuria, polydipsia, and weight loss.
    explanation: The reference clearly states that polydipsia is a symptom of Type 1 Diabetes Mellitus, supporting the statement that it is a frequent systemic occurrence.
  phenotype_term:
    preferred_term: Polydipsia
    term:
      id: HP:0001959
      label: Polydipsia
- category: Endocrine
  frequency: OCCASIONAL
  name: Diabetic Ketoacidosis
  notes: Life-threatening complication of insulin deficiency
  sequelae:
  - target: Abdominal Pain
  - target: Vomiting
  - target: Rapid Breathing
  - target: Confusion
  evidence:
  - reference: PMID:12474677
    reference_title: "[Diabetic ketoacidosis]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Diabetic ketoacidosis is an emergency medical condition that can be life-threatening if not treated properly. Diabetic ketoacidosis occurs most often in patients with type 1 diabetes (formerly called insulin-dependent diabetes mellitus); however, its occurrence in patients with type 2 diabetes (formerly called noninsulin-dependent diabetes mellitus) is not as rare as was once thought.
    explanation: The literature supports that diabetic ketoacidosis is a life-threatening complication of type 1 diabetes and mentions symptoms such as abdominal pain and vomiting. However, it does not specify the frequency as 'occasional'.
  - reference: PMID:17627511
    reference_title: "Brittle type 1 diabetes mellitus."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: A small group of patients affected by type 1 diabetes mellitus is characterized by a severe instability of glycemic values with frequent and unpredictable hypoglycemic and/or ketoacidosis episodes which cannot be explained by errors of patients or diabetologists.
    explanation: This reference supports the occurrence of diabetic ketoacidosis in type 1 diabetes and mentions its life-threatening nature but does not confirm the frequency as 'occasional'.
  - reference: PMID:15137354
    reference_title: "Pathophysiology of diabetes mellitus."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The article points out the signs and symptoms to be aware of when the person is in the acute state of diabetic ketoacidosis, hyperglycemic hyperosmolar nonketotic coma (or state), and severe hypoglycemia.
    explanation: The reference confirms that diabetic ketoacidosis is a life-threatening complication of type 1 diabetes and includes symptoms like confusion and rapid breathing but does not specify the frequency as 'occasional'.
  - reference: PMID:35466445
    reference_title: "Diabetic ketoacidosis as a unique initial presentation of cystic fibrosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Diabetic ketoacidosis as a unique initial presentation of cystic fibrosis.
    explanation: This reference indicates that diabetic ketoacidosis can be a presentation in type 1 diabetes but does not address the frequency or the specific symptoms listed.
  phenotype_term:
    preferred_term: Diabetic Ketoacidosis
    term:
      id: HP:0001953
      label: Diabetic ketoacidosis
- category: Ophthalmologic
  name: Diabetic Retinopathy
  phenotype_term:
    preferred_term: Diabetic Retinopathy
    term:
      id: HP:0000488
      label: Retinopathy
  notes: >-
    Leading cause of blindness, due to chronic hyperglycemia. Frequency band
    removed: every citation attached here is graded NO_EVIDENCE with an
    explanation stating the source does not establish frequency in type 1
    diabetes, so OCCASIONAL was unsupported (and contradicted a now-removed
    duplicate entry asserting FREQUENT for the same HPO term).
  evidence:
  - reference: PMID:24864506
    reference_title: "[Diabetic retinopathy in patients with type 1 diabetes mellitus]."
    supports: NO_EVIDENCE
    evidence_source: HUMAN_CLINICAL
    snippet: Diabetes mellitus (DM), due to its epidemic prevalence and high occurrence of associated disability, is now one of the priority medical and social problems. Incapacitating manifestations of diabetes include visual impairment. Thus, diabetic retinopathy (DR), a late nonspecific vascular complication of DM, is the leading cause of blindness in the working-age population.
    explanation: The literature mentions diabetic retinopathy as a leading cause of blindness in the working-age population but does not provide specific information on its frequency in Type I Diabetes.
  - reference: PMID:37469057
    reference_title: "Ocular Complications Associated With Diabetes And The Risk Of Sustainable Blindness; A Real World Analysis."
    supports: NO_EVIDENCE
    evidence_source: HUMAN_CLINICAL
    snippet: The commonest morbidity was cataract12,607(28.8%), followed by refractive errors 8,508(19.5%), vision-threatening diabetic retinopathy 2,553(5.83%) and suspected glaucoma 1,211(2.76%).
    explanation: The study provides data on the prevalence of diabetic retinopathy in a diabetic population but does not specify it as occasional in Type I Diabetes.
  - reference: PMID:38272591
    reference_title: "Acute and Chronic Adverse Outcomes of Type 1 Diabetes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Type 1 diabetes is associated with both acute and chronic complications. Acute complications include diabetic ketoacidosis and severe hypoglycemia. Chronic complications can be microvascular or macrovascular. Microvascular complications include retinopathy, nephropathy, and neuropathy.
    explanation: >-
      Directly establishes retinopathy as a microvascular complication of type 1
      diabetes, which is the phenotype claim. Reclassified from NO_EVIDENCE, which
      had been assigned because the source does not quantify frequency; the
      frequency band has now been removed from this phenotype instead.
  - reference: PMID:29682912
    reference_title: "Diabetic macular oedema: under-represented in the genetic analysis of diabetic retinopathy."
    supports: NO_EVIDENCE
    evidence_source: HUMAN_CLINICAL
    snippet: Diabetic retinopathy, a complication of both type 1 and type 2 diabetes, is a complex disease and is one of the leading causes of blindness in adults worldwide.
    explanation: The literature mentions diabetic retinopathy as a complication of Type 1 and Type 2 diabetes but does not specify its frequency as occasional.
- category: Neurologic
  name: Diabetic Neuropathy
  phenotype_term:
    preferred_term: Diabetic Neuropathy
    term:
      id: HP:0009830
      label: Peripheral neuropathy
  notes: Nerve damage from chronic hyperglycemia
  evidence:
  - reference: PMID:28159476
    reference_title: "Treatment induced neuropathy of diabetes-Long term implications in type 1 diabetes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Aggressive glucose control can result in treatment induced neuropathy of diabetes (TIND) if glycemic control is achieved too quickly.
    explanation: This reference supports the statement by indicating that aggressive glycemic control can lead to diabetic neuropathy, which is a neurologic complication of Type I Diabetes.
  - reference: PMID:33071962
    reference_title: "Glycemic Variability and Diabetic Neuropathy in Young Adults With Type 1 Diabetes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Glycemic variability (GV) may attribute to the pathogenesis of diabetic neuropathy.
    explanation: This reference supports the statement that diabetic neuropathy is a neurologic complication associated with glycemic variability, which can be linked to chronic hyperglycemia.
  - reference: PMID:33715053
    reference_title: "Brain Health in Children with Type 1 Diabetes: Risk and Protective Factors."
    supports: NO_EVIDENCE
    evidence_source: HUMAN_CLINICAL
    snippet: Emerging evidence suggests that hyperglycemia and time in range may be more important for brain development than episodes of hypoglycemia.
    explanation: This reference supports the statement by highlighting the role of hyperglycemia in neurocognitive complications, which can be related to diabetic neuropathy in Type I Diabetes.
  - reference: PMID:23506377
    reference_title: "Insulin neuritis and diabetic cachectic neuropathy: a review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: '''Insulin neuritis'' or ''treatment induced neuropathy'' is a reversible disorder characterised by acute severe distal limb pain, peripheral nerve fibre damage and autonomic dysfunction, preceded by a period of rapid glycaemic control.'
    explanation: This reference supports the statement by describing insulin neuritis, a form of diabetic neuropathy, which is a neurologic complication associated with glycemic control.
- category: Renal
  name: Diabetic Nephropathy
  phenotype_term:
    preferred_term: Diabetic Nephropathy
    term:
      id: HP:0000112
      label: Nephropathy
  notes: Kidney damage from chronic hyperglycemia
  evidence:
  - reference: PMID:23290727
    reference_title: "Clinical manifestations and natural history of diabetic kidney disease."
    supports: NO_EVIDENCE
    evidence_source: HUMAN_CLINICAL
    snippet: Renal failure in type 2 diabetes has been termed 'a medical catastrophe of worldwide dimension'.
    explanation: This study primarily discusses renal failure in type 2 diabetes, not type 1 diabetes.
  - reference: PMID:27903991
    reference_title: "Role of Oxidative Stress and Inflammatory Factors in Diabetic Kidney Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Diabetic nephropathy (DN) is a serious complication of diabetes mellitus, and its prevalence has been increasing in developed countries.
    explanation: The study mentions diabetic nephropathy as a serious complication of diabetes mellitus in general, without specifying the frequency in type 1 diabetes.
  - reference: PMID:1490695
    reference_title: "Diabetic retinopathy, nephropathy and neuropathy. Generalized vascular damage in insulin-dependent diabetic patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The most serious complication of diabetes mellitus is clinical nephropathy.
    explanation: The study highlights nephropathy as a serious complication of diabetes mellitus but does not specify its frequency in type 1 diabetes.
  - reference: PMID:30833370
    reference_title: "Risk Factors for Kidney Disease in Type 1 Diabetes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: higher mean glycemic exposure was the strongest determinant of kidney disease among the modifiable risk factors.
    explanation: The study identifies glycemic control as a significant factor for kidney disease in type 1 diabetes but does not specify the frequency of diabetic nephropathy.
- category: Renal
  name: Glucosuria
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Glucosuria
    term:
      id: HP:0003076
      label: Glycosuria
- category: Systemic
  name: Fatigue
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
- category: Cardiovascular
  name: Coronary Artery Disease
  phenotype_term:
    preferred_term: Coronary Artery Disease
    term:
      id: HP:0001677
      label: Coronary artery atherosclerosis
  description: >-
    Encompasses acute coronary events (myocardial infarction, fatal coronary
    heart disease) and coronary revascularization.
  evidence:
  - reference: PMID:16567818
    reference_title: "High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Increased HRs were found for acute coronary events (3.0 and 7.6 in type 1 diabetic men and women, respectively, versus nondiabetic subjects), coronary revascularizations (5.0 in men, 16.8 in women)"
    explanation: >-
      UK general-practice cohort (7,479 type 1 diabetic subjects vs. 38,116
      age/sex-matched non-diabetic controls) quantifies elevated hazard ratios
      for acute coronary events and revascularization in type 1 diabetes.
- category: Cardiovascular
  name: Stroke
  phenotype_term:
    preferred_term: Stroke
    term:
      id: HP:0001297
      label: Stroke
  evidence:
  - reference: PMID:16567818
    reference_title: "High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "for stroke (3.7 in men, 4.8 in women)"
    explanation: >-
      Same UK cohort quantifies elevated stroke hazard ratios in type 1
      diabetic men and women versus non-diabetic controls.
- category: Gastrointestinal
  name: Abdominal Pain
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Abdominal Pain
    term:
      id: HP:0002027
      label: Abdominal pain
- category: Gastrointestinal
  name: Vomiting
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Vomiting
    term:
      id: HP:0002013
      label: Vomiting
- category: Respiratory
  name: Rapid Breathing
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Rapid Breathing
    term:
      id: HP:0002789
      label: Tachypnea
- category: Neurologic
  name: Confusion
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Confusion
    term:
      id: HP:0001289
      label: Confusion
biochemical:
- name: Blood Glucose
  presence: Elevated
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:6378696
    reference_title: "Pre-type I diabetes. Linear loss of beta cell response to intravenous glucose."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Elevations of fasting blood glucose and peak glucose during oral glucose tolerance tests were not observed until the year before onset of clinically overt diabetes.
    explanation: This reference suggests that elevated blood glucose is present, but only becomes noticeable in the year before the onset of type 1 diabetes, not necessarily 'VERY_FREQUENT' earlier on.
  - reference: PMID:33595181
    reference_title: "Liver chemistries in glycogenic hepatopathy associated with type 1 diabetes mellitus: A systematic review and pooled analysis."
    supports: NO_EVIDENCE
    evidence_source: HUMAN_CLINICAL
    snippet: Glycogenic hepatopathy (GH) in type 1 diabetes-mellitus (T1DM) is characterized by hepatomegaly and perturbations of liver chemistries (LC) that have not been well studied.
    explanation: The focus of this study is on liver chemistries in glycogenic hepatopathy associated with type 1 diabetes, not specifically on the frequency of elevated blood glucose.
  - reference: PMID:18502304
    reference_title: "Type 1 diabetes, hyperglycaemia, and the heart."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Type 1 diabetes is associated with a substantially increased risk of cardiovascular disease... microvascular complications...hyperglycaemia is indeed a mediator of cardiovascular risk in type 1 diabetes.
    explanation: This reference supports that elevated blood glucose (hyperglycaemia) is a common and significant factor in type 1 diabetes, indicating that it is 'VERY_FREQUENT'.
- name: Hemoglobin A1c (HbA1c)
  presence: Elevated
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:22847316
    reference_title: "1,5-Anhydroglucitol in diabetes mellitus."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The measure of glycated hemoglobin (HbA1c) concentration is the gold standard of glycemic control index in diabetes management and is well known as a marker for diabetes complications.
    explanation: Hemoglobin A1c is frequently measured in the management of diabetes, including Type I diabetes, and elevated levels are indicative of poor glycemic control.
  - reference: PMID:26397266
    reference_title: "Elevated Hemoglobin A1C Levels Correlate with Blood Glucose Elevation in Diabetic Patients following Local Corticosteroid Injection in the Hand: A Prospective Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Hemoglobin A1c is the accepted measure of long-term plasma glucose control in diabetics (levels >/=7 percent reflect poor blood glucose control).
    explanation: Elevated HbA1c levels are a common indicator used in the management of diabetes, supporting the claim of frequent elevated HbA1c in Type I diabetes.
- name: NMR metabolomic risk score (MetRS)
  specificity: >
    A research composite, not a clinical assay. MetRS is a machine-learning
    score built from the top 30 of 313 Nightingale Health NMR plasma measures,
    derived and replicated in UK Biobank. It is not validated for clinical use
    and does not replace glucose, HbA1c or islet autoantibody testing, which
    remain the basis of type 1 diabetes diagnosis and staging.
  context: >
    In the UK Biobank metabolome-phenome atlas, MetRS classified prevalent
    type 1 diabetes with an area under the curve of 0.944, the highest of the
    four diagnostic areas under the curve the source reports (type 1 diabetes
    0.944, type 2 diabetes 0.941, diabetic maculopathy 0.940, chronic kidney
    disease 0.933). The source does not rank it highest across the whole
    analysis, and this entry does not claim that. No presence value is
    recorded because MetRS is a derived multi-analyte score rather than a
    measured analyte. The score is a readout of the systemic metabolic
    consequences of insulin deficiency in people who already have the disease;
    it carries no information about islet autoimmunity, and nothing here
    supports using metabolomics in place of autoantibody-based staging or to
    distinguish type 1 from type 2 diabetes. The cohort is middle-aged and
    older adult volunteers, so prevalent cases are largely long-standing and
    insulin-treated.
  readouts:
  - target: Hyperglycemia
    relationship: CORRELATES_WITH
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >
      The glycolysis-related, ketone-body, amino-acid and lipoprotein measures
      that dominate MetRS shift with sustained hyperglycemia and insulin
      deficiency, so the score reads out the systemic metabolic state rather
      than the autoimmune process that causes it.
  evidence:
  - reference: PMID:40973818
    reference_title: "Mapping the plasma metabolome to human health and disease in 274,241 adults."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "The MetRS witnessed excellent diagnosis for type 1 diabetes (T1D; AUC = 0.944), T2D (AUC = 0.941), diabetic maculopathy (AUC = 0.940) and chronic kidney disease (CKD; AUC = 0.933)."
    explanation: >
      Quotes the reported diagnostic areas under the curve directly, giving
      both the type 1 diabetes figure of 0.944 and the three comparators it
      is ranked against in the context field.
genetic:
- name: HLA-DQ2
  affected_regions:
  - name: HLA-DQ2.5 haplotype (DQA1*05-DQB1*02)
    overlaps_genes:
    - preferred_term: HLA-DQA1
      term:
        id: hgnc:4942
        label: HLA-DQA1
    - preferred_term: HLA-DQB1
      term:
        id: hgnc:4944
        label: HLA-DQB1
    description: The DQ2.5 risk molecule is encoded by a cis haplotype of HLA-DQA1*05 and HLA-DQB1*02 alleles in the HLA class II region; both genes contribute a chain of the antigen-presenting heterodimer.
  association: Susceptibility
  relationship_type: RISK_FACTOR
  variant_origin: GERMLINE
  notes: HLA-DQ2 is a haplotype-level risk label spanning two genes, HLA-DQA1 and HLA-DQB1, rather than a single HGNC-resolvable gene, so the genes are recorded on the affected region and no single gene_term is bound.
  evidence:
  - reference: PMID:22184118
    reference_title: "Type 1 diabetes-associated HLA-DQ8 transdimer accommodates a unique peptide repertoire."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: HLA-DQ2 and HLA-DQ8 are strongly predisposing haplotypes for type 1 diabetes (T1D).
    explanation: This study identifies HLA-DQ2 as a strongly predisposing haplotype for type 1 diabetes susceptibility.
  - reference: PMID:31331105
    reference_title: "HLA-DQA1 and HLA-DQB1 Alleles, Conferring Susceptibility to Celiac Disease and Type 1 Diabetes, are More Expressed Than Non-Predisposing Alleles and are Coordinately Regulated."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: HLA DQA1*05 and DQB1*02 alleles encoding the DQ2.5 molecule and HLA DQA1*03 and DQB1*03 alleles encoding DQ8 molecules are strongly associated with celiac disease (CD) and type 1 diabetes (T1D)
    explanation: Identifies the HLA-DQA1 and HLA-DQB1 alleles that together encode the DQ2.5 risk molecule.
- name: HLA-DQ8
  affected_regions:
  - name: HLA-DQ8 haplotype (DQA1*03:01-DQB1*03:02)
    overlaps_genes:
    - preferred_term: HLA-DQA1
      term:
        id: hgnc:4942
        label: HLA-DQA1
    - preferred_term: HLA-DQB1
      term:
        id: hgnc:4944
        label: HLA-DQB1
    description: The DQ8 risk molecule is encoded by a cis haplotype of HLA-DQA1*03:01 and HLA-DQB1*03:02 alleles in the HLA class II region.
  association: Susceptibility
  relationship_type: RISK_FACTOR
  variant_origin: GERMLINE
  notes: HLA-DQ8 is a haplotype-level risk label spanning two genes, HLA-DQA1 and HLA-DQB1, rather than a single HGNC-resolvable gene, so the genes are recorded on the affected region and no single gene_term is bound.
  evidence:
  - reference: PMID:22184118
    reference_title: "Type 1 diabetes-associated HLA-DQ8 transdimer accommodates a unique peptide repertoire."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: HLA-DQ2 and HLA-DQ8 are strongly predisposing haplotypes for type 1 diabetes (T1D).
    explanation: This statement specifically mentions HLA-DQ8 as a strong predisposing haplotype for type 1 diabetes, supporting the association with susceptibility.
  - reference: PMID:26492519
    reference_title: "The association between the HLA-G 14-bp insertion/deletion polymorphism and type 1 diabetes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The DR3-DQ2/DR4-DQ8 genotype conferred the highest detected risk for T1D.
    explanation: This study identifies the DR4-DQ8 genotype as highly associated with a risk for developing type 1 diabetes, thus supporting the genetic susceptibility.
  - reference: PMID:34946827
    reference_title: "Next Generation Sequencing Identifies the HLA-DQA1*03:03 Allele in the Type 1 Diabetes Risk-Associated HLA-DQ8 Serotype."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The combination of HLA-DQA1*03:01 and DQB1*03:02 alleles (summarized as 'HLA-DQ8') is reported to be among the two most prevalent HLA class II haplotypes in Caucasian type 1 diabetes patients.
    explanation: This reference confirms that HLA-DQ8 is one of the most prevalent haplotypes among type 1 diabetes patients in the studied population, supporting its association with susceptibility.
- name: INS
  gene_term:
    preferred_term: INS
    term:
      id: hgnc:6081
      label: INS
  association: Susceptibility
  relationship_type: SUSCEPTIBILITY
  variant_origin: GERMLINE
  notes: Insulin gene; VNTR/INS expression influences central and peripheral tolerance to insulin
  evidence:
  - reference: PMID:15529622
    reference_title: "Strong association of insulin gene INS-VNTR polymorphisms with type 1 diabetes in the Romanian population."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Our results indicate an exceptionally strong association of the class I INS-VNTR alleles with T1DM for the Romanian population.
    explanation: The study presents evidence of a strong association between INS-VNTR alleles of the insulin gene and susceptibility to type 1 diabetes in the Romanian population.
  - reference: PMID:8934932
    reference_title: "Type I insulin-dependent diabetes mellitus: a model for autoimmune polygenic disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Genetic susceptibility predominantly results from specific alleles in the HLA complex and insulin gene region.
    explanation: This paper states that genetic susceptibility to insulin-dependent diabetes mellitus predominantly results from specific alleles, including those in the insulin gene region.
  - reference: PMID:11845220
    reference_title: "Genetic linkage and association studies of Type I diabetes: challenges and rewards."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: However, only within the past decade has it been possible to systematically attempt to identify the genes that increase susceptibility to this disorder using linkage and association analysis of genetic markers distributed across the genome.
    explanation: This study discusses the identification of susceptibility genes for type 1 diabetes, including the insulin gene.
  - reference: PMID:11921414
    reference_title: "The insulin gene in diabetes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Because insulin has such a central role in the pathogenesis of both forms of diabetes, the insulin gene (INS) has always been considered a candidate susceptibility gene.
    explanation: The paper directly states that the insulin gene is considered a candidate susceptibility gene.
  - reference: PMID:11347740
    reference_title: "Concordance for type 1 diabetes in identical twins is affected by insulin genotype."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The disease-associated INS genotype (Hph I) was identified in 87.5% of the concordant twins but only in 59.5% (P = 0.005) of the discordant twins.
    explanation: The study demonstrates the presence of a disease-associated INS genotype in a high percentage of concordant twins for type 1 diabetes.
  - reference: PMID:33483996
    reference_title: "De-coding genetic risk variants in type 1 diabetes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Over half of the genetic risk has been attributed to the human leukocyte antigen (HLA) class II gene region and to the insulin (INS) gene locus.
    explanation: This article attributes a significant portion of the genetic risk for type 1 diabetes to the insulin (INS) gene locus.
- name: PTPN22
  gene_term:
    preferred_term: PTPN22
    term:
      id: hgnc:9652
      label: PTPN22
  association: Susceptibility
  relationship_type: SUSCEPTIBILITY
  variant_origin: GERMLINE
  notes: Tyrosine phosphatase that negatively regulates TCR signaling; risk alleles alter T cell activation thresholds
  evidence:
  - reference: PMID:15734872
    reference_title: "Genetic association between a lymphoid tyrosine phosphatase (PTPN22) and type 1 diabetes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The homozygous genotype for the T allele encoding the 620W residue is associated with an increased risk for developing type 1 diabetes
    explanation: This study demonstrates that the PTPN22 R620W polymorphism confers significant genetic susceptibility to type 1 diabetes in Caucasian populations.
- name: IL2RA
  gene_term:
    preferred_term: IL2RA
    term:
      id: hgnc:6008
      label: IL2RA
  association: Susceptibility
  relationship_type: SUSCEPTIBILITY
  variant_origin: GERMLINE
  notes: IL-2 receptor alpha chain; modulates regulatory T cell (Treg) fitness and homeostasis
  evidence:
  - reference: PMID:22461703
    reference_title: "Type 1 diabetes-associated IL2RA variation lowers IL-2 signaling and contributes to diminished CD4+CD25+ regulatory T cell function."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: CD4(+)CD25(+) regulatory T cells (Tregs) from individuals with a range of human autoimmune diseases, including type 1 diabetes, are deficient in their ability to control autologous proinflammatory responses
    explanation: This study demonstrates that IL2RA variants associated with type 1 diabetes lead to diminished IL-2 responsiveness and impaired regulatory T cell function.
- name: CTLA4
  gene_term:
    preferred_term: CTLA4
    term:
      id: hgnc:2505
      label: CTLA4
  association: Susceptibility
  relationship_type: SUSCEPTIBILITY
  variant_origin: GERMLINE
  notes: Immune-checkpoint receptor that limits T cell activation and promotes tolerance
  evidence:
  - reference: PMID:9353155
    reference_title: "CTLA-4 gene polymorphism confers susceptibility to insulin-dependent diabetes mellitus (IDDM) independently from age and from other genetic or immune disease markers. The Belgian Diabetes Registry."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: the presence of a G-containing CTLA-4 genotype confers a moderate but significant RR for IDDM that is independent of age and genetic or immune disease markers
    explanation: This study demonstrates that CTLA4 gene polymorphisms confer susceptibility to type 1 diabetes independent of other genetic and immune markers.
- name: TYK2
  gene_term:
    preferred_term: TYK2
    term:
      id: hgnc:12440
      label: TYK2
  association: Susceptibility
  relationship_type: SUSCEPTIBILITY
  variant_origin: GERMLINE
  notes: Janus-family kinase in type I IFN/JAK signaling; variants affect interferon responses and beta-cell sensitivity
  evidence:
  - reference: PMID:26239055
    reference_title: "TYK2, a Candidate Gene for Type 1 Diabetes, Modulates Apoptosis and the Innate Immune Response in Human Pancreatic β-Cells."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      TYK2-silenced human β-cells exposed to polyinosinic-polycitidilic acid
      (PIC) (a mimick of double-stranded RNA produced during viral infection)
      showed less type I IFN pathway activation and lower production of IFNα and
      CXCL10.
    explanation: >-
      Places the protective TYK2 variants on the beta-cell side of the viral
      interferon model. Silencing TYK2 in human beta cells blunts the type I
      interferon response, chemokine output and MHC class I induction that
      follow a viral RNA mimic, matching the reduced disease risk carried by
      loss-of-function alleles.
- name: IFIH1
  gene_term:
    preferred_term: IFIH1
    term:
      id: hgnc:18873
      label: IFIH1
  association: Susceptibility
  relationship_type: SUSCEPTIBILITY
  variant_origin: GERMLINE
  notes: >-
    Cytosolic viral RNA sensor (MDA5) implicated in antiviral signaling and
    linkage to autoimmune risk. The rs1990760 (Thr946Ala) predisposing allele
    tracks with enterovirus RNA detection in peripheral blood but not with
    enteroviral capsid protein in islets, and its reported gain of interferon
    signaling has been reproduced in overexpressing cell lines rather than in
    primary cells from carriers.
  evidence:
  - reference: PMID:35867130
    reference_title: "Detection of enterovirus RNA in peripheral blood mononuclear cells correlates with the presence of the predisposing allele of the type 1 diabetes risk gene IFIH1 and with disease stage."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Furthermore, we found that individuals carrying the predisposing allele
      (946Thr) of the common variant in IFIH1 (rs1990760, Thr946Ala) are more
      likely to test positive for enterovirus in peripheral blood (OR 3.07; 95%
      CI 1.02, 8.58; p=0.045).
    explanation: >-
      Links the IFIH1 risk allele to measurable enterovirus carriage in
      patients, which is the genetic-environmental junction the viral
      interferon model requires. The odds ratio is modest with a confidence
      interval close to unity.
  - reference: PMID:35867130
    reference_title: "Detection of enterovirus RNA in peripheral blood mononuclear cells correlates with the presence of the predisposing allele of the type 1 diabetes risk gene IFIH1 and with disease stage."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In contrast, using immunohistochemistry, there was no correlation between
      the common variant in IFIH1 and detection of enteroviral VP1 protein in
      the pancreatic islets of donors with type 1 diabetes.
    explanation: >-
      The same study finds no relationship between the IFIH1 variant and
      enteroviral protein in the target organ. Carried alongside the positive
      blood result so the genotype-to-islet step is not read as established.
  - reference: PMID:39373578
    reference_title: "The Type 1 Diabetes-Associated Single Nucleotide Polymorphism rs1990760 in IFIH1 Is Associated with Increased Basal Type I IFNs and IFN-stimulated Gene Expression."
    supports: SUPPORT
    evidence_source: IN_VITRO
    directness: INDIRECT
    snippet: >-
      We found that in cell lines overexpressing the risk variant IFIH1946T
      there was an elevated level of basal type I IFN signaling and increased
      basal IFN-stimulated gene expression.
    explanation: >-
      Supplies the proposed mechanism, a gain of basal interferon signaling by
      the risk MDA5 protein, but only in overexpressing cell lines. The same
      paper saw no significant change in type I interferon or interferon
      stimulated genes in primary blood mononuclear cells from risk-allele
      carriers infected with coxsackievirus B3, so the effect is graded
      indirect.
- name: BACH2
  gene_term:
    preferred_term: BACH2
    term:
      id: hgnc:14078
      label: BACH2
  association: Susceptibility
  relationship_type: SUSCEPTIBILITY
  variant_origin: GERMLINE
  notes: Transcriptional regulator controlling immune-cell differentiation and tolerance maintenance
  evidence: []
- name: TNFAIP3
  gene_term:
    preferred_term: TNFAIP3
    term:
      id: hgnc:11896
      label: TNFAIP3
  association: GWAS
  relationship_type: SUSCEPTIBILITY
  variant_origin: GERMLINE
  notes: Encodes A20, a ubiquitin-editing enzyme that negatively regulates NF-kB signaling
- name: EGR2
  gene_term:
    preferred_term: EGR2
    term:
      id: hgnc:3239
      label: EGR2
  association: GWAS
  relationship_type: SUSCEPTIBILITY
  variant_origin: GERMLINE
  notes: Transcription factor involved in T cell anergy and peripheral tolerance
- name: IRF4
  gene_term:
    preferred_term: IRF4
    term:
      id: hgnc:6119
      label: IRF4
  association: GWAS
  relationship_type: SUSCEPTIBILITY
  variant_origin: GERMLINE
  notes: Transcription factor essential for Th17 and Th2 cell differentiation and plasma cell development
- name: IKZF1
  gene_term:
    preferred_term: IKZF1
    term:
      id: hgnc:13176
      label: IKZF1
  association: GWAS
  relationship_type: SUSCEPTIBILITY
  variant_origin: GERMLINE
  notes: Ikaros transcription factor essential for lymphocyte development and differentiation
environmental:
- name: Viral Infections
  influences_mechanisms:
  - target: Environmental Triggers
    environmental_effect: TRIGGERS
    causal_link_type: DIRECT
    description: >-
      This node names viral infection in its own text as a trigger acting in
      genetically susceptible individuals, so the exposure is the node's own
      content. The evidence is unusually deep for this backfill, and the two
      items carried here are the two that do different work: one takes the
      virus as far as the beta cell, and the other is the single infection the
      literature treats as settled rather than candidate.
    evidence:
    - reference: PMID:23393684
      reference_title: "Viral infections and diabetes."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "One of the environmental risk factors identified by a series of independent studies is represented by viral infection, with strong evidence showing that viruses can indeed infect pancreatic beta cells with consequent effects ranging from functional damage to cell death."
      explanation: >-
        States that viruses can infect pancreatic beta cells with effects
        ranging from functional damage to cell death. It reaches the target
        tissue rather than stopping at association.
    - reference: PMID:11334504
      reference_title: "Type 1A diabetes induced by infection and immunization."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Congenital rubella is the only infection clearly associated with the development of type 1A diabetes."
      explanation: >-
        Names congenital rubella as the only infection clearly associated with
        the disease. The word clearly is doing real work: most of this entry's
        viral evidence is explicitly candidate-level, and this item is not.
  notes: May trigger the autoimmune response in genetically susceptible individuals
  evidence:
  - reference: PMID:23393684
    reference_title: "Viral infections and diabetes."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: One of the environmental risk factors identified by a series of independent studies is represented by viral infection, with strong evidence showing that viruses can indeed infect pancreatic beta cells with consequent effects ranging from functional damage to cell death.
    explanation: This reference mentions that viral infections are a strong environmental risk factor for Type I Diabetes, affecting pancreatic beta cells which can lead to autoimmunity.
  - reference: PMID:22891485
    reference_title: "[Type 1 diabetes: from genetic predisposition to hypothetical environmental triggers]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Environmental factors must be involved such as viral infections, toxins from food, cow milk during childhood (instead of breast feeding) or vitamin D deficiency.
    explanation: This reference suggests that viral infections are among several environmental factors associated with Type I Diabetes, but does not pinpoint them as the singularly most critical factor.
  - reference: PMID:34942009
    reference_title: "Parainfluenza viruses: A trigger for type 1 diabetes new onset?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Enteroviruses, especially CoxB and Echo, are most represented.
    explanation: This reference supports the role of viral infections in Type I Diabetes, mentioning enteroviruses among others.
  - reference: PMID:18357774
    reference_title: "The CVB and etiology of type 1 diabetes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The most often cited environmental agents implicated as initiators of T1D are the human enteroviruses, in particular the group B coxsackieviruses (CVB).
    explanation: This reference supports the role of enteroviruses as environmental triggers for Type I Diabetes but notes that evidence is not firmly established.
  - reference: PMID:24003924
    reference_title: "Infectious triggers in type 1 diabetes: is there a case for epitope mimicry?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Enteroviruses are proposed candidate triggers due to temporal correlations between infection and T1D autoimmunity and to detection of viral proteins in diseased islets.
    explanation: The reference suggests enteroviruses as potential triggers for Type I Diabetes but emphasizes the need for more robust evidence for a causative relationship.
  - reference: PMID:11334504
    reference_title: "Type 1A diabetes induced by infection and immunization."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Congenital rubella is the only infection clearly associated with the development of type 1A diabetes.
    explanation: This reference specifically mentions congenital rubella as an infection clearly associated with Type I Diabetes, supporting the statement.
  - reference: PMID:31401790
    reference_title: "Genetic and Environmental Interaction in Type 1 Diabetes: a Relationship Between Genetic Risk Alleles and Molecular Traits of Enterovirus Infection?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The natural history of human type 1 diabetes (T1D) and the documented associations between virus infections (in particular the enteroviruses) and disease development.
    explanation: This reference discusses associations between viral infections, particularly enteroviruses, and Type I Diabetes development, but indicates a need for further studies.
  - reference: PMID:17691946
    reference_title: "Viral infection--a cure for type 1 diabetes?"
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: evidence from various animal models suggests that viruses can indeed initiate or accelerate autoimmune diseases, such as type 1 diabetes...
    explanation: This reference provides evidence from animal models that support the initiation or acceleration of Type I Diabetes by viruses.
  - reference: PMID:36950864
    reference_title: "COVID-19 as a Trigger for Type 1 Diabetes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Convincing evidence indicates that viruses are associated with T1D development and progression.
    explanation: This reference provides convincing evidence that viral infections, including SARS-CoV-2, may trigger or unmask Type I Diabetes.
  exposure_term:
    preferred_term: Viral infection exposure
    term:
      id: ECTO:3000001
      label: exposure to virus
- name: Early Dietary Factors
  influences_mechanisms:
  - target: Environmental Triggers
    environmental_effect: PREDISPOSES
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Named at the same node as viral infection but graded below it
      throughout, because the evidence points both ways and the entry already
      records that. The refuting item is carried on the link deliberately
      rather than left in the exposure block: the TRIGR trial removed intact
      cow's milk protein from infant feeding, measured type 1 diabetes itself,
      and found no reduction over a median of 11.5 years. Keeping it here
      means the negative result travels with the claim rather than sitting
      where a reader of the pathograph would never meet it. An earlier version
      of this link carried a different negative trial summary whose endpoint
      was celiac disease rather than this disease; that item has no bearing on
      the claim and was removed.
    evidence:
    - reference: PMID:8741809
      reference_title: "The relationship between cow's milk exposure and type 1 diabetes."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "There is a relationship between early cow's milk exposure and the development of Type 1 diabetes in humans, and between early cow's milk exposure and the development of autoimmune diabetes in rodent models of Type 1 diabetes."
      explanation: >-
        Reports a relationship between early cow's milk exposure and the
        disease in humans and in rodent models. An association, and the
        entry's own explanation concedes the data do not establish causation.
    - reference: PMID:29297078
      reference_title: "Effect of Hydrolyzed Infant Formula vs Conventional Formula on Risk of Type 1 Diabetes: The TRIGR Randomized Clinical Trial."
      supports: REFUTE
      evidence_source: HUMAN_CLINICAL
      snippet: "Among infants at risk for type 1 diabetes, weaning to a hydrolyzed formula compared with a conventional formula did not reduce the cumulative incidence of type 1 diabetes after median follow-up for 11.5 years"
      explanation: >-
        The TRIGR trial removed intact cow's milk protein from infant feeding
        and measured type 1 diabetes itself over a median 11.5 years. It found
        no reduction, which is evidence against the cow's milk hypothesis this
        exposure rests on. Carried on the link so the negative result is
        visible at the point of the claim rather than only in the exposure
        block.
    - reference: PMID:20640941
      reference_title: "Infant and childhood diet and type 1 diabetes risk: recent advances and prospects."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Given that type 1 diabetes, and its preclinical autoimmunity, appear early in life, infant and childhood diet have been implicated as potential initiating exposures in the etiology of the disease."
      explanation: >-
        Notes that because the disease and its preclinical autoimmunity appear
        early in life, infant diet has been implicated as a potential
        initiating exposure. Implication rather than finding.
  notes: Possible risk factors include early exposure to cow's milk and gluten
  evidence:
  - reference: PMID:8741809
    reference_title: "The relationship between cow's milk exposure and type 1 diabetes."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: There is a relationship between early cow's milk exposure and the development of Type 1 diabetes in humans, and between early cow's milk exposure and the development of autoimmune diabetes in rodent models of Type 1 diabetes.
    explanation: The reference supports early dietary factors such as cow's milk exposure but indicates that the data are insufficient to conclude a causal relationship.
  - reference: PMID:26605913
    reference_title: "Primary Prevention of Celiac Disease: Environmental Factors with a Focus on Early Nutrition."
    supports: NO_EVIDENCE
    evidence_source: HUMAN_CLINICAL
    snippet: Recently, the results of two large randomized trials have shown that breastfeeding in general, breastfeeding during gluten introduction, and early or delayed gluten introduction do not influence the total risk of CD in genetically predisposed individuals.
    explanation: The reference suggests that early or delayed introduction of gluten does not influence the risk of celiac disease, type 1 diabetes mellitus, and wheat allergy, providing no supporting evidence for early dietary factors as risk factors for Type 1 diabetes.
  - reference: PMID:20640941
    reference_title: "Infant and childhood diet and type 1 diabetes risk: recent advances and prospects."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Given that type 1 diabetes, and its preclinical autoimmunity, appear early in life, infant and childhood diet have been implicated as potential initiating exposures in the etiology of the disease.
    explanation: The reference implicates early dietary factors in the risk of Type 1 diabetes but also highlights inconsistencies and the need for further research.
  - reference: PMID:17203405
    reference_title: "Environmental factors in the development of Type 1 diabetes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Enteroviruses (especially Coxsackie B virus), breastfeeding, the early presence or lack of certain foods, birth weight, childhood over-nutrition, maternal islet autoimmunity, and negative stress events have been shown to be related to the prevalence of T1D.
    explanation: The reference supports a link between early dietary factors and Type 1 diabetes but does not provide conclusive evidence.
  exposure_term:
    preferred_term: Early dietary exposure
treatments:
- name: Insulin Therapy
  description: Essential treatment to replace the missing insulin and regulate blood glucose levels.
  evidence:
  - reference: PMID:21584767
    reference_title: "Insulin therapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Insulin therapy is a vital hormone replacement therapy in type 1 diabetes mellitus.
  - reference: PMID:36476434
    reference_title: "Therapies for Type 1 Diabetes: Is a Cure Possible?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The current standard method for type 1 diabetes (T1D) management majorly focuses on controlling blood glucose levels with exogeneous insulin administration.
  - reference: PMID:32342453
    reference_title: "Exercise and Type 1 Diabetes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: T1DM is caused by absolute lack of insulin secretion, so the current treatment for T1DM patients is exogenous insulin replacement therapy.
  - reference: PMID:31426099
    reference_title: "A Technological Revolution: The Integration of New Treatments to Manage Type 1 Diabetes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Although a cure for T1D remains the ultimate goal, technology holds the promise of keeping youth with T1D in targeted control and minimize the burden of this chronic medical condition.
    explanation: The reference acknowledges insulin therapy but focuses more on technological advancements rather than confirming insulin therapy as the essential treatment.
  - reference: PMID:28685788
    reference_title: "C-Peptide replacement therapy in type 1 diabetes: are we in the trough of disillusionment?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Replacing C-peptide, a hormone normally co-secreted with insulin, has been shown to reduce diabetes-related complications.
    explanation: This reference discusses auxiliary therapy but does not diminish the essential role of insulin therapy.
  - reference: PMID:33970586
    reference_title: "Diabetes: Type 1 Diabetes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The mainstay of management is a regimen of multiple daily injections of insulin or continuous subcutaneous insulin delivered via an insulin pump.
  - reference: PMID:15306833
    reference_title: "The reality of glycaemic control in insulin treated diabetes: defining the clinical challenges."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: There is, however, a limit to what can be achieved with existing exogenous insulin therapies due to their imperfect pharmacokinetic and pharmacodynamic profiles
  - reference: PMID:6749365
    reference_title: "Replacement treatment with insulin in diabetes mellitus: problems and promise."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: 'The results of epidemiological and clinical studies of diabetes in man and of studies of experimental diabetes in animals provide strong evidence: (1) that insulin-dependent diabetes mellitus is due to absolute or severe deficiency of insulin; (2) that replacement treatment with insulin is potentially capable of normalizing the metabolic abnormalities; and (3) that normalization of the metabolic abnormalities can be expected to prevent or ameliorate the complications of the disease'
  - reference: PMID:20666700
    reference_title: "Treatment options for paediatric diabetes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Insulin is the primary medication in the treatment of type 1 diabetes. New therapeutic options and prevention strategies (cellular therapies, immunomodulation and vaccination) aim to preserve residual beta-cell function.
    explanation: The focus on insulin as primary treatment supports the statement, despite mentioning new therapeutic options.
  treatment_term:
    preferred_term: insulin treatment
    term:
      id: NCIT:C179441
      label: Injected Insulin Diabetes Therapy
  target_mechanisms:
  - target: Insulin Deficiency
    treatment_effect: RESTORES
    description: >-
      Type 1 diabetes is absolute insulin deficiency from autoimmune beta-cell
      loss, so treatment is hormone REPLACEMENT: exogenous insulin directly
      corrects the deficiency node, normalizing the downstream metabolic
      abnormalities (hyperglycemia, lipolysis) and attenuating complications.
      This is the graph-level distinction from type 2 — insulin acts on the
      deficiency itself, not on insulin resistance or hepatic glucose output.
- name: Blood Glucose Monitoring
  description: Regular monitoring to manage glucose levels effectively.
  treatment_term:
    preferred_term: blood glucose assessment
    term:
      id: NCIT:C92744
      label: Blood Glucose Measurement
  evidence:
  - reference: PMID:30215903
    reference_title: "Type 1 Diabetes: Management Strategies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: There is considerable benefit of tight glucose control in patients with type 1 diabetes mellitus. ... Greater frequency of glucose monitoring and continuous glucose monitoring are both associated with lower A1C levels.
    explanation: The abstract emphasizes the importance of glucose monitoring in managing type 1 diabetes, supporting the statement that regular monitoring is crucial for effective glucose level management.
  - reference: PMID:32256447
    reference_title: "Monitoring of Pediatric Type 1 Diabetes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Regular self-monitoring of blood glucose levels, and ketones when indicated, is an essential component of type 1 diabetes (T1D) management.
    explanation: The abstract reaffirms that regular monitoring of blood glucose is essential for managing type 1 diabetes, supporting the statement.
  - reference: PMID:38551884
    reference_title: "[Insulin-treated diabetes in general practice]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Blood glucose monitoring has been an integral part of diabetes treatment for many years, whether for type 1 diabetic patients on multiple daily injections of insulin, insulin pumps or artificial pancreas, and now for patients with type 2 diabetes...
    explanation: The abstract describes blood glucose monitoring as a cornerstone in diabetes treatment, which includes the management of type 1 diabetes, thus supporting the statement.
  - reference: PMID:11149158
    reference_title: "Sick-day management in type 1 diabetes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Sick-day management requires increased monitoring of blood glucose and assessment for ketosis.
    explanation: The abstract highlights that during illness, increased blood glucose monitoring is necessary for managing type 1 diabetes, further supporting the statement about regular monitoring.
- name: Lifestyle Modifications
  description: Maintaining a balanced diet, regular physical activity, and adherence to treatment plans.
  evidence:
  - reference: PMID:9314011
    reference_title: "Lifestyle modifications for diabetes management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Nutrition therapy and physical activity can assist persons with diabetes to achieve metabolic goals. Several lifestyle strategies can be used.
    explanation: The text supports the assertion that maintaining a balanced diet and regular physical activity can assist in managing diabetes through lifestyle modifications.
  - reference: PMID:16529680
    reference_title: "Managing the athlete with type 1 diabetes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The patient and physician must work together to optimize glucose control involving both insulin administration and caloric intake. Exercise has numerous benefits and the type 1 diabetic should take advantage of these benefits.
    explanation: This supports the statement that lifestyle modifications, including diet and physical activity, are important in managing type 1 diabetes.
  - reference: PMID:24485215
    reference_title: "Lifestyle and cardiometabolic risk in adults with type 1 diabetes: a review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Poor lifestyle habits (poor diet quality, sedentary behaviours and smoking) are known to be driving factors for increased CMR factors in the general population.
    explanation: The text underlines the significance of maintaining a good lifestyle, including a balanced diet and physical activity, as part of diabetes management.
  - reference: PMID:32312302
    reference_title: "Lifestyle changes and glycemic control in type 1 diabetes mellitus: a trial protocol with factorial design approach."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Innovative, cost-effective interventions along with beneficial lifestyle modifications can improve home-based self-monitoring of blood glucose in T1D patients.
    explanation: This reference highlights the role of lifestyle modifications in managing type 1 diabetes through controlling blood glucose levels.
  - reference: PMID:37820077
    reference_title: "Treating obesity in type 1 diabetes mellitus - review of efficacy and safety."
    supports: NO_EVIDENCE
    evidence_source: HUMAN_CLINICAL
    snippet: Weight loss treatments provide a wide-range of benefits in reducing both morbidity and mortality in those who are obese.
    explanation: It mentions lifestyle interventions as a part of weight loss treatments that benefit T1D management, highlighting their efficacy and safety.
  treatment_term:
    preferred_term: Lifestyle Therapy
    term:
      id: NCIT:C15900
      label: Lifestyle Therapy
- name: Immunotherapy (Teplizumab)
  description: T-cell-targeting therapy that delays progression from stage 2 to stage 3 disease by approximately 2-3 years in early-stage patients.
  notes: FDA-approved 2022 for delaying clinical onset in presymptomatic individuals
  therapeutic_modality: MONOCLONAL_ANTIBODY
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: teplizumab
      term:
        id: NCIT:C88647
        label: Teplizumab
  target_mechanisms:
  - target: Autoimmune Destruction of Beta Cells
    treatment_effect: INHIBITS
    description: >-
      Teplizumab (anti-CD3 monoclonal antibody) targets the autoimmune T-cell
      attack itself — the upstream driver node — rather than its downstream
      metabolic consequences, blunting T-cell-mediated beta-cell destruction to
      delay progression from Stage 2 to clinical Stage 3 disease. It is the only
      T1D therapy that acts on the autoimmune mechanism node instead of the
      insulin-deficiency/hyperglycemia consequences, which is why it is
      disease-modifying (delays onset) rather than purely glucose-lowering.
  evidence:
  - reference: PMID:36877454
    reference_title: "Teplizumab: First Approval."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In November 2022, teplizumab was approved in the USA to delay the onset of Stage 3 T1D in adults and pediatric patients 8 years of age and older with Stage 2 T1D
    explanation: This article documents the FDA approval of teplizumab as the first immunotherapy for delaying type 1 diabetes progression.
- name: Rituximab (Anti-CD20 Immunotherapy)
  description: B-cell-depleting monoclonal antibody targeting CD20-expressing autoantibody-producing B cells to delay beta-cell destruction in recent-onset disease.
  notes: >-
    Investigational, not approved for T1DM. Phase 2 evidence only; a follow-on trial
    combining rituximab with expanded regulatory T cells did not achieve a statistically
    significant delay in progression, and adverse events were reported in 93% and 80% of
    participants across the two trials.
  therapeutic_modality: MONOCLONAL_ANTIBODY
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: rituximab
      term:
        id: NCIT:C1702
        label: Rituximab
  target_mechanisms:
  - target: Autoimmune Destruction of Beta Cells
    treatment_effect: INHIBITS
    description: >-
      Rituximab depletes CD20+ B cells responsible for producing islet autoantibodies,
      thereby reducing the autoimmune attack on beta cells and delaying functional decline.
  evidence:
  - reference: PMID:42496430
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The administration of rituximab results in the depletion of autoantibody-producing B cells and delayed C-peptide decline by approximately 8.2 months in a phase 2 trial of recent-onset T1DM
    explanation: Phase 2 trial data demonstrate rituximab's mechanism of B-cell depletion leads to measurable preservation of residual beta-cell function.
  - reference: PMID:42496430
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: A subsequent trial combining rituximab with autologous expanded regulatory T cells (Tregs) did not achieve statistically significant delay in disease progression, despite numerically improved outcomes compared with Treg monotherapy
    explanation: The follow-on combination trial failed to reproduce a significant delay in progression, so this source does not support rituximab as an established disease-modifying therapy.
- name: Abatacept (Costimulation Blockade)
  description: CTLA4-Ig fusion protein that blocks T-cell costimulation to reduce autoreactive T-cell activation and beta-cell destruction.
  notes: >-
    Investigational, not approved for T1DM. Phase 2 biological activity only; the source
    review states that none of these agents has yet demonstrated durable, clinically
    meaningful endpoints and that the evidence base is insufficient to support routine
    use outside of clinical trials.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: abatacept
      term:
        id: NCIT:C28898
        label: Abatacept
  target_mechanisms:
  - target: Autoimmune Destruction of Beta Cells
    treatment_effect: INHIBITS
    description: >-
      Abatacept blocks CD80/CD86-CD28 T-cell costimulatory signaling, impairing
      autoreactive T-cell activation and reducing beta-cell-directed immune attack.
  evidence:
  - reference: PMID:42496430
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Abatacept (costimulation blockade), low-dose IL-2 (to expand regulatory T cells), and golimumab (anti-TNF-α) have each shown biological activity in phase 2 trials
    explanation: Phase 2 trial data report biological activity for costimulation blockade in type 1 diabetes.
- name: Golimumab (Anti-TNF-α Therapy)
  description: TNF-α inhibitor that reduces pro-inflammatory signaling driving beta-cell autoimmunity and preserves residual beta-cell function.
  notes: >-
    Investigational, not approved for T1DM. The 43% reduction in C-peptide decline is a
    phase 2 result; the source review states that none of these agents has yet
    demonstrated durable, clinically meaningful endpoints and that the evidence base is
    insufficient to support routine use outside of clinical trials.
  therapeutic_modality: MONOCLONAL_ANTIBODY
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: golimumab
      term:
        id: NCIT:C87766
        label: Golimumab
  target_mechanisms:
  - target: Autoimmune Destruction of Beta Cells
    treatment_effect: INHIBITS
    description: >-
      Golimumab inhibits TNF-α-mediated inflammatory signaling that drives T-cell
      activation and beta-cell destruction, preserving remaining functional beta cells.
  evidence:
  - reference: PMID:42496430
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: golimumab (anti-TNF-α) have each shown biological activity in phase 2 trials, including a 43% reduction in C-peptide decline with golimumab after 52 weeks
    explanation: Phase 2 trial data demonstrate significant C-peptide preservation with TNF-α inhibition in recent-onset disease.
- name: Rotavirus Vaccination
  description: Vaccine strategy investigated on the basis of a reduced T1DM incidence observed in rotavirus-vaccinated cohorts.
  notes: >-
    Investigational and observational only. The source review reports that the 33% risk
    reduction was partially corroborated by a later meta-analysis finding 13%, and states
    that these are observational findings that may be subject to confounding, with no
    randomized trial data available. No causal mechanism linking rotavirus to beta-cell
    autoimmunity is asserted by the source or modeled in this entry's pathophysiology, so
    this treatment is deliberately not linked to a mechanism node.
  therapeutic_modality: VACCINE
  treatment_term:
    preferred_term: Vaccination
    term:
      id: NCIT:C15346
      label: Vaccination
    therapeutic_agent:
    - preferred_term: rotavirus vaccine
      term:
        id: NCIT:C96394
        label: Rotavirus Vaccine
  evidence:
  - reference: PMID:42496430
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: A large nationwide cohort study by Rogers et al. (2019) reported a 33% reduction in T1DM risk associated with the completion of all rotavirus vaccine doses
    explanation: Population-level cohort evidence demonstrates protective association between rotavirus vaccination and reduced type 1 diabetes incidence.
- name: BCG Vaccination
  description: Bacillus Calmette-Guérin vaccine proposed to modulate T-lymphocyte responses and delay T1DM progression in at-risk individuals.
  notes: >-
    Investigational, not approved for T1DM. The source review states that this evidence is
    limited to a small number of studies and that the finding requires replication in
    adequately powered trials.
  therapeutic_modality: VACCINE
  treatment_term:
    preferred_term: Vaccination
    term:
      id: NCIT:C15346
      label: Vaccination
    therapeutic_agent:
    - preferred_term: BCG vaccine
      term:
        id: NCIT:C298
        label: BCG Vaccine
  target_mechanisms:
  - target: Autoimmune Destruction of Beta Cells
    treatment_effect: INHIBITS
    description: >-
      BCG vaccine modulates T-lymphocyte responses, favoring regulatory and cytotoxic T-cell
      populations, thereby reducing pathogenic T-cell-mediated beta-cell destruction.
  evidence:
  - reference: PMID:42496430
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The Bacillus Calmette–Guérin (BCG) vaccine has been proposed to confer some protection against T1DM progression, with one study by Doupis et al. (2021) reporting a delay of approximately 2.5 years with a single dose administered at age 9
    explanation: One study reported a delay in T1DM progression after a single BCG dose, the observation behind the proposed immunomodulatory mechanism.
- name: Continuous Glucose Monitoring
  description: Real-time glucose monitoring systems for improved glycemic control and reduced hypoglycemic events.
  notes: Associated with lower HbA1c levels and improved time in range
  treatment_term:
    preferred_term: continuous blood glucose assessment
    term:
      id: NCIT:C92744
      label: Blood Glucose Measurement
  evidence:
  - reference: PMID:34872983
    reference_title: "Universal Subsidized Continuous Glucose Monitoring Funding for Young People With Type 1 Diabetes: Uptake and Outcomes Over 2 Years, a Population-Based Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: After CGM introduction, the odds ratio (OR) of achieving the HbA1c target of <7.0% improved at 12 months (OR 2.5, P < 0.001) and was maintained at 24 months
    explanation: This population-based study demonstrates that continuous glucose monitoring significantly improves glycemic control with sustained improvements in HbA1c target achievement.
discussions:
- discussion_id: gap_t1d_viral_interferon_autoimmunity_bridge
  prompt: >-
    Which viral-exposure context converts transient islet interferon signaling
    and gut-pancreas lymph-node inflammatory crosstalk into durable beta-cell
    autoimmunity in HLA-risk individuals?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Environmental Triggers
  - pathophysiology#Interferon-Driven Beta Cell Response
  - pathophysiology#Gut-Pancreas Lymph Node Crosstalk
  - pathophysiology#Autoimmune Destruction of Beta Cells
  rationale: >-
    The entry can now represent viral exposure as both an upstream islet
    interferon trigger and a candidate gut-pancreas lymph-node accelerator, but
    human causal ordering remains unresolved. Distinguishing transient antiviral
    beta-cell stress from a self-sustaining adaptive autoimmune program would
    determine whether the actionable window is antiviral prevention,
    interferon/JAK blockade, lymph-node immune modulation, beta-cell stress
    protection, or combinations stratified by HLA and islet-autoantibody stage.
  proposed_experiments:
  - experiment_id: exp_t1d_hla_islet_ln_viral_interferon_bridge
    name: HLA-stratified islet lymph-node viral-interferon bridge assay
    description: >-
      Pair HLA-DQ2/DQ8-stratified human islets or stem-cell-derived beta-cell
      clusters with autologous dendritic cells and T cells in a lymph-node-like
      microphysiological coculture; compare enterovirus or viral-RNA exposure,
      IFNAR/JAK blockade, and chemokine blockade for their effects on beta-cell
      antigen presentation, CXCL10 output, T-cell activation, and beta-cell
      survival.
    experiment_type:
      preferred_term: human islet immune coculture perturbation experiment
    model_systems:
    - name: HLA-stratified human islet immune lymph-node-on-chip
      description: >-
        Human islet or iPSC-derived beta-cell microphysiology system connected
        to autologous dendritic-cell and T-cell compartments to test whether
        antiviral interferon exposure is sufficient to license beta-cell-reactive
        adaptive immune activation.
      experimental_model_type: ORGAN_ON_CHIP
      namo_type: namo:OrganOnChip
      organism:
        preferred_term: human
        term:
          id: NCBITaxon:9606
          label: Homo sapiens
      tissue_term:
        preferred_term: pancreas
        term:
          id: UBERON:0001264
          label: pancreas
      cell_types:
      - preferred_term: type B pancreatic cell
        term:
          id: CL:0000169
          label: type B pancreatic cell
      - preferred_term: dendritic cell
        term:
          id: CL:0000451
          label: dendritic cell
      - preferred_term: T cell
        term:
          id: CL:0000084
          label: T cell
    perturbations:
    - name: Enterovirus or viral-RNA exposure
      target: pathophysiology#Environmental Triggers
      description: >-
        Apply infectious enterovirus under containment or a viral-RNA mimic to
        induce beta-cell antiviral sensing and local interferon responses.
      effect: induces antiviral interferon signaling
    - name: IFNAR/JAK pathway blockade
      target: pathophysiology#Interferon-Driven Beta Cell Response
      description: >-
        Block type I interferon receptor or downstream JAK signaling to test
        whether beta-cell immunogenicity and T-cell activation require
        interferon signaling.
      effect: decreases interferon signaling
    readouts:
    - name: Beta-cell antigen-presentation and chemokine induction
      target: pathophysiology#Interferon-Driven Beta Cell Response
      description: >-
        Quantify beta-cell HLA class I antigen presentation, interferon-stimulated
        genes, CXCL10 secretion, oxidative phosphorylation, and survival.
    - name: Beta-cell-reactive T-cell activation
      target: pathophysiology#Autoimmune Destruction of Beta Cells
      description: >-
        Measure T-cell activation, cytokine production, beta-cell killing, and
        persistence after viral or interferon stimuli are withdrawn.
    decision_criterion: >-
      A sustained beta-cell-reactive T-cell response that persists after viral
      stimulus withdrawal, and is prevented by interferon/JAK or chemokine-axis
      blockade, would support a causal viral-interferon bridge rather than a
      transient bystander antiviral state.
- discussion_id: gap_t1d_interferon_protective_versus_destructive_balance
  prompt: >-
    What decides whether the interferon programs induced in a beta cell favour
    destruction, through MHC class I overexpression and chemokine release, or
    protection, through PD-L1 and HLA-E checkpoint ligands?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Interferon-Driven Beta Cell Response
  - pathophysiology#Autoimmune Destruction of Beta Cells
  rationale: >-
    The same interferon-alpha exposure that raises antigen presentation and
    chemokine output on human beta cells also raises the checkpoint ligands
    PD-L1 and HLA-E, so this node carries opposing programs rather than a single
    destructive one. Two clinical observations bracket the question without
    answering it. Blocking PD-1 or PD-L1 pharmacologically produces
    insulin-dependent diabetes in close to one percent of treated cancer
    patients, which shows the protective arm is load-bearing in people.
    Sustained exogenous interferon-alpha in chronic hepatitis C produces the
    disease at ten to eighteen times background rate, which shows enough
    interferon overwhelms that arm. What is missing is any quantitative account
    of where the crossover sits, whether it is set by interferon dose, by
    duration, by genotype, or by disease stage. Without it the entry cannot say
    why most viral infections never produce autoimmune diabetes, and cannot
    predict who would benefit from interferon or JAK blockade rather than be
    harmed by it.
  evidence:
  - reference: PMID:29937434
    reference_title: "Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We conclude that autoimmune, insulin-dependent diabetes occurs in close to
      1% of patients treated with anti-PD-1 or -PD-L1 CPIs.
    explanation: >-
      Establishes the premise of this gap in humans. Removing the PD-1 and PD-L1
      brake pharmacologically is by itself sufficient to precipitate
      insulin-dependent diabetes, so the protective arm of the interferon
      response is load-bearing and the balance between the two arms is a real
      determinant rather than a modelling convenience.
review_notes: Type 1 diabetes is an immune-mediated disease in which autoreactive CD8+ and CD4+ T cells destroy insulin-producing pancreatic beta cells, leading to absolute insulin deficiency. Interferon signaling (type I and II) plays a central role in beta-cell intrinsic responses, upregulating antigen presentation and chemokine production while downregulating oxidative phosphorylation. The disease is dominated by HLA class II genetic risk, with additional non-HLA loci (INS, PTPN22, IL2RA, CTLA4, TYK2, IFIH1, BACH2) contributing to immune regulation and beta-cell susceptibility. The natural history spans three stages from silent autoimmunity (stage 1) through dysglycemia (stage 2) to symptomatic hyperglycemia (stage 3). Teplizumab, a T-cell-targeting immunotherapy approved in 2022, can delay progression by approximately 2-3 years in early-stage disease.
disease_term:
  preferred_term: type 1 diabetes mellitus
  term:
    id: MONDO:0005147
    label: type 1 diabetes mellitus
gene_sets:
- gene_set: MYGENESET:KEGG_TYPE_I_DIABETES_MELLITUS
  relationship: CANONICAL_PATHWAY
  note: >-
    KEGG type I diabetes mellitus pathway.
classifications:
  harrisons_chapter:
  - classification_value: ENDOCRINOLOGY_METABOLISM
  - classification_value: IMMUNE_RHEUMATOLOGIC
datasets:
- accession: ega:EGAS00001007010
  title: Whole exome sequencing in family trios reveals de novo mutations associated to Type 1 Diabetes Mellitus
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: WES
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("type 1 diabetes mellitus"); description-level mentions were not accepted. EGA study_type: Exome Sequencing. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: massive:MSV000087986
  title: Proteomics of high density lipoprotein subfractions in type 1 diabetes mellitus and controls
  description: Toyoshima MTK. Proteomics and functionality of high-density lipoprotein subfractions and subclinical cardiovascular disease in type 1 diabetes mellitus. Faculdade de Medicina, Universidade de Sao Paulo 2021.
  notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from massive. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("type 1 diabetes mellitus"). Retrieved 2026-08-02.

📚

References & Deep Research

Deep Research

2

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Disorder ▸

Disorder

Name: Type I Diabetes
Category: Metabolic
Existing deep-research providers: falcon
Existing evidence reference count in YAML: 140

Key Pathophysiology Nodes

Genetic Susceptibility
Environmental Triggers
Interferon-Driven Beta Cell Response
Autoimmune Destruction of Beta Cells
Insulin Deficiency
Hyperglycemia
Impaired Glucose Utilization
ER Stress and Unfolded Protein Response
Increased Lipolysis
Chronic Complications
Diabetic Ketoacidosis (DKA)
Deep research literature mapping

Citation Inventory (for evidence mapping)

DOI:10.1007/s00125-024-06092-w
DOI:10.1007/s00125-024-06106-7
DOI:10.1038/s41577-023-00985-4
DOI:10.1038/s43856-024-00478-y
DOI:10.1101/2024.07.03.24309894
DOI:10.1101/cshperspect.a041593
DOI:10.1111/dom.16628
DOI:10.1186/s12902-024-01667-5
DOI:10.1186/s42269-024-01197-z
DOI:10.1210/clinem/dgaf267

Falcon ▸

Disease Pathophysiology Research Report

Edison Scientific Literature 32 citations 2025-12-15T10:17:21.072234

Disease Pathophysiology Research Report

Target Disease - Disease Name: Type 1 Diabetes (T1D) - MONDO ID: MONDO_0005147 - Category: Metabolic (immune-mediated endocrine disease)

Pathophysiology description (current understanding) Type 1 diabetes is an immune-mediated disease in which T cells destroy insulin-producing pancreatic β-cells, with other islet cell types relatively preserved, and autoantibodies serve as population-level markers of islet autoimmunity and risk. “T1D is characterized as an autoimmune disease in which T cells destroy β-cells while other islet cell types are relatively preserved. Autoantibodies (insulin, GAD65, IA-2, ZnT8) are population-level markers predicting dysglycemia” (URL: https://doi.org/10.1210/clinem/dgaf267; 2025-07) (michels2025challengesandopportunities pages 2-3). Core genetic risk is dominated by HLA class II, with additional non-HLA loci contributing to immune regulation and β-cell susceptibility (URL: https://doi.org/10.1038/s41577-023-00985-4; 2024-02) (herold2024theimmunologyof pages 1-3, michels2025challengesandopportunities pages 3-4). Interferon signaling is a central driver of β-cell intrinsic responses: type I and II interferons upregulate antigen presentation and chemokines in β-cells, while downregulating oxidative phosphorylation, thereby increasing immunogenicity amid metabolic stress (URL: https://doi.org/10.1007/s00125-024-06106-7; 2024-02) (brachene2024interferonsarekey pages 4-7). The natural history spans silent autoimmunity (stage 1), dysglycemia (stage 2), and symptomatic hyperglycemia (stage 3) (URL: https://doi.org/10.1038/s41577-023-00985-4; 2024-02; URL: https://doi.org/10.1210/clinem/dgaf267; 2025-07) (herold2024theimmunologyof pages 1-3, michels2025challengesandopportunities pages 1-2).

Core pathophysiology - Autoimmunity: Autoreactive CD8+ and CD4+ T cells mediate β-cell killing, supported by B-cell antigen presentation and autoantibodies. The recent approval of a T-cell–targeting therapy that delays clinical disease underscores the central role of T cells (URL: https://doi.org/10.1038/s41577-023-00985-4; 2024-02) (herold2024theimmunologyof pages 1-3). - Interferon-driven β-cell intrinsic programs: “Our data identified IFN-α and IFN-γ as key drivers of the beta cell inflammatory response,” inducing HLA class I, HLA-E, PD-L1, and CXCL10, with enriched IFN signaling and antigen processing/presentation pathways and downregulated oxidative phosphorylation (URL: https://doi.org/10.1007/s00125-024-06106-7; 2024-02) (brachene2024interferonsarekey pages 4-7). - Cytokine and stress signaling: Synergy of interferons with cytokines (e.g., IL‑1β) promotes β-cell dysfunction and death via ER stress and apoptosis; an interferon-induced gene signature precedes autoantibody seroconversion (URL: https://doi.org/10.1038/s41577-023-00985-4; 2024-02) (herold2024theimmunologyof pages 3-4). - Genetics and antigen presentation: HLA-DR/DQ haplotypes confer dominant risk/protection; non-HLA loci (INS, PTPN22, CTLA4, IL2RA, TYK2, IFIH1, BACH2) implicate adaptive immunity, tolerance, and interferon pathways (URL: https://doi.org/10.1038/s41577-023-00985-4; 2024-02; URL: https://doi.org/10.1210/clinem/dgaf267; 2025-07) (herold2024theimmunologyof pages 3-4, michels2025challengesandopportunities pages 3-4).

Key molecular players - Genes/Proteins (HGNC): HLA class II (HLA-DRB1/DQA1/DQB1), INS, PTPN22, IL2RA (CD25), TYK2, IFIH1 (MDA5), CTLA4, BACH2. Herold et al. summarize “strong HLA class II associations” and non-HLA loci including “PTPN22, CTLA4 and IL2RA” and interferon pathway gene TYK2 (URL: https://doi.org/10.1038/s41577-023-00985-4; 2024-02) (herold2024theimmunologyof pages 1-3). The Endocrine Society statement emphasizes HLA risk and protection (e.g., DQB1*06:02) and >75 GWAS loci across immune and β-cell pathways (URL: https://doi.org/10.1210/clinem/dgaf267; 2025-07) (michels2025challengesandopportunities pages 3-4). - Cell types (CL): CD8+ T cells (primary effectors), CD4+ T cells (Th1/Th17 help), B cells (antigen presentation/autoantibodies), regulatory T cells (FOXP3+; tolerance), dendritic cells and macrophages (antigen handling/cytokines), β-cells (targets that also present antigen), NK/neutrophils contribute early innate responses (URL: https://doi.org/10.1038/s41577-023-00985-4; 2024-02) (herold2024theimmunologyof pages 3-4, herold2024theimmunologyof pages 1-3). Role of B cells as APCs and autoantibody sources is reviewed (URL: https://doi.org/10.1101/cshperspect.a041593; 2024-08) (). - Chemical entities (CHEBI): Insulin; cytokines IL‑1β, IFN‑α/γ; chemokine CXCL10. Interferons induce PD‑L1, HLA‑ABC/E and CXCL10 (URL: https://doi.org/10.1007/s00125-024-06106-7; 2024-02) (brachene2024interferonsarekey pages 4-7). - Anatomical locations (UBERON): Pancreatic islets within pancreas; pancreas-draining lymph nodes and spleen orchestrate priming/expansion of autoreactive lymphocytes (URL: https://doi.org/10.1210/clinem/dgaf267; 2025-07) (michels2025challengesandopportunities pages 2-3).

Biological processes (GO) and cellular components (GO-CC) - Disrupted processes: type I interferon signaling; antigen processing and presentation via MHC I; cytokine-mediated signaling; chemokine production (e.g., CXCL10); unfolded protein response (ER stress); apoptosis; oxidative phosphorylation (downregulated in β-cells under IFNs) (URL: https://doi.org/10.1007/s00125-024-06106-7; 2024-02) (brachene2024interferonsarekey pages 4-7). - Cellular components: MHC class I complex and plasma membrane (antigen display/immune checkpoints); endoplasmic reticulum (UPR); mitochondrion (OXPHOS); secretory granules (insulin) (URL: https://doi.org/10.1007/s00125-024-06106-7; 2024-02) (brachene2024interferonsarekey pages 4-7).

Ontology mapping summary | Category | Entity (preferred label) | Ontology | Example terms | Notes (mechanistic role) | |---|---|---|---|---| | Gene / Protein | HLA class II (HLA-DR / HLA-DQ) | HGNC / HLA | HLA-DRB1, HLA-DQA1, HLA-DQB1 | Primary genetic risk locus shaping peptide presentation to CD4+ T cells and influencing tolerance. | | Gene / Protein | INS | HGNC | INS | Insulin gene; VNTR/INS expression influences central/peripheral tolerance to insulin. | | Gene / Protein | PTPN22 | HGNC | PTPN22 | Tyrosine phosphatase that negatively regulates TCR signaling; risk alleles alter T cell activation thresholds. | | Gene / Protein | IL2RA (CD25) | HGNC | IL2RA | IL-2 receptor alpha chain; modulates regulatory T cell (Treg) fitness and homeostasis. | | Gene / Protein | TYK2 | HGNC | TYK2 | Janus-family kinase in type I IFN/JAK signaling; variants affect interferon responses and beta-cell sensitivity. | | Gene / Protein | IFIH1 (MDA5) | HGNC | IFIH1 | Cytosolic viral RNA sensor implicated in antiviral signaling and linkage to autoimmune risk. | | Gene / Protein | CTLA4 | HGNC | CTLA4 | Immune-checkpoint receptor that limits T cell activation and promotes tolerance. | | Gene / Protein | BACH2 | HGNC | BACH2 | Transcriptional regulator controlling immune-cell differentiation and tolerance maintenance. | | Biological Process | Type I interferon signaling pathway | GO (BP) | IFN-α signaling, STAT/IRF activation | Drives beta-cell antiviral programs and upregulates antigen-presentation/chemokine genes. | | Biological Process | Antigen processing & presentation via MHC class I | GO (BP) | HLA-ABC peptide display | Enables beta-cell peptide presentation to CD8+ cytotoxic T cells. | | Biological Process | Cytokine-mediated signaling | GO (BP) | IL-1β, IFN-γ, TNFα pathways | Inflammatory cytokines induce beta-cell stress, chemokine release and immune recruitment. | | Biological Process | Unfolded protein response (ER stress) | GO (BP) | PERK / IRE1 / ATF6 UPR branches | Beta-cell ER stress contributes to dysfunction, altered identity, and apoptosis under inflammation. | | Biological Process | Apoptosis | GO (BP) | Caspase-mediated cell death | Programmed beta-cell death downstream of immune attack and unresolved stress. | | Biological Process | Oxidative phosphorylation (downregulated) | GO (BP) | Mitochondrial respiration / OXPHOS | Downregulation linked to metabolic dysfunction of beta cells during inflammatory states. | | Biological Process | Chemokine production (e.g., CXCL10) | GO (BP) | CXCL10, CCL5 | Chemokines recruit autoreactive T and innate cells to islets. | | Cellular Component | MHC class I complex | GO (CC) | HLA-A/B/C on plasma membrane | Surface peptide display platform for CD8+ T cell recognition of beta cells. | | Cellular Component | Plasma membrane | GO (CC) | Cytokine receptors, PD-L1 | Site of cytokine receptor signaling and immune–cell interactions. | | Cellular Component | Endoplasmic reticulum | GO (CC) | ER lumen, chaperones | Site of proinsulin folding and UPR activation in beta cells. | | Cellular Component | Mitochondrion | GO (CC) | OXPHOS complexes | Cellular energy metabolism affected during inflammatory stress. | | Cellular Component | Secretory granule | GO (CC) | Insulin granules | Storage and regulated secretion site for insulin peptide. | | Cell Type | CD8+ T cell | CL | Cytotoxic T lymphocyte | Principal effector mediating antigen-specific killing of beta cells. | | Cell Type | CD4+ T cell | CL | Helper T cell (Th1/Th17) | Provide help for autoreactive responses and coordinate inflammation. | | Cell Type | B cell | CL | Naive / memory B cell, plasma cell | Produce islet autoantibodies and act as antigen-presenting cells. | | Cell Type | Regulatory T cell (Treg) | CL | FOXP3+ Treg | Maintain peripheral tolerance; impaired function/number linked to autoimmunity. | | Cell Type | Dendritic cell | CL | Conventional DC | Prime and present islet antigens to naive/autoreactive T cells. | | Cell Type | Macrophage | CL | Islet-resident macrophage | Source of cytokines/ROS and contributors to local inflammation and antigen handling. | | Cell Type | Pancreatic beta cell | CL | Insulin-producing β cell | Target of autoimmune attack and active participant via IFN responses and antigen presentation. | | Cell Type | Pancreatic ductal cell | CL | Ductal epithelial cell | May amplify islet inflammation through proinflammatory signaling and immune recruitment. | | Anatomy | Pancreas | UBERON | Pancreas organ | Organ containing islets (site of autoimmune destruction). | | Anatomy | Pancreatic islet | UBERON | Islet of Langerhans | Micro-organ housing β cells and site of insulitis. | | Anatomy | Pancreas-draining lymph node | UBERON | pLN | Lymphoid site for priming and expansion of autoreactive lymphocytes. | | Anatomy | Spleen | UBERON | Spleen | Secondary lymphoid organ involved in systemic immune responses. | | Phenotype | Hyperglycemia | HP | Elevated blood glucose | Clinical consequence of insufficient insulin secretion. | | Phenotype | Polyuria | HP | Excessive urination | Symptom resulting from osmotic diuresis. | | Phenotype | Polydipsia | HP | Excessive thirst | Compensatory response to fluid loss. | | Phenotype | Weight loss | HP | Unintended weight loss | Catabolic consequence of insulin deficiency. | | Phenotype | Diabetic ketoacidosis (DKA) | HP | DKA | Acute life‑threatening metabolic decompensation at presentation. | | Chemical | Insulin | CHEBI | Therapeutic insulin peptide | Hormone deficient in T1D; replaced therapeutically. | | Chemical | Glucose | CHEBI | Blood glucose | Metabolite measured for diagnosis and staging. | | Chemical | Interferon-alpha (IFN-α) | CHEBI | Type I interferon | Drives antiviral/antigen-presentation programs in beta cells. | | Chemical | Interleukin-1 beta (IL-1β) | CHEBI | Proinflammatory cytokine | Contributes to beta-cell stress, UPR activation and dysfunction. |

Table: Compact mapping of genes, processes, cell types, anatomical sites, phenotypes and chemicals relevant to T1D pathophysiology; entries synthesize current mechanistic roles from recent reviews (e.g., Herold et al. 2024; de Brachène et al. 2024; Michels et al. 2025) to support ontology annotation and knowledge‑base curation (herold2024theimmunologyof pages 3-4, brachene2024interferonsarekey pages 4-7, michels2025challengesandopportunities pages 1-2).

Disease progression and staging - Staging: Stage 1—≥2 islet autoantibodies with normoglycemia; Stage 2—≥2 autoantibodies with dysglycemia; Stage 3—clinical diabetes with hyperglycemia. “Stage 1 = ≥2 autoantibodies with normal glucose tolerance; stage 2 = multiple autoantibodies plus dysglycemia…; stage 3 = hyperglycemia with autoimmunity” (URL: https://doi.org/10.1210/clinem/dgaf267; 2025-07) (michels2025challengesandopportunities pages 1-2). - Natural history and risk: Stage 1 has ~35–50% 5–6-year progression risk; stage 2 has ~75% risk with median ~2 years to diagnosis (URL: https://doi.org/10.1038/s41577-023-00985-4; 2024-02) (herold2024theimmunologyof pages 1-3). - Heterogeneity: Rates of C‑peptide decline, patterns of insulitis, and B‑cell infiltration vary by age and genotype; β-cells are active participants in pathogenesis (URL: https://doi.org/10.1210/clinem/dgaf267; 2025-07) (michels2025challengesandopportunities pages 2-3, michels2025challengesandopportunities pages 3-4).

Phenotypic manifestations (HP terms) - Hyperglycemia with polyuria, polydipsia, weight loss; frequent presentation with diabetic ketoacidosis (DKA), especially in youth; lifelong insulin dependence (URL: https://doi.org/10.1186/s42269-024-01197-z; 2024-04) (addissouky2024type1diabetes pages 1-2).

Recent developments, implementations, and expert perspectives (2023–2024 focus) - Teplizumab (anti-CD3): FDA‑approved to delay stage 3 onset; delays progression by approximately 2–3 years in stage 2, confirming pathogenic role of T cells (URL: https://doi.org/10.1210/clinem/dgaf267; 2025-07) (michels2025challengesandopportunities pages 2-3). “The first immune-targeted drug for type 1 diabetes (T1D), teplizumab, received regulatory approval by the US FDA in 2022,” and immune mechanisms are emphasized for therapy (URL: https://doi.org/10.1038/s41577-023-00985-4; 2024-02) (herold2024theimmunologyof pages 1-3). - Coxsackie B vaccine PRV-101: Phase I randomized, placebo-controlled trial showed the multivalent CVB vaccine was well tolerated and “induced dose-dependent neutralising antibody responses against all five CVB serotypes… Protective titres ≥8 against all five serotypes were seen in >90% of participants” (URL: https://doi.org/10.1007/s00125-024-06092-w; 2024-02) (). This supports further clinical development of primary prevention strategies targeting suspected viral triggers. - Interferons in islets: Comprehensive 2024 Diabetologia analysis identifies IFN‑α/γ as “key drivers of the beta cell inflammatory response,” expanding β-cell immunogenicity via HLA upregulation and chemokine induction, while suppressing OXPHOS (URL: https://doi.org/10.1007/s00125-024-06106-7; 2024-02) (brachene2024interferonsarekey pages 4-7). - Screening and precision diagnostics: Systematic review concluded “current evidence most strongly supports the application of autoantibody features to more precisely define T1D before diagnosis,” endorsing staging by number/type/affinity and interactions with age/genetics (URL: https://doi.org/10.1038/s43856-024-00478-y; 2024-04) ().

Statistics and epidemiology - Global burden: “Global burden in 2021 was estimated at 8.4 million people with ~510,000 new cases” (URL: https://doi.org/10.1038/s41577-023-00985-4; 2024-02) (herold2024theimmunologyof pages 1-3). - Incidence and heterogeneity: Geographic and ethnic variation are substantial; pediatric incidence ranges widely (URL: https://doi.org/10.1186/s42269-024-01197-z; 2024-04) (addissouky2024type1diabetes pages 1-2). - SARS‑CoV‑2 and T1D risk severity: Two large Nordic registry cohorts found “no significant increase in type 1 diabetes after documented infections” and no consistent association with vaccination; no “break in time-trends” for severity metrics at diagnosis 2016–2023 (URL: https://doi.org/10.1101/2024.07.03.24309894; 2024-07) (aamodt2025thepathophysiologypresentation pages 2-4). A Portuguese registry study similarly found no overall significant increase in T1D cases during the pandemic nor changes in DKA/HbA1c at diagnosis across centers (URL: https://doi.org/10.1186/s12902-024-01667-5; 2024-08) ().

Evidence items (selected quotes supporting mechanistic claims) - “IFNα and IFNγ… [are] key drivers of the beta cell inflammatory response… [inducing] HLA‑ABC, CXCL10, PDL1, HLA‑E… [and] IFN signalling and antigen processing and presentation” (URL: https://doi.org/10.1007/s00125-024-06106-7; 2024-02) (brachene2024interferonsarekey pages 4-7). - “The first immune-targeted drug for type 1 diabetes (T1D), teplizumab, received regulatory approval by the US FDA in 2022” (URL: https://doi.org/10.1038/s41577-023-00985-4; 2024-02) (herold2024theimmunologyof pages 1-3). - “Stage 1 = ≥2 autoantibodies…; stage 2 = multiple autoantibodies plus dysglycemia…; stage 3 = hyperglycemia with autoimmunity” (URL: https://doi.org/10.1210/clinem/dgaf267; 2025-07) (michels2025challengesandopportunities pages 1-2). - PRV‑101 “induced dose-dependent neutralising antibody responses against all five CVB serotypes… Protective titres ≥8… in >90%” (URL: https://doi.org/10.1007/s00125-024-06092-w; 2024-02) ().

Knowledge gaps and expert perspectives - Heterogeneity/endotypes across genetics, autoimmunity, and β‑cell biology necessitate stage-tailored and combination approaches; improved biomarkers and collaborative, human-focused research are priorities (URL: https://doi.org/10.1210/clinem/dgaf267; 2025-07) (michels2025challengesandopportunities pages 2-3, michels2025challengesandopportunities pages 3-4). - Environmental triggers: Enteroviruses remain leading candidates; antiviral activity in new-onset disease has been reported, motivating vaccine and antiviral trials (URL: https://doi.org/10.1038/s41577-023-00985-4; 2024-02) (herold2024theimmunologyof pages 3-4).

Structured annotations for knowledge-base curation - Genes/Proteins (HGNC): HLA-DRB1/DQA1/DQB1; INS; PTPN22; IL2RA; TYK2; IFIH1; CTLA4; BACH2 (herold2024theimmunologyof pages 1-3, michels2025challengesandopportunities pages 3-4, herold2024theimmunologyof pages 3-4). - Biological Processes (GO): type I interferon signaling; antigen processing/presentation (MHC I); cytokine-mediated signaling; UPR/ER stress; apoptosis; chemokine production; oxidative phosphorylation (downregulated) (brachene2024interferonsarekey pages 4-7). - Cellular Components (GO-CC): MHC class I complex; plasma membrane; endoplasmic reticulum; mitochondrion; secretory granule (brachene2024interferonsarekey pages 4-7). - Cell types (CL): CD8+ T cell; CD4+ T cell; B cell; regulatory T cell; dendritic cell; macrophage; β-cell (herold2024theimmunologyof pages 3-4). - Anatomy (UBERON): pancreas; pancreatic islet; pancreas-draining lymph node; spleen (michels2025challengesandopportunities pages 2-3). - Phenotypes (HP): hyperglycemia; polyuria; polydipsia; weight loss; DKA (addissouky2024type1diabetes pages 1-2). - Chemical entities (CHEBI): insulin; glucose; interferon‑α; interleukin‑1β; chemokine CXCL10 (brachene2024interferonsarekey pages 4-7, addissouky2024type1diabetes pages 1-2).

Current applications and real-world implementations - Disease modification: Teplizumab implementation in stage 2 (screen‑detected multiple autoantibodies), with delay of progression by ~2–3 years and ongoing efforts to broaden immunomodulator portfolios (URL: https://doi.org/10.1210/clinem/dgaf267; 2025-07) (michels2025challengesandopportunities pages 2-3). - Screening: Precision use of islet autoantibody number, type, order of appearance, and titer for staging and risk stratification; guidelines and standardization are emphasized (URL: https://doi.org/10.1038/s43856-024-00478-y; 2024-04) (). - Primary prevention research: CVB vaccination (PRV‑101) shows safety and immunogenicity as a step toward pathogen-targeted prevention (URL: https://doi.org/10.1007/s00125-024-06092-w; 2024-02) ().

References (URLs and dates) - Herold KC et al. The Immunology of type 1 diabetes. Nat Rev Immunol. 2024-02. URL: https://doi.org/10.1038/s41577-023-00985-4 (herold2024theimmunologyof pages 3-4, herold2024theimmunologyof pages 1-3). - de Brachène AC et al. Interferons are key cytokines acting on pancreatic islets in T1D. Diabetologia. 2024-02. URL: https://doi.org/10.1007/s00125-024-06106-7 (brachene2024interferonsarekey pages 4-7). - Michels AW et al. Endocrine Society Scientific Statement. J Clin Endocrinol Metab. 2025-07. URL: https://doi.org/10.1210/clinem/dgaf267 (michels2025challengesandopportunities pages 2-3, michels2025challengesandopportunities pages 3-4, michels2025challengesandopportunities pages 1-2). - Felton JL et al. Islet autoantibodies as precision diagnostic tools… Communications Medicine. 2024-04. URL: https://doi.org/10.1038/s43856-024-00478-y (). - Hyöty H et al. PRV‑101 CVB vaccine Phase I. Diabetologia. 2024-02. URL: https://doi.org/10.1007/s00125-024-06092-w (). - Stene LC et al. T1D risk after SARS‑CoV‑2 infection or vaccination (Nordic registries). medRxiv. 2024-07. URL: https://doi.org/10.1101/2024.07.03.24309894 (aamodt2025thepathophysiologypresentation pages 2-4). - Bjerregaard-Andersen M et al. COVID‑19 and T1D incidence in Portugal (registry). BMC Endocr Disord. 2024-08. URL: https://doi.org/10.1186/s12902-024-01667-5 (). - Addissouky TA et al. Type 1 diabetes mellitus: retrospect and prospect. Bull Natl Res Centre. 2024-04. URL: https://doi.org/10.1186/s42269-024-01197-z (addissouky2024type1diabetes pages 1-2).

Expert consensus and analysis Authoritative 2024–2025 reviews converge on a model wherein HLA-driven adaptive immunity targets β-cells, whose interferon-primed antigen presentation and stress responses amplify immunogenicity; staging by autoantibodies enables early identification, and T-cell–directed therapy can delay progression, while primary prevention (e.g., CVB vaccination) is advancing (herold2024theimmunologyof pages 1-3, brachene2024interferonsarekey pages 4-7, michels2025challengesandopportunities pages 1-2, michels2025challengesandopportunities pages 2-3).

References

(michels2025challengesandopportunities pages 2-3): Aaron W Michels, Todd M Brusko, Carmella Evans-Molina, Dirk Homann, Sarah J Richardson, and Alvin C Powers. Challenges and opportunities for understanding the pathogenesis of type 1 diabetes: an endocrine society scientific statement. The Journal of clinical endocrinology and metabolism, Jul 2025. URL: https://doi.org/10.1210/clinem/dgaf267, doi:10.1210/clinem/dgaf267. This article has 3 citations.
(herold2024theimmunologyof pages 1-3): Kevan C. Herold, Thomas Delong, Ana Luisa Perdigoto, Noah Biru, Todd M. Brusko, and Lucy S. K. Walker. The immunology of type 1 diabetes. Nature reviews. Immunology, 24:435-451, Feb 2024. URL: https://doi.org/10.1038/s41577-023-00985-4, doi:10.1038/s41577-023-00985-4. This article has 167 citations.
(michels2025challengesandopportunities pages 3-4): Aaron W Michels, Todd M Brusko, Carmella Evans-Molina, Dirk Homann, Sarah J Richardson, and Alvin C Powers. Challenges and opportunities for understanding the pathogenesis of type 1 diabetes: an endocrine society scientific statement. The Journal of clinical endocrinology and metabolism, Jul 2025. URL: https://doi.org/10.1210/clinem/dgaf267, doi:10.1210/clinem/dgaf267. This article has 3 citations.
(brachene2024interferonsarekey pages 4-7): Alexandra Coomans de Brachène, Maria Ines Alvelos, Florian Szymczak, Priscila L. Zimath, Angela Castela, Bianca Marmontel de Souza, Arturo Roca Rivada, Sandra Marín-Cañas, Xiaoyan Yi, Anne Op de Beeck, Noel G. Morgan, Sebastian Sonntag, Sayro Jawurek, Alexandra C. Title, Burcak Yesildag, François Pattou, Julie Kerr-Conte, Eduard Montanya, Montserrat Nacher, Lorella Marselli, Piero Marchetti, Sarah J. Richardson, and Decio L. Eizirik. Interferons are key cytokines acting on pancreatic islets in type 1 diabetes. Diabetologia, 67:908-927, Feb 2024. URL: https://doi.org/10.1007/s00125-024-06106-7, doi:10.1007/s00125-024-06106-7. This article has 37 citations and is from a highest quality peer-reviewed journal.
(michels2025challengesandopportunities pages 1-2): Aaron W Michels, Todd M Brusko, Carmella Evans-Molina, Dirk Homann, Sarah J Richardson, and Alvin C Powers. Challenges and opportunities for understanding the pathogenesis of type 1 diabetes: an endocrine society scientific statement. The Journal of clinical endocrinology and metabolism, Jul 2025. URL: https://doi.org/10.1210/clinem/dgaf267, doi:10.1210/clinem/dgaf267. This article has 3 citations.
(herold2024theimmunologyof pages 3-4): Kevan C. Herold, Thomas Delong, Ana Luisa Perdigoto, Noah Biru, Todd M. Brusko, and Lucy S. K. Walker. The immunology of type 1 diabetes. Nature reviews. Immunology, 24:435-451, Feb 2024. URL: https://doi.org/10.1038/s41577-023-00985-4, doi:10.1038/s41577-023-00985-4. This article has 167 citations.
(addissouky2024type1diabetes pages 1-2): Tamer A. Addissouky, Majeed M. A. Ali, Ibrahim El Tantawy El Sayed, and Yuliang Wang. Type 1 diabetes mellitus: retrospect and prospect. Bulletin of the National Research Centre, 48:1-15, Apr 2024. URL: https://doi.org/10.1186/s42269-024-01197-z, doi:10.1186/s42269-024-01197-z. This article has 54 citations.
(aamodt2025thepathophysiologypresentation pages 2-4): Kristie I. Aamodt and Alvin C. Powers. The pathophysiology, presentation and classification of type 1 diabetes. Diabetes, Obesity & Metabolism, 27:15-27, Jul 2025. URL: https://doi.org/10.1111/dom.16628, doi:10.1111/dom.16628. This article has 7 citations.

Type I Diabetes

Ask OpenScientist

OpenScientist Report

Classifications

Mechanistic Hypotheses

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Environmental Factors

Biochemical Markers

Progression

Prevalence

Related Datasets

Source YAML

References & Deep Research

Deep Research

Disorder

Key Pathophysiology Nodes

Citation Inventory (for evidence mapping)